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Riassunto: 
Questa tesi riguarda aspetti della farmacologia di due polifenoli: il Resveratrolo e lo 
Pterostilbene.  
 
Queste molecole di origine vegetale sono oggetto di intensa ricerca alla luce dei loro 
effetti biologici e biomedici, d’interesse per varie e distinte patologie legate all’età, 
infiammazione, cancro, obesità, neurodegenerazione e diabete. Tuttavia i meccanismi alla 
base dell’attività del Resveratrolo ed in particolare dello Pterostilbene non sono 
completamente noti. Inoltre, la presenza di gruppi idrossilici liberi (caratteristica tipica dei 
polifenoli) rende queste molecole un buon substrato per gli enzimi del metabolismo di 
fase II, la cui attività ne limita fortemente la biodisponibilità e lo sfruttamento 
farmacologico. 
Nel corso del mio dottorato mi sono occupato di entrambi questi temi.  Descriverò prima 
il lavoro fatto per aumentare la biodisponibilità delle molecole precedentemente 
menzionate. In secondo luogo riassumerò le indagini sui meccanismi molecolari che 
sottendono l’attività dello Pterostilbene e del Resveratrolo. 
La strategia adottata dal mio gruppo per aumentare la biodisponibilità di questi polifenoli, 
considerati alla stregua di farmaci, si basa sull’uso di pro-farmaci. I pro-farmaci sono 
essenzialmente versioni protette di una determinata molecola. Il Resveratrolo in 
particolare presenta tre siti principali che dovrebbero essere protetti dagli enzimi del 
metabolismo di fase II, i gruppo idrossilici. Attraverso un processo di derivatizzazione 
chimica (svolto dal gruppo della prof.ssa Cristina Paradisi) i gruppi idrossilici sono stati 
protetti con dei gruppi sostituenti. La scelta della funzionalità chimica e dei sostituenti 
usati per la protezione è fondamentale per ottenere un pro-farmaco utile. Noi intendiamo 
i pro-farmaci come molecole terapeutiche adatte per la somministrazione orale. Questa 
via di somministrazione presume un’elevata stabilità negli ambienti gastrici ed intestinali, 
seguita da una moderata instabilità in altri ambiti fisiologici (sangue, tessuti, fluidi 
extracellulari) così da rigenerare il polifenolo naturale, attivo. Durante il mio progetto di 
dottorato abbiamo ottimizzato questi componenti dei pro-farmaci, il legame ed il gruppo 
sostituente, lavorando con il Resveratrolo, e poi abbiamo applicato i risultati ottenuti allo 
Pterostilbene. 
Ho iniziato lavorando su derivati acetalici del Resveratrolo. Abbiamo prodotto e testato 
una serie di composti “decorati” con brevi oligomeri di glicole etilenico legati agli ossigeni 
fenolici con dei legami di tipo acetalico. Tramite esperimenti ex vivo ed in vivo abbiamo 
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identificato la molecola con quattro unità di glicole etilenico ed il legame acetale 
propriamente detto (Resv-O-CH(CH3)-OR) come pro-farmaco più promettente di questa 
serie di composti (capitolo 1: “Acetal derivatives as prodrugs of resveratrol”). 
La deprotezione completa per rigenerare Resveratrolo è risultata tuttavia piuttosto lenta. 
Abbiamo quindi deciso di testare nuovi derivati aventi un diverso legame chimico e diversi 
gruppi sostituenti. Il capitolo 2, “New water-soluble carbamate ester derivatives of 
resveratrol”, presenta i risultati ottenuti con derivati del Resveratrolo recanti PEG 350 o 
sostituenti di tipo zuccherino incorporati come carbammato N,N-di-sostituito. Queste 
molecole presentano il vantaggio di essere più idrosolubili, mantenendo al contempo la 
stessa capacità di permeazione delle membrane cellulari. Tuttavia, l’elevata stabilità di 
questi composti è risultata ancora problematica. 
La stabilità del legame carbammico può essere modulata variando il numero e 
caratteristiche dei sostituenti sull’atomo di azoto; abbiamo quindi testato il legame estere 
carbammato N-mono-sostituito, che ci attendevamo fosse più labile rispetto al suo 
equivalente di-sostituito. I capitoli 3 e 4 (rispettivamente “N-monosubstituted carbamate 
ester derivatives of resveratrol” and “Synthesis and evaluation of hydrophilic carbamate 
ester analogos of resveratrol”) presentano due serie di derivati del Resveratrolo 
contenenti aminoacidi, brevi oligomeri di glicole etilenico o sostituenti zuccherini collegati 
allo “scaffold” stilbenico con questo gruppo. La versione N-mono-sostituita del legame 
estere carbammato presenta un’elevata stabilità in ambiente acido, una buona stabilità a 
pH neutro e viene idrolizzata con un’opportuna cinetica in sangue di ratto. La stabilità di 
questi composti dipende in parte dal gruppo sostituente legato all’azoto. Tuttavia la 
maggior parte di essi ha dimostrato una reattività idonea all’uso come pro-farmaci del 
Resveratrolo (capitolo 3). 
Oltre a subire un rapido metabolismo di fase II, il Resveratrolo è anche poco solubile in 
acqua. La sua somministrazione è limitata a pillole o all’uso di eccipienti. Derivati del 
Resveratrolo solubili in acqua potrebbero quindi facilitarne la somministrazione, 
specialmente se cronica. Nel capitolo 4 presento derivati del Resveratrolo tri- di- e mono-
derivatizzati come esteri carbammici N-monosostituiti; in queste molecole il gruppo 
sostituente è di tipo poliidrossilico (diidrossipropile o 6-deossigalattosio), e conferisce 
un’elevata solubilità in acqua.  I derivati con il galattosio sono sostanzialmente confinati 
nell’intestino, dove si accumulano in particolare nei tratti finali, subendovi la progressiva 
perdita dei gruppi protettori. I derivati con il diidrossipropile vengono invece assorbiti 
dall’intestino. In particolare, i risultati migliori sono stati ottenuti somministrando i 
derivati mono-sostituiti. 
Ho quindi applicato le conoscenze acquisite lavorando con il Resveratrolo allo 
Pterostilbene, l’analogo 3,5-dimetilato del Resveratrolo. Poiché lo Pterostilbene è ancora 
poco caratterizzato abbiamo innanzitutto eseguito una dettagliata analisi sulla 
distribuzione della molecola negli organi dopo la sua somministrazione orale (capitolo 5, 
“Pharmacokinetics and tissue distribution of pterostilbene in the rat”). I livelli di 
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Pterostilbene negli organi sono risultati molto elevati in paragone a quelli misurati nel 
sangue. Tuttavia, eccetto che nel cervello, il suo metabolita solfato è risultato la specie 
più abbondante nei tessuti esaminati. Abbiamo quindi testato una piccola libreria di pro-
farmaci dello Pterostilbene basati sul legame carbammico N-monosostituito e 
amminoacidi naturali. Come ci attendavamo, la stabilità di questi derivati è compresa in 
un intervallo utile per l’uso come pro-farmaci. L’assorbimento dei derivati recanti 
amminoacidi apolari è fortemente incrementato (capitolo 6, “Boosting pterostilbene’s 
effects: a prodrug approach”). Oltre ad un intenso e sostenuto assorbimento intestinale, 
alcuni precursori si sono distinti per i livelli di Pterostilbene rigenerati nel sangue. Uno di 
questi composti è stato selezionato come più promettente e la sua distribuzione negli 
organi dopo somministrazione orale è stata mappata seguendo gli stessi criteri adottati 
per lo Pterostilbene (descritti nel capitolo 5). Il derivato stesso è stato la specie più 
abbondante misurata negli organi esaminati, eccetto che nel cervello, mentre i livelli del 
metabolita solfato erano diminuiti e quelli dello Pterostilbene aumentati nella maggior 
parte degli organi esaminati. I pro-farmaci possono quindi essere utili strumenti per 
aumentare la biodisponibilità di alcuni polifenoli. 
Nella seconda parte del mio dottorato ho condotto indagini, ancora in corso, su aspetti 
dei meccanismi cellulari con cui agiscono Resveratrolo e Pterostilbene. A tal scopo 
abbiamo adottato un duplice approccio, sia in vitro che in vivo, presentati in questa sede 
in due diversi capitoli (capitoli 7 e 8, rispettivamente “Transcription factor EB is a crucial 
transducer of the biomedical action of pterostilbene and resveratrol” and “Pterostilbene 
and cognitive performance in the aged rat model: preliminary findings”). 
Gli effetti pleiotropici attribuiti al Resveratrolo ed allo Pterostilbene possono essere 
spiegati da interazioni multiple con proteine che occupano posizioni apicali in importanti 
processi cellulari. L’autofagia è stata a lungo considerata come un banale processo 
catabolico che si svolge in sottofondo tra le varie attività cellulari. Oggi è invece 
considerata come uno dei processi che controllano l’omeostasi cellulare, e la sua errata 
regolazione è implicata in varie patologie. Oltretutto è stato recentemente scoperto un 
fattore di trascrizione, TFEB, che governa la maggior parte degli eventi correlati con 
l’autofagia lisosomiale. Abbiamo verificato se lo Pterostilbene e il Resveratrolo potessero 
agire anche sulla regolazione di questo fattore di trascrizione. Entrambi si sono dimostrati 
in grado di indurre la traslocazione di TFEB dal citoplasma, dove è normalmente 
confinato, al nucleo, dove può promuovere gli eventi correlati all’autofagia. Abbiamo 
inoltre incluso nel nostro lavoro lo studio di alcuni dei principali metaboliti del 
Resveratrolo e dello Pterostilbene. Mentre i solfati di entrambe le molecole sono risultati 
poco attivi, le forme ridotte, tipicamente prodotte dalla flora intestinale, hanno 
dimostrato un’efficacia simile a quella delle molecole non modificate. Ulteriore lavoro 
rimane per poter chiarire quale via di segnalazione sia a monte dell’attivazione di TFEB. 
Sia il Resveratrolo che (ed in particolare) lo Pterostilbene determinano un aumento dei 
livelli di AMPciclico citosolico in cellule HeLa in coltura, probabilmente inibendo 
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determinate classi di fosfodiesterasi. Ulteriore lavoro sarà necessario per valutare il 
coinvolgimento di altre vie di segnalazione (capitolo 7). 
Nel capitolo 5 riporto che lo Pterostilbene presenta un elevato tropismo per il cervello. Le 
concentrazioni misurate in tale organo danno valore ad alcuni lavori che riportano un 
effetto dello Pterostilbene nel contrastare il deterioramento cognitivo legato all’età ed 
alle patologie neurodegenerative come l’Alzheimer e il Parkinson. I meccanismi 
sottostanti questi effetti dello Pterostilbene sono tuttora poco caratterizzati. Lo 
Pterostilbene, attraverso un incremento di AMPciclico citosolico può attivare la via di 
segnalazione PKA/CREB/CBP che, come illustrato dal premio Nobel Eric Kandel, può 
giustificare gli effetti sulla memoria e sull’apprendimento. La sola attivazione di questa via 
tuttavia non può spiegare gli effetti dello Pterostilbene nel trattamento del 
deterioramento cognitivo legato all’età. Recentemente, è stato scoperto che la proteina 
RbAp48 è negativamente regolata in soggetti anziani, sia topi che umani. Questa proteina 
è fortemente coinvolta nei processi di rimodellamento della cromatina, quindi 
nell’espressione genica. I processi complessi come la formazione della memoria 
richiedono l’espressione coordinata di molti geni. I fattori di trascrizione come CREB 
possono indurre l’espressione genica qualora i geni siano loro accessibili. Il 
rimodellamento della cromatina è quindi un processo richiesto e necessario per l’azione 
del CREB. Abbiamo quindi deciso di verificare se l’attività dello Pterostilbene fosse, 
almeno in parte, mediata dalla modulazione di RbAp48. Allo stato attuale i risultati sono 
ancora preliminari, ma sembra che nel giro dentato di ratti anziani TFEB, RbAp48 e Rest 
siano positivamente regolati dopo somministrazione cronica di Pterostilbene. Altro lavoro 
è però necessario per poter chiarire questi punti, inoltre il numero di animali esaminato 
deve essere incrementato per poter avere un dato statisticamente significativo. 
Infine, nel corso del mio dottorato sono stato coinvolto in altri progetti in corso nel 
gruppo. Questa partecipazione ha fatto sì che io fossi incluso fra gli autori di tre 
pubblicazioni, che includo in questa tesi come capitoli 9, 10 ed 11. 
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Summary: 
This thesis deals with aspects of the pharmacology of two polyphenols: Resveratrol and 
Pterostilbene. 
 
These plant-made molecules are the object of intensive research due to their biological 
and biomedical activities, of interest in the context of various pathologies related to age, 
inflammation, neurodegeneration, cancer, obesity and diabetes. However, the 
mechanisms underlying the activity of Resveratrol, and in particular of Pterostilbene, are 
not completely known. Moreover, the presence of free hydroxyl group(s) (the common 
feature of polyphenols) renders both molecules good substrates for enzymes of phase II 
metabolism, whose activity strongly limits the bioavailability and the pharmacological 
exploitation of polyphenols. 
During my graduate studies I have worked on both these themes. I will describe first what 
has been done to increase the bioavailability of both molecules. Second, I will summarize 
my ongoing investigation of the molecular mechanisms accounting for the activity of 
Pterostilbene and Resveratrol.  
The strategy adopted by my research group to improve the efficacy of these polyphenols, 
viewed more as pharmaceuticals than as nutrients, involves the use of prodrugs. Prodrugs 
are essentially protected versions of a given molecule. Resveratrol in particular presents 
three main sites that ought to be protected from phase II enzymes, the hydroxyl groups. 
Through chemical derivatization (performed by the group of prof. Cristina Paradisi) the 
hydroxyl groups were reversibly protected with pro-moieties. The choice of linker group 
and of the pro-moiety is of fundamental importance to construct a useful prodrug. We 
intend prodrugs as therapeutic molecules designed for oral administration. This route of 
administration demands a suitable stability in gastric and intestinal environments, and a 
moderate instability in other physiological matrices (e.g. blood, tissues, extracellular 
fluids) so as to regenerate the active polyphenol once in the latter. During my PhD project 
we have optimized the two key components of the prodrug, the bond and the substituent 
group, working with Resveratrol, and we have then applied the results to Pterostilbene. 
I started my project working on acetal derivatives of Resveratrol. We produced and tested 
a series of derivatives bearing short ethyleneglycol oligomers (OEG) linked to the phenolic 
oxygens via acetal/formal/ketal bonds. Through ex vivo and in vivo tests we have 
identified the acetal derivative Resv-O-CH(CH3)-OR, with R = tetrameric OEG, as the most 
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promising prodrug of this series (chapter 1, “Acetal derivatives as prodrugs of 
resveratrol”). 
Complete deprotection to give Resveratrol was however rather slow. We thus decided to 
test new derivatives based on a different bond system, and different substituent groups. 
Chapter 2, “New water-soluble carbamate ester derivatives of resveratrol”, presents the 
results obtained with Resveratrol derivatives bearing a PEG 350 or a sugar promoiety 
joined to the stilbenoid core through a N,N-di-substituted carbamate ester functionality. 
These molecules present the advantage of an increased water solubility, while 
maintaining to some degree the ability to permeate membranes. However, the high 
stability of these molecules was again problematic. 
The stability vs. hydrolysis of the carbamate bond can be modulated varying the number 
and characteristics of the substituents on the Nitrogen atom; we tested therefore the N-
mono-substitute carbamate group, which we expected to be more labile than its di-
substitued analog. Chapters 3 and 4 (respectively “N-monosubstituted carbamate ester 
derivatives of resveratrol” and “Synthesis and evaluation of hydrophilic carbamate ester 
analogos of resveratrol”) present two series of derivatives of Resveratrol comprising 
amino acids, short ethyleneglycol oligomers (OEG) or sugar promoities linked to the 
scaffold via this group. The N-mono-substituted version of the carbamate bond shows 
high stability in acid, a suitable stability at near-neutral pH, and it undergoes hydrolysis 
with opportune kinetics in rat blood. The stability of these molecules depends in part on 
the substituent group on Nitrogen. However most of our derivatives hydrolyzed with a 
time course compatible with their use as prodrugs of Resveratrol (chapter 3). 
Besides its rapid phase II metabolism, Resveratrol is also poorly soluble in water. Its 
administration is therefore usually as pills or with excipients. Water-soluble prodrugs 
would facilitate Resveratrol administration, especially if given chronically. In chapter 4 I 
present Resveratrol derivatives in which all three, two or one hydroxyl group(s) are 
incorporated into N-monosubstituted carbamate ester moieties; in these molecules the 
pro-moiety is a polyhydroxylated group (dihydroxypropyl or 6-deoxygalactose), and 
confers high water solubility. Galactosyl derivatives were substantially confined to the 
intestine, where they accumulated especially in the lower segments, undergoing the 
progressive loss of the protecting groups. Dihydroxypropyl derivatives instead were partly 
absorbed. Notably, the best results were achieved using mono-substituted derivatives.  
I have then applied the knowledge and know-how gained working with Resveratrol to 
Pterostilbene, the 3,5-dimethylated analogue of Resveratrol. Since Pterostilbene is still 
poorly characterized from a pharmacological point of view we first of all performed a 
detailed analysis of the distribution of the molecule and its major metabolite in the 
organs of rat after its oral administration (chapter 5, “Pharmacokinetics and tissue 
distribution of pterostilbene in the rat”). The levels of Pterostilbene in the organs were 
much higher than those measured in blood. Nonetheless, its sulfate was the predominant 
specie in all tissues examined except the brain.  
Summary 
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We tested a small library of pro-drugs of Pterostilbene bearing amino acids linked to the 
phenolic oxygen via the N-monosubstitute carbamate ester group. As expected, the rates 
of hydrolysis of these derivatives fell in a range suitable for their use as prodrugs. 
Absorption of Pterostilbene derivatives bearing apolar amino acids was greatly increased 
(chapter 6, “Boosting pterostilbene’s effects: a prodrug approach”). Apart from an intense 
and sustained absorption from the intestinal wall, a few precursors were notable for the 
levels of Pterostilbene they regenerated in blood. One of these compounds was selected 
as the most promising one and its distribution in rat organs was analyzed, following the 
same criteria adopted for Pterostilbene (described in chapter 5). The prodrug itself was 
the major specie measured in all organs examined, except the brain, while levels of the 
sulfate metabolite were decreased and those of regenerated Pterostilbene increased in 
most of the organs examined (in comparison with the administration of Pterostilbene 
itself). Prodrugs can thus be a useful tool to increase the bioavailability of some 
polyphenols. 
In the second phase of my PhD project I conducted an investigation, still to be completed 
at this point, of the cellular processes set in motion by Pterostilbene and Resveratrol. For 
this purpose we adopted in vitro and in vivo approaches, presented here in two separate 
chapters (chapter 7 and chapter 8, respectively “Transcription factor EB is a crucial 
transducer of the biomedical action of pterostilbene and resveratrol: work in progress” 
and “Pterostilbene and cognitive performance in the aged rat model: preliminary 
findings”). 
The pleiotropic effects attributed to Resveratrol and Pterostilbene can be explained by 
multiple interactions with proteins occupying apical positions in important and 
interconnected signaling cascades. Autophagy has been long considered as a “banal” 
background catabolic process. Currently it is instead recognized to be one of the 
important processes that maintain cell homeostasis, and its dysregulation is implicated in 
various pathologies. A transcription factor, TFEB, that governs most of the events in 
lysosomal autophagy has recently attracted much interest. We thus verified whether 
Pterostilbene and Resveratrol might have an impact on the regulation of this transcription 
factor. Both proved capable of inducing the translocation of TFEB from the cytosol, where 
it is normally confined, to the nucleus, where it can promote autophagy-related events. 
We also included in our work the study of some of the major metabolites of Resveratrol 
and Pterostilbene. While sulfates of both molecules were poorly active, the reduced 
forms, typical products of the colonic flora, showed an efficacy comparable to that of the 
unmodified parent molecules. Further work is needed to clarify what signaling  pathways 
are involved upstream of TFEB activation. Both Resveratrol and (in particular) 
Pterostilbene determined an increase of cytosolic cAMP concentration in cultured HeLa 
cells, probably by inhibiting certain classes of phosphodiesterases, but more work is 
needed to explore the possible involvement of other pathways, suggested by some 
aspects of our results (chapter 7). 
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In chapter 5 I have reported that Pterostilbene presents an elevated tropism for the brain. 
The concentrations measured in this organ strengthen the reports showing an effect of 
Pterostilbene in contrasting cognitive aging and neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s. The mechanisms accounting for these effects are however 
poorly characterized. Pterostilbene, through an increase in cytosolic cAMP, can activate 
the PKA/CREB/CBP pathway, which, as shown by Nobel prize winner Eric Kandel, can 
account for the effects on memory formation and learning, boosted by this molecule. The 
activation of this pathway cannot however explain by itself the striking effects of 
Pterostilbene in the treatment of cognitive aging. Recently, the protein RbAp48 has been 
discovered to be downregulated in aged individuals (humans and mice). This protein is 
deeply involved in the chromatin remodeling, thus in the modulation of gene expression. 
Processes like memory formation require the coordinated expression of many genes. 
Transcription factors, such as CREB, can induce gene expression provided that the genes 
themselves are accessible. Chromatin remodeling is thus required for the action of CREB. 
We thus decided to investigate if Pterostilbene activity might be, at least in part, 
mediated by a functional  interaction with RbAp48. Our results are still preliminary, but it 
seems that in the Dentate Gyrus of old rats the transcription factor TFEB, RbAp48 and 
Rest are upregulated upon chronic administration of Pterostilbene. Further work needs to 
be done in order to clarify these points, and the statistical set ought to be increased to 
achieve significance.  
Finally, during my doctoral training I have also been involved in other ongoing projects in 
my group. This involvement has led to my presence in the author list of three 
publications, which I include in this thesis as chapters 9, 10 and 11. 
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Organization of the thesis: 
After a relatively brief general introduction, the bulk of this thesis is organized in chapters 
corresponding to individual topics of research. This organization has been favoured over a more 
traditional, monograph-style layout in part because my work actually developed as a series of 
closely related - but distinct - activities, and mainly with the intent of facilitating reading. Some of 
the chapters correspond to papers already published or almost ready to be submitted, in other 
cases the specific parcel of work was still unfinished as the thesis was due. The corresponding 
section reports the available data and comments, and mentions what remains to be done. At the 
end I have included three papers of which I am a co-author, but which fall outside my main 
research project, although they are related to it. Thus, the chapters are not homogenous in length 
and relevance, and there are may be repetitions. I hope the benefits of such an organization 
outweigh this disadvantage.  
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Introduction:  
Polyphenols are a large and diversified class of plant-derived compounds. Their precise 
definition has been a matter of debate. In 2011 Stephen Quideau proposed this 
definition: “the term polyphenol should be used to define plant secondary metabolites 
derived exclusively from the shikimate-derived phenylpropanoid and/or the polyketide 
pathway(s), featuring more than one phenolic ring and being devoid of any nitrogen-
based functional group in their basic structural expression”.1 However more relaxed 
definitions of polyphenols are generally accepted. Fig 1 presents some of the most 
common and studied classes of polyphenols.  
 
Polyphenols are normally produced by plants in response to stressors such as pathogens 
2, 3 or U.V. radiation,3, 4 or in the regulation of physiological processes (i.e. hormone 
production; 5). 
Much evidence (at least in in vitro studies) suggests that these compounds can be 
potentially useful for human health care. Currently it is widely accepted that these 
molecules can have a role in contrasting cancer, obesity, cardiovascular diseases and 
disorders related to aging, such as neurodegeneration, diabetes and chronic inflammation 
(e.g. 3, 6-13). 
Among the thousands of known plant polyphenols (5000 - 8000 different molecules), 
during my PhD project I worked with Resveratrol and its analogue Pterostilbene (fig 2), 
which were already the major model polyphenols in use in my group when I joined it. The 
choice had been motivated in part by the eminence of these two compounds (especially 
Fig. 1. Some of the most important polyphenol subfamilies. Fig. 1. Some of the most importa  l henol subfamilies. 
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resveratrol) in the field, due to the evidence linking their intake to a variety of (potential) 
positive effects on consumers’ health, and in part by their relatively simple structure and 
fair stability, which obviously facilitate their chemical elaboration and analysis. 
 
Resveratrol (3,5,4’-trihydroxy-trans-stilbene) is one of the polyphenols that have 
attracted the most attention from scientists and physicians. It is a stilbene found in 
grapes, wine, certain roots and its celebrity can probably be traced back to the “French 
paradox”.14, 15 Two decades of intensive research support Resveratrol as a promising drug 
for the treatment or prevention of many human diseases such as type 2 diabetes, 
Alzheimer, Parkinson, cancer, inflammation-related pathologies, cardiovascular problems 
and obesity (e.g. 16-24). 
Pterostilbene (3,5-dimethoxy-4’-hydroxy-stilbene) is found primarily in blueberries and 
grapes. The presence of the two methyl groups renders Pterostilbene more lipophilic than 
Resveratrol. This property in turn leads to a higher bioavailability of the molecule since it 
can diffuse across membranes and tissues more easily. The effects of Pterostilbene are 
still little known, since research has focused mainly on Resveratrol, but it is nowadays 
accepted that its bioavailability makes Pterostilbene even more interesting than 
Resveratrol.25-32 
The biological effects of polyphenols have been ascribed both to their redox properties 
and to interaction with proteins. The structure of polyphenols allows delocalization of 
charges and unpaired electrons, rendering them good radical scavengers (and thus 
antioxidants; 33, 34). An excessive load of radical oxygen species (ROS) can cause damage at 
both cellular and tissue level. A model that remained popular for several years thus 
ascribed the beneficial activities of polyphenols to a direct anti-oxidant action. However, 
in vitro studies that demonstrate the ROS scavenging activity of polyphenols are usually 
performed at high concentrations (20-200 µM), which can hardly be relevant in vivo 
because of their poor bioavailability (see below) and because cells normally possess a 
pool of effective antioxidants, e.g. glutathione, with an overall concentration in the mM 
range. Furthermore, depending on factors such as their concentration, the pH, the 
presence of metal ions capable of maintaining a redox cycle (Fe2+/3+, Cu+/2+) or of oxidizing 
enzymes such as tyrosinases (“polyphenol oxidases”), polyphenols can act as pro-oxidants 
rather than anti-oxidants.34-43 
Fig 2: Molecular structure of Resveratrol and Pterostilbene. 
Resveratrol Pterostilbene 
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Some evidence suggests that a mild ROS intoxication can lead to an increase in health and 
lifespan by inducing the production of proteins involved in the regulation of the oxidative 
level and of mitochondrial homeostasis (mitochondria are the main site of ROS 
production; 44-48). This is the concept of hormesis, which may help explain, in particular, 
preventive effects.49-56 The scheme envisions redox-sensitive transcription factors and 
enzymes driving a feedback loop to maintain the cell’s oxidative balance (fig. 3).55, 57-60 
Potentiation of antioxidant defenses induced by mild pro-oxidants such as dietary 
polyphenols may help blunt a major oxidative challenge, as occurring, for example, at 
reperfusion after ischemia,61, 62 and have positive effects on health and lifespan in 
general.  
On the other hand, current opinion attributes a major role to the interaction of 
polyphenols with proteins, which may account for hormetic or preconditioning effects as 
well. Several such interactions have been documented. For example, resveratrol has been 
shown to interact with hemoglobin,63 human and bovine serum albumin,63-66 caseins,67 β-
lactoglobulin,68, 69 glutathione sulfotransferase-π (GSTP1),70 the mitochondrial ATPase 
(F1),71 PKC-α and –β (but not -ε and -ζ),72 integrin αVβ3,73 estrogen receptor-β (ER-β),70 
dihydronicotinamide riboside quinone reductase 2 (NQO2),74 cycloxygenase-1 and -2,75 
phosphodiesterases,76, 77 peroxisome proliferator-activated receptor (PPAR) -γ and -α78 
and several other proteins.17 In some cases interactions are known to exist, but the 
binding partner has not yet been identified. For example, high-affinity (10-8 M range) 
binding of stilbenoids to brain and skin receptors has been observed by Quirion and 
coworkers.79-81 Whether this involves the EGCG-binding laminin receptor82-86 or other 
membrane protein(s) remains to be established. In other cases functional effects suggest 
a direct interaction, which however remains to be proven. Examples are PKC-γ87 and a 
splice variant of PKC-δ.88 In most cases these interactions occur with relatively low 
affinity. Thus, e.g., COX-1 and -2 are inhibited by Resveratrol with IC50’s of 2.27 and 3.40 
µM respectively,75 IKK at about 1 µM,89 PKC isoforms α and β are half-inhibited at about 2 
µM,72 PDE’s 1-4 at about 6-14 µM,76 DNA topoisomerase II at an irrelevant 65 µM,90 while 
binding to PPAR-γ occurs with an affinity of 1.4 µM,78 to BSA of about 4 µM.64, 66 These 
data highlight the importance of finding ways to increase the levels of active polyphenolic 
species in the organism, where concentrations in the µM range are seldom reached (see 
below).  
 
 
 
Fig 3: A complex molecular role for ROS in promoting health and 
lifespan. Michael Ristow. Nature Medicine, 2014 
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These various mechanisms and multiple molecular interactions impact on many branches 
of the vast and interconnected signaling network in cells. An intense activity is underway 
in many laboratories to characterize the seemingly endless mechanistic facets of 
polyphenol action, and there appears to be no shortage of work in sight in this field of 
investigation. The cellular biochemistry engaged depends not only on the specific 
phytochemical under study, but also on cell type and conditions. Effects on the apical 
elements of signaling cascades, e.g. on PDE’s, integrins or NF-kB, can impact on a plethora 
of enzymes and transcription factors. Modulation of gene expression via epigenetic 
mechanisms is also important. Resveratrol, to keep the focus on stilbenes, can influence 
the cellular transcriptome and proteome via the nucleosome remodeling and 
deacetylating (NuRD) complex91 and, most famously, via activation of SIRT1, an enzyme 
with multiple activities including that of NAD-dependent lysine deacetylase. The action of 
resveratrol on SIRT1 has been a controversial issue, but a consensus seems to have been 
reached: resveratrol does activate the sirtuin, although it might do so indirectly, with the 
intermediacy of AMPK (92-95 but see 96, 97). A direct interaction and modulation has been 
demonstrated for SIRT3 and SIRT5, two of the three mitochondrial isoforms of the 7-
membered family.98, 99 Sirtuins are thought to modulate gene expression, metabolic 
control, cell survival, development, inflammation, aging, neuroprotection (e.g. 100-105). 
This multi-faceted character of polyphenol action has been identified by some authors as 
their key asset: according to this view the simultaneous engagement of multiple 
pathways and processes hampers a re-adjustment of the system to neutralize the action 
of the drug, as often happens with single-target medicinals.17, 106 For diet-or herbal 
preparation-associated effects, cooperativity among the polyphenolic components, as 
well as with other ingredients of food is also considered important, precisely because 
multiple pathways can be activated.107-111 
In this complex scenario the real effectiveness of polyphenols in vivo is still questioned.112-
114 
Despite the multitude of effects and applications proposed for Resveratrol and 
Pterostilbene, their low bioavailability limits their full pharmacological exploitation.115-117 
An extensive phase II metabolism affects the efficacy of these two compounds in in vivo 
studies. After oral administration in fact mainly metabolites are present in the 
bloodstream (118-120; this thesis, chapter 5 121), a statement that applies to all polyphenols, 
since their hydroxyl groups make them ideal substrates for methyl, glucuronyl- and 
sulpho-transferases. Hence the well-founded suspicion that metabolites, rather than the 
parent aglycones, may actually be responsible for the effects of polyphenols. Work is 
underway to explore this obviously complex matter (e.g. 122-129). What seems clear so far 
is that generalizations ought not to be made: whether a metabolite is active (and at what 
levels) or not depends on the specific molecule and cellular process under study. The 
conjugation step leading to the formation of glucuronides or sulphates is reversible, so 
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that these metabolites may well act as a “reservoir” of aglycone, which can be gradually 
regenerated by the action of glucuronidases and sulfatases.88, 130, 131 
A topic which had received insufficient attention until recently (see for example the 
assessment by Scalbert et al., 132, 133), except for some cases, notably equol (revs.: 134-137), 
is that of the metabolites (catabolites) formed by the intestinal flora in the lower segment 
of the intestine (e.g 138-142). These seem to be more bioavailable than the parent 
polyphenols, accounting probably for most of the total absorption of polyphenol-derived 
species, and may well be responsible for a large part of the benefits provided by 
polyphenol consumption.143-155 
More details on these various aspects can be found in the introductory sections of the 
following chapters, where more specific information is presented to provide a context for 
each aspect of this work. 
The project:  
My Ph.D. thesis work has evolved coming to address two aspects of polyphenol research. 
The final goals of these related projects are to increase polyphenol bioavailability, and 
thus, presumably, efficacy, and to gain a better understanding of mechanistic aspects of 
their biological action. Both lines contribute to the development of a pharmacology of 
these natural compounds, which are generally thought of as nutrients, but arguably 
deserve the status of medicinal compounds as well. As briefly mentioned above, much of 
the research concerning polyphenols has been rightly criticized as involving solely in vitro 
systems and unrealistically high concentrations of the compounds (e.g. 156). To avoid this 
pitfall I have adopted throughout mainly an in vivo approach. 
Bioavailability:  
Continuing a previously established 
project in my research group, I have 
spent the first part of my PhD 
period working on the 
bioavailability of Resveratrol and 
Pterostilbene (chapters 1-6). Most 
of the efforts to improve absorption 
and effectiveness of polyphenols has relied so far on the use of sophisticated 
formulations: a variety of colloidal preparates, nanoparticles, liposomes and other carrier 
systems have been deployed, in many cases using mainly in vitro systems to assess their 
efficacy (for an overview see, e.g., chapter 9 and  157-160). My group has taken the 
alternative – or complementary – prodrug approach: the chemical manipulation of the 
“parent” molecule to optionally modify its physico-chemical properties, e.g. 
solubility/lipophilicity, and uptake from the gastrointestinal tract, and most importantly 
to insert protecting groups which prevent metabolic modifications during absorption and 
Fig 4: Schematic example of a prodrug of Resveratrol 
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distribution to the body organs, until they are eventually eliminated by unassisted or 
enzymatic reactions (hydrolysis), regenerating the active compound. Thus, a prodrug 
comprises the parent molecule (or scaffold, cargo), whose sensitive groups (hydroxyls) 
are linked via a labile bond to a promoiety which can impart desirable properties to the 
construct (fig 4). A key feature is the stability of the linker bond group under physiological 
conditions: it must be neither too high, because of the need to regenerate the active 
compound before excretion, nor, obviously, so low as to make the modification 
meaningless. Another point to be kept in mind is the possible bioactivity of the 
compounds that are generated upon shedding of the protecting groups. The prodrug 
approach is popular in the pharmaceutical industry, but has so far found limited 
application with polyphenols (for an overview see chapter 9, 161 and Biasutto & Zoratti, 
162).  
In collaboration with the group of prof. Cristina Paradisi (Dept. of Chemical Sciences, 
University of Padua) we developed new derivatives of both, Resveratrol and 
Pterostilbene, bearing linker and substituent groups. The stability of each of these 
molecules was assessed in acid and near-neutral solution and in blood. The compounds 
performing satisfactorily in these assays were then assessed for absorption, distribution 
and regeneration of the parent compound in pharmacokinetic experiments. 
Mechanisms of action: 
Despite a consistent number of papers devoted to the interactions and mechanisms of 
action of Resveratrol and related stilbenoids, there is still a strong need for further 
elucidation in order to clarify how these molecules work and thus how they can be 
properly exploited. Furthermore Pterostilbene has gained attention only recently, thus its 
mechanisms of action are still poorly characterized, even though it seems logical to 
anticipate that they may be similar to those of Resveratrol. Recent literature suggests that 
Pterostilbene may be even more potent than Resveratrol, presumably due to its higher 
lipophilicity and built-in partial protection from metabolic modifications. 
In chapters 7 and 8 I will present two investigations, still incomplete at this point, 
centered on the cellular mechanisms underlying the activity of Resveratrol and 
Pterostilbene. We adopted both in vitro and in vivo approaches to clarify - at least in part 
- the molecular readout. Since my research group is part of the CNR Institute of 
Neuroscience we are devoting attention to the activity of Pterostilbene on the Central 
Nervous System. Future developments will include a comparison of its efficacy and of that 
of its prodrugs. Given the relevance of autophagy in many biological processes, we are 
exploring its induction by our two stilbenoids. 
Finally, in chapters 10 and 11 I include two already published articles regarding the 
mitochondrial targeting of resveratrol. The specific targeting of Resveratrol was a parallel 
activity running in my lab, carried out especially by dr. Nicola Sassi and dr. Andrea 
Introduction 
 
17 
 
Mattarei. I was partially involved in this project as well, performing some experiments 
with dr. Sassi.  
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3. N-monosubstituted carbamate ester derivatives of resveratrol 
 
Abstract:  
Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) has demonstrated several biological 
activities, but its pharmacological exploitation in vivo is hindered by its rapid elimination 
via phase II conjugative metabolism at the intestinal level and, most importantly, in the 
liver. One approach to bypass this problem relies on prodrugs. We report here the 
synthesis, characterization, stability and in vivo pharmacokinetic behavior of 7 prodrugs 
of resveratrol, in which the OH groups are engaged in an N-monosubstituted carbamate 
ester (-OC(O)NHR) linkage. The purpose was to modulate the physicochemical properties 
and promote the absorption of the parent compound. Each -NHR group derived from the 
corresponding amine RNH2, selected from methoxyoligoethylene glycol amines and 
natural amino acids. 
We report also a convenient, mild-conditions, high-yield protocol for the synthesis of 
3,4’,5-trisubstituted-resveratrol N-monosubstituted carbamate esters involving the 
synthesis and isolation of activated 4-nitrophenyl urethanes followed by 
transesterification with resveratrol. The N-monosubstituted carbamate ester linkage 
showed good stability under acidic conditions, while it underwent slow hydrolysis at 
physiological pH and in whole blood. After administration of carbamate ester-based 
prodrugs to rats by oral gavage, only the methoxyoligoethylene glycol amines- and 
isoleucine-containing prodrugs were absorbed, reaching the circulation as non-
metabolized and partially hydrolyzed species. 
The results suggest that prodrugs of resveratrol based on the carbamate ester bond have 
the appropriate stability profile to be a convenient tool for the systemic delivery of the 
unconjugated parent compound. The choice of promoiety linked to the nitrogen atom in 
the carbamate linkage is a key factor in modulating the properties of the prodrug (i.e., 
water solubility, LogP, chemical and enzymatic stability, absorbtion through 
biomembranes (or via transporters)). Tri-substituted derivatives of Rv may however be 
too bulky to be efficiently absorbed by the intestine.  
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Introduction: 
Resveratrol (trans-3,5,4’-trihydroxystilbene), is a naturally occurring phytoalexin 
produced by plants in response to fungal, bacterial or viral infection or abiotic stresses, 
such as heavy metal ions or ultraviolet light (UV).1  
A large number of studies have identified a range of activities of biomedical interest for 
this compound, including lifespan extension in model systems,2 protection of the 
cardiovascular apparatus,3-6 anti-inflammatory activity,3 improvement of glucose handling 
in diabetes,7, 8 decrease of fat and cholesterol load,9-12 improvements of functionality in 
aging,2, 13-15 neuroprotection,16 cancer chemoprevention17, 18 and potentiation of 
chemotherapy.19, 20  
The efficacy of orally administered resveratrol depends on its absorption, metabolism, 
and tissue distribution. Clinical studies with humans reported mostly small effects, and 
sometimes controversial results.21, 22 Beneficial effects in vivo are in fact limited by low 
bioavailability. Thus, for example, only trace amounts (below 5 ng/mL, i.e., 0.022 µM) of 
intact resveratrol could be detected in blood after administration of a 25 mg oral dose to 
human volunteers.23 Even when a very large dose (2.5 g - 5.0 g) was administered, 
circulating levels of non-metabolized resveratrol were so low as to be considered 
insufficient for any bioactivity.24 Resveratrol, like other polyphenols, is rapidly converted 
to phase II metabolites (mainly glucuronides and sulfates) during absorption and first pass 
through the liver. These hydrophilic metabolites are re-exported to the intestinal lumen 
by enterocyte ABC transporters, and/or rapidly excreted with feces and urine.24, 25 
Nonetheless, they represent the vast majority of resveratrol-derived species in the body 
and their bioactivities are now under investigation to verify whether they may account for 
resveratrol’s effects. The available data suggest that a level of activity may well be 
maintained in specific contexts (e.g.26-29), but conjugation often determines at least a 
partial loss of bioefficacy.30-35 Retention of bioactivity in vivo may be due in part to the 
metabolites acting as a temporary reservoir from which the more active species may be 
regenerated through the activity of enzymes such as glucuronidases and sulfatases.36, 37 
While investigation of these aspects continues, a reduction or delay of phase II 
metabolism would allow progress in the exploitation of resveratrol for biomedical 
purposes.  
One of the strategies used to prevent drug metabolism and enhance bioavailability and 
effectiveness is based on prodrugs: the sites undergoing phase II conjugation (in this case 
the phenolic hydroxyls) are temporarily protected by removable groups during 
absorption, first pass through the liver and distribution. This approach is expected to 
increase circulating levels of non-metabolized species, with final regeneration of 
resveratrol, thanks to the removal of protective groups by chemical and/or enzyme-
catalyzed hydrolysis.  
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The carbamoyl moiety provides a promising and versatile protecting group for phenols.38, 
39 It is also suitable for fine-tuning the properties of the molecule, since the nitrogen atom 
can carry one or two substituents which can be used to modulate the stability and 
physicochemical properties of the resulting prodrug. Many prodrugs have been 
developed to improve oral bioavailability of phenolic compounds40-42 but surprisingly 
there are only few examples of carbamate ester prodrugs of polyphenols. Mulholland et 
al.
43 reported the synthesis and evaluation of a water-soluble glycine N-monosubstituted 
carbamate ester prodrug (QC12) of the natural occurring flavonoid quercetin. The 
advantage of QC12 was its high aqueous solubility compared to that of quercetin, 
eliminating the need for formulation in DMSO. Quercetin conjugates with amino acids, 
linked through the N-monosubstituted carbamate ester, were also synthesized by Kim et 
al.,
44 and showed remarkable increases in water solubility, stability, and cell permeability 
compared with the parent polyphenol.  
We report here the synthesis of a series of resveratrol prodrugs, consisting of 
methoxyoligoethylene glycol amines and natural amino acids attached to the resveratrol 
phenolic functions via the N-monosubstituted carbamate linkage (scheme 1). 
Short methoxyoligoethylene glycol chains were previously shown to be very useful in 
modulating physicochemical and absorption properties of derivatives, maintaining many 
properties of longer PEG chains with a more favorable drug loading capacity.45 Among all 
possible amino acid substituents, Leu, Ile and Phe were chosen because they are LAT1 
substrates with affinities in the µM range; aminoacid transporters LAT1 and LAT2 have 
been previously exploited for the transport/absorption of drugs, and they are especially 
useful for the permeation of the blood brain barrier.46-48 Threonine was used as “control”. 
Pharmacokinetic studies were then performed in rats, in order to evaluate in vivo 
absorption, stability and metabolism of these new prodrugs.  
 
Scheme 1. Molecular structure of resveratrol (trans-3,5,4’-trihydroxy stilbene) and 
its carbamate esters. 
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Experimental protocols:  
Materials and instrumentation. Resveratrol was purchased from Waseta Int. Trading Co. 
(Shangai, P.R.China). Other starting materials and reagents were purchased from Aldrich, 
Fluka, Merck-Novabiochem, Riedel de Haen, J.T. Baker, Cambridge Isotope Laboratories 
Inc., Acros Organics, Carlo Erba and Prolabo, and were used as received. TLCs were run on 
silica gel supported on plastic (Macherey-Nagel Polygram®SIL G/UV254, silica thickness 0.2 
mm) and visualized by UV detection. Flash chromatography was performed on silica gel 
(Macherey-Nagel 60, 230-400 mesh granulometry (0.063-0.040 mm)) under air pressure. 
The solvents were analytical or synthetic grade and were used without further 
purification. 1H NMR spectra were recorded with a Bruker AC250F spectrometer 
operating at 250 MHz and a Bruker AVII500 spectrometer operating at 500 MHz. 
Chemical shifts (δ) are given in ppm relative to the signal of the solvent. HPLC-UV analyses 
were performed with an Agilent 1290 Infinity LC System (Agilent Technologies), equipped 
with binary pump and a diode array detector (190-500 nm). HPLC/ESI-MS analyses and 
mass spectra were performed with a 1100 Series Agilent Technologies system, equipped 
with binary pump (G1312A) and MSD SL Trap mass spectrometer (G2445D SL) with ESI 
source. ESI-MS positive spectra of reaction intermediates and final purified products were 
obtained from solutions in acetonitrile, eluting with a water:acetonitrile, 1:1 mixture 
containing 0.1% formic acid. All experiments reported were performed in triplicate unless 
otherwise stated, and means ± standard deviation values are reported. 
Stability assays: 
Stability under physiological-like conditions. The chemical stability of all new compounds 
was tested in aqueous media imitating gastric (0.1 N HCl, NormaFix) and intestinal (0.1 M 
PBS buffer, pH 6.8) conditions. A 5 µM solution of the compound was prepared from a 5 
mM stock solution in DMSO, and incubated at 37°C for 24 hours; samples withdrawn at 
different times were analysed by HPLC-UV. Hydrolysis products were identified by 
HPLC/ESI-MS analysis of selected samples. Stability of compounds 5e and 7d was also 
studied in 0.1 M PBS buffer, pH 7.4 in the absence or in the presence of 35 mg/ml HSA. 
Samples withdrawn at different time points (0, 10 and 30 min; 1, 2, and 4 h) were 
deproteinized adding 1 vol of acetone, and the supernatants obtained after centrifugation 
(12,000 g, 7 min, 4°C) were analysed by HPLC-UV. 
Non-linear curve fitting was performed using Origin 8.0 data analysis software, using the 
equations described in 45, 49. 
Stability in murine whole blood. Rats were anesthetised and blood was withdrawn from 
the jugular vein, heparinised and transferred into tubes containing EDTA. Blood samples 
(1 mL) were spiked with 5 µM compound (dilution from a 5 mM stock solution in DMSO), 
and incubated at 37°C for 4 hours (the maximum period allowed by blood stability). 
Aliquots were taken after 10 min, 30 min, 1 h, 2 h and 4 h and treated as described below 
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(blood sample treatment and analysis). Cleared blood samples were finally subjected to 
HPLC-UV analysis. 
Blood sample treatment and analysis. Before starting the treatment, 4,4’-
dihydroxybiphenyl was added as internal standard to a carefully measured blood volume 
(25 µM final concentration). Blood was then stabilized with a freshly-prepared 10 mM 
solution of ascorbic acid (0.1 vol) and acidified with 0.6 M acetic acid (0.1 vol); after 
mixing, an excess of acetone (4 vol) was added, followed by sonication (2 min) and 
centrifugation (12,000 g, 7 min, 4°C). The supernatant was finally collected and stored at -
20°C. Before analysis, acetone was allowed to evaporate at room temperature using a 
Univapo 150H (UniEquip) vacuum concentrator centrifuge, and up to 40 µL of CH3CN 
were added to precipitate residual proteins. After centrifugation (12,000 g, 5 min, 4°C), 
cleared samples were directly subjected to HPLC-UV analysis. An alternative treatment 
was used for the aminoacid derivatives to achieve acceptable recovery yields: 0.1 vol of 
0.6 M TEA (pH 8.0) and 4 vol of methanol were added to blood samples (previously spiked 
with the internal standard), then sonicated (2 min) and centrifuged (12,000 g, 7 min, 4°C). 
The supernatant was finally collected and stored at -20°C. Before analysis, methanol was 
allowed to evaporate at room temperature using a Univapo 150H (UniEquip) vacuum 
concentrator centrifuge, and up to 40 µL of CH3CN were added to precipitate residual 
proteins. After centrifugation (12,000 g, 5 min, 4°C), cleared samples were directly 
subjected to HPLC-UV analysis. Metabolites and hydrolysis products were identified by  
comparison of chromatographic retention time with true samples. 
The recovery yields of resveratrol and its metabolites have been reported previously.50, 51 
Internal standard recovery from the two different treatments used to extract OEG- or AA- 
derivatives was 68.7 ± 6.3%45 and 91.8 ± 10.7%, respectively. For the new prodrugs the 
corresponding recoveries, expressed as ratio to the recovery of internal standard, were as 
follows: 7d: 0.903 ± 0.104; 8d: 0.967 ± 0.100; 3e: 0.633 ± 0.088. Recoveries of partially 
protected (disubstituted) derivatives were assumed to be the same as those of the 
corresponding fully substituted prodrug. Knowledge of these ratios allowed us to 
determine the unknown amount of analyte in a blood sample by measuring the recovery 
of the internal standard.52 
Since sample treatment includes an evaporation/concentration step, and there are no 
interfering peaks from the tissue matrix, LOD and LOQ were determined relatively to the 
analytical part of the method (HPLC/UV analysis). The derivatives showed the same 
absorption coefficient of resveratrol itself; LOD and LOQ were thus the same of 
resveratrol (i.e., 0.04 and 0.12 M, respectively; 50), and quantification of the analytes in 
blood samples was done using the same calibration curve of resveratrol (y = 5.3085 x), 
taking into account the recovery ratio of each analyte to that of the internal standard.52  
Pharmacokinetics studies. Derivatives 2e-5e and 6d-8d were administered to overnight-
fasted male Wistar rats from the facility of the Department of Biomedical Sciences, 
University of Padova, as a single intragastric dose (88 µmol/Kg, dissolved in 250 µl DMSO). 
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Blood samples were obtained by the tail bleeding technique: before drug administration, 
rats were anesthetised with isoflurane and the tip of the tail was cut off; blood samples 
(80-100 µL each) were then taken from the tail tip at different time points after drug 
administration. Blood was collected in heparinised tubes, kept in ice and treated as 
described above within 10 min. The AUC values were calculated using the trapezoidal 
rule. All experiments involving animals were performed with the permission and 
supervision of the University of Padova Ethical Committee for Experimentation on 
Animals (CEASA) and Central Veterinary Service, in compliance with Italian Law DL 
116/92, embodying UE Directive 86/609. 
Statistics. Significance in comparisons was assessed using the Wilcoxon Rank Test. 
Results and discussion: 
Chemistry (Prof. C. Paradisi’s group): 
Scheme 2 presents the structures of all resveratrol carbamate esters (-OC(O)NHR) 
synthesized in this piece of work. Different R groups were selected, with the aim of 
modulating and optimizing the physicochemical properties of the derivative (see below, 
Section 3.3). Each -NHR group derives from the corresponding methoxyoligoethylene 
glycol amine (RNH2), with 3 (6d), 4 (7d) and 6 (8d) monomeric units or from a natural 
amino acid (leucine (2e), isoleucine (3e), threonine (4e), phenylalanine (5e)).  
Synthesis of N-monosubstituted carbamate esters is usually carried out in two steps: 
reaction of the desired primary amine with phosgene or its equivalent to give a reactive 
isocyanate derivative, followed by its coupling with the phenolic function.53 These 
Scheme 2. Chemical structure of resveratrol and synthetic resveratrol carbamate ester 
prodrugs 
Chapter 3 
 
67 
 
procedures tested on resveratrol led to low yields for the trisubstituted derivatives, 
probably due to the high reactivity of the isocyanate group promoting side reactions of 
polymerization entraining the stilbene double bond function. In this study we prepared N-
monosubstituted resveratrol carbamate esters through conversion of the corresponding 
primary amines (2-8) to the activated 4-nitrophenyl carbamates (scheme 3).  
Isolation of the activated 4-nitrophenyl carbamate esters (2c-8c) followed by 
transesterification with resveratrol provided the desired N-methoxyoligoethylen glycol 
(6d-8d) derivatives as well as the t-butyl ether-protected resveratrol-amino acid 
carbamate ester conjugates (2d-5d) in good to excellent yields under mild conditions. 
Amino acids attached to the resveratrol phenolic functions via the N-monosubstituted 
carbamate ester linkage (2e-5e) were obtained by removal of the tert-butyl protecting 
group by treatment with TFA (iii in scheme 3). 
Methoxyoligoethylene glycol amines (6-8) (reagents for the synthesis of 6d-8d) were 
synthesized under mild conditions and with high yields by Staudinger reduction of the 
corresponding methoxyoligoethylene glycol azides, in turn obtained by substitution of the 
tosylate function with sodium azide (scheme 4).  
Hydrolysis studies:  
We previously reported that N,N-disubstituted carbamoyl derivatives are too stable 
under physiological conditions to be used as prodrugs.54 In this work, we thus synthesized 
Scheme 3. Synthesis of resveratrol N-monosubstituted carbamate ester prodrugs. 
Reagents and conditions: (i) bis(4-nitrophenyl) carbonate, DMAP, ACN, 50 °C, 3 h; (ii) Resveratrol, 
DMAP, ACN, 50 °C, 24 h; (iii) TFA, DCM, TIPS, from 0 °C to RT., overnight. 
Scheme 4: Synthesis of methoxyoligoethylene glycol amines. 
Reagents and conditions: (i) TsCl, Pyridine, DMAP, DCM, from 0 °C to RT., 6 h; (ii) NaN
3
, 
water/acetone (1:3), 75 °C, overnight; (iii) PPh
3
, THF, RT, 5 h; (iv) Water, 80 °C, overnight. 
Chapter 3 
68 
 
N-monosubstituted carbamoyl derivatives, and assessed their hydrolytic reactivity in 
solutions mimicking gastric and intestinal pH and in blood.  
All the tested derivatives turned out to be stable at pH values close to that of the human 
stomach (no reaction over 24 hours at 37°C in 0.1 N HCl), but underwent hydrolysis at 
near-neutral pH (pH 6.8, representing intestinal pH) and in blood, with kinetics that may 
be suitable for use in vivo.  
Kinetic analysis of the data was performed by assuming that hydrolysis to resveratrol 
occurred via consecutive loss of the three protecting groups in pseudo-first order 
processes and by considering each pair of isomeric intermediates (potentially) resulting 
from the first and second hydrolysis steps as a single species, i.e. the two 
monosubstituted and the two disubstituted intermediates were handled as species B and 
C, respectively (scheme 5).  
Figure 1 shows, as an example, the time course of the four species (A, B, C and D) 
involved in the case of derivative 6d (incorporating methoxytriethylene glycol amine) and 
the fit of the experimental data obtained using a set of equations analogous to those 
utilized by Kozerski et al.49 and in our previous work.45 
 
A: trisubstituted resveratrol derivative
B: disubstituted resveratrol derivatives
C: monosubstituted resveratrol derivatives
D: resveratrol
k1, k2, k3: observed pseudo-first order rate constants
A          B          C          Dk1 k2 k3
Scheme 5. Kinetic scheme for hydrolysis of 2e-5e and 6d-8d 
PBS 0.1 M, pH 6.8 Blood a b 
Figure 1. Kinetics of the hydrolysis of derivative 6d in PBS 0.1 M, pH 6.8, 37°C (a) and in rat blood (b). 
Data from a single representative experiment. Kinetic fit of the experimental data (i.e., time profiles 
of derivative 6d and its hydrolysis products), according to scheme 5.  
Chapter 3 
 
69 
 
The full set of kinetic constants resulting from fits of this type is presented in table 1 and 
in fig 2. 
Interestingly, the first hydrolysis rate constants of the methoxyoligoethylene glycol 
derivatives (6d-8d) in PBS were considerably higher than those of the amino acid 
derivatives. Within the N-Oligo Ethylene Glycol group, the rates increased slightly as the 
length of the chain increased.  
The stability of the carbamate group in acidic solution and its reactivity at higher pH’s are 
coherent with a mechanism of non-enzymatic hydrolysis for phenolic carbamates which 
envisions the deprotonation of the amidic nitrogen  [R(CO)NHR’] followed by loss of the 
phenate anion to give an isocyanate which rapidly adds water and decomposes releasing 
the amine55 (scheme 6).  
 
 
 
t1/2 (h) k1 (h-1) k2 (h-1) k3 (h-1) t1/2 (h) k1 (h-1) k2 (h-1) k3 (h-1)
6d 6 0,104 ± 0,002 0,030 ± 0,002 0,005 ± 0,002 0,5 1,47 ± 0,07 0,43 ± 0,04 0,155 ± 0,009
7d 3,5 0,134 ± 0,007 0,042 ± 0,005 0,007 ± 0,003 0,3 2,0 ± 0,2 0,42 ± 0,06 0,17 ± 0,03
8d 4,5 0,158 ± 0,002 0,0510 ± 0,0006 0,0250 ± 0,0002 0,5 1,25 ± 0,08 0,48 ± 0,05 0,22 ± 0,03
5e 17 0,0425 ± 0,0002 0,0136 ± 0,0004 0,002 ± 0,001 0,3 1,86 ± 0,06 0,056 ± 0,007 0,09 ± 0,02
4e 15 0,0530 ± 0,0008 0,014 ± 0,001 0,006 ± 0,001 0,17 3,9 ± 0,2 0,057 ± 0,006 0,45 ± 0,09
3e > 24 0,0221 ± 0,0002 0,004 ± 0,004 * 1 0,63 ± 0,04 0,12 ± 0,03 0,4 ± 0,1
2e > 24 0,0198 ± 0,0003 0,009 ± 0,002 * 1 0,57 ± 0,06 ND# ND#
*: k3 not calculated; monosubstituted derivative detected only at the latest time point
#: k2 and k3 not determined because of co-elution of di- and mono-substituted derivatives with matrix background interfering peaks
Derivative
PBS 0.1 M, pH 6.8, 37°C Blood
Table 1. Observed pseudo first-order rate constants for the hydrolysis of resveratrol derivatives 2e-5e 
and 6d-8d in PBS 0.1M, pH 6.8, 37°C and in rat blood. Values ± standard error are reported as obtained 
from the fit of all the available data. 
0
0,04
0,08
0,12
0,16
6d 7d 8d 5e 4e 3e 2e
k1
k2
k3
k
 (
h
-1
)
PBS 0.1 M, pH 6.8
0
0,5
1
1,5
2
2,5
3
3,5
4
6d 7d 8d 5e 4e 3e 2e
k1
k2
k3
k
 (
h
-1
)
Blood
a b 
Figure 2. Observed pseudo first-order rate constants for the hydrolysis of resveratrol derivatives 2e-5e 
and 6d-8d in PBS 0.1M, pH 6.8, 37°C (a) and in rat blood (b). Values ± standard error are reported as 
obtained from the fit of all the available data.  
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This mechanism may help explain the differences in reactivity in PBS solution just 
mentioned: in aminoacid derivatives the presence of a (deprotonated) carboxy group in α 
to the amidic nitrogen would be expected to increase the pKa value of the latter, thus 
slowing down the reaction. The relationship between OEG chain length and rate of 
hydrolysis may on the other hand be tentatively attributed to an increasing 
destabilization of the reagent as the chain length increases due to steric crowding.  
While the fits obtained in analyses such as the one exemplified in fig 1 are satisfactory, 
some features of the data indicate that the assumption of equal reactivity of the 
carbamate group in all three possible species (tri-, di- and mono-substituted resveratrol) 
may not be correct. If it were, one would expect a 3:2:1 proportion for the k1:k2:k3 values. 
This is not the case. In particular, in most cases k1 > 1.5k2, suggesting that one of the 
carbamate groups is hydrolyzed preferentially. Indeed, further data obtained in this 
project and presented in chapter 4  indicate that hydrolysis of the substituent groups in 
positions 3,5 is favoured over hydrolysis of the third substituent, in position 4’.   
Hydrolysis rates greatly increased in blood, suggesting the involvement of enzymes. This 
notion is reinforced by the variability of the rates from one compound to the other.  
 
Scheme 6: Hydrolysis scheme of carbamate in alkaline solution. 
0
0,4
0,8
1,2
1,6
2
PBS pH 6.8 PBS pH 7.4 PBS pH 7.4 +
HSA
blood
k1
k2
k3
k
 (
h
-1
)
5e
0
0,5
1
1,5
2
2,5
 PBS pH 6.8 PBS pH 7.4 PBS pH 7.4 +
HSA
blood
k
 (
h
-1
)
k1
k2
k3
7d
a b 
Figure 3. Observed pseudo first-order rate constants for the hydrolysis of resveratrol derivatives 5e 
(a) and 7d (b) in PBS at pH 6.8, at pH 7.4 in the absence or presence of 35 mg/mL human serum 
albumin, and in rat blood. Values ± standard error are reported as obtained from the fit of all the 
available data.  
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Since plasma albumin is thought to have carbamoyl esterase activity (e.g.56, 57) and it was 
reported to be the predominant component of human plasma catalyzing the hydrolysis of 
phenolic carbamate esters,39 we verified its involvement performing hydrolysis studies in 
aqueous buffer at blood pH values (PBS 0.1M, pH 7.4), in the absence or in the presence 
of a physiological concentration of albumin (35 mg/mL). Two representative members of 
the two different families of derivatives were used for these experiments (7d for OEG 
derivatives; 5e (Phe) for aminoacid derivatives). A slight increase in the hydrolysis rate 
was observed increasing pH from 6.8 to 7.4, but a considerably greater increase was 
indeed observed in the presence of albumin.  
Rates measured in rat blood are considerably higher than achieved with 35 mg/mL of 
human serum albumin. There are multiple possible explanations for this observation: rat 
albumin may be more active than its human counterpart; it may be considerably more 
concentrated than 35 mg/mL; blood may contain a significant level of other carbamate 
esterase activities, not present in commercial albumin; a combination of the above may 
apply.  
It is interesting that the acceleration in blood in comparison with albumin is only 
observed for k1 and, to a lesser extent, k3. k2, the rate of loss of a second protecting group 
from the di-substituted hydrolysis intermediate, is similar with 35 mg/mL HSA or BSA and 
in rat blood. This suggests that a non-albumin hydrolase activity in rat blood may be 
responsible for the strong acceleration observed for k1.  
Pharmacokinetics studies: 
All the N-monosubstituted carbamate ester derivatives were tested for their in vivo 
absorption and metabolism. Pharmacokinetic studies were performed with rats, and each 
compound was administered as a single intragastric bolus, in an equimolar dose/kg body 
weight (88 µmol/kg). Blood samples were taken at different time points, treated as 
described in the Materials and Methods section and analyzed.  
Administration of compounds 6d, 4e, 5e did not result in the appearance of detectable 
amounts of resveratrol, derivatives or any metabolites in blood samples. Measurable 
levels of stilbene derivatives could be found in blood samples only in the case of 
compounds 7d, 8d and 3e.  The products of partial hydrolysis of 2e unfortunately turned 
out to co-migrate with background masking blood components carried over by the 
extraction procedure. Their presence, at low concentrations, cannot therefore be 
excluded. 
The pharmacokinetic profiles for 7d, 8d and 3e are presented in fig 4. 
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Both 7d and 8d were rapidly, although poorly, absorbed, peaking 10min after their oral 
administration. In agreement with the results previously obtained with acetal prodrugs 
(45, chapter 1), the derivative with four units of ethyleneglycol (7d) was better absorbed 
than its counterpart with 6 units (0.3µM vs 0.1µM). In both cases the di-substituted 
hydrolysis products were also present. No measurable amounts of mono-substituted 
derivatives or of Resveratrol could be detected. 
The pharmacokinetic profile of 3e was undoubtedly more rewarding than those of 7d and 
8d. After the oral administration of the amino acid derivative, levels of the tri-substituted 
prodrug in the blood were higher than 0.5µM and, notably, remained at this level for 
several hours. This may indicate that the derivative is constantly absorbed from the 
intestinal mucosae or that it is poorly cleared from the body, so that its level in blood may 
be in equilibrium with its level in the various organs. Di-substituted hydrolysis products 
are also present, and, interestingly, their level is similar to that of the tri-substituted 
molecule. 
Conclusions: 
As hypothesized, the N-monosubstituted carbamate bond is a convenient linker for 
prodrugs of Resveratrol. We previously tested the N,N-disubstituited carbamate linker54 
concluding that it was too stable to regenerate Resveratrol with opportune kinetics. The 
N-monosubsituted version as expected is more labile and presents hydrolysis kinetics 
suitable for a prodrug.  
c 
a b 
Figure 4. Pharmacokinetic profiles after 
oral administration of derivatives 3e (a), 
7d (b) and 8d (c). Data represent average 
values ± standard deviation. N = 3 in all 
cases. 
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The pharmacokinetic performance of the derivatives presented here is however poor. Of 
the whole set of molecules tested, only three derivatives could be measured in blood 
after their oral administration. The one incorporating isoleucine gave the best results.  
While the stability of derivatives bearing the N-monosubstituted carbamate linker is 
satisfactory, absorption is still problematic. More work needs to be done in this sense in 
order to enhance intestinal absorption of carbamate ester derivatives of resveratrol. 
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Appendix:  
Synthesis of derivatives 2e-8d:  
Derivatives were synthesized by the group of prof. Cristina Paradisi, Department  of Chemical 
Sciences, University of Padova. 
Preparation of methoxyoligoethylene glycol-amines (6-8, Scheme 2). 
General Procedure for the preparation of methoxyoligoethylene glycol-p-toluenesulfonates (6a-
8a). Pyridine (1.09 mL, 13.5 mmol, 2.0 eq.) and DMAP (1.65 g, 13.5 mmol, 2.0 eq.) were added to 
a solution of methoxyoligoethylene glycol (6.75 mmol, 1.0 eq.) in DCM (10 mL), and the mixture 
was stirred at 0 °C for 15 min. A solution of tosyl chloride (1.93 g, 10.1 mmol, 1.5 eq.) in DCM (10 
mL) was then added dropwise and the reaction mixture was stirred at room temperature for 6 
hours. The resulting mixture was diluted in DCM (150 mL) and washed with 0.5 N HCl (100 mL). 
The aqueous layer was washed with DCM (5 × 75 mL) and all the organic fractions were collected, 
dried over MgSO4 and filtered. The solvent was evaporated under reduced pressure and the 
residue was purified by flash chromatography. 
2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (6a). Purified by flash 
chromatography using DCM:EtOAc 8:2 as eluent. 95 % yield as a colourless oil. 1H-NMR (250 MHz, 
CDCl3) δ (ppm): 2.43 (s, 3 H, Ar-CH3), 3.35 (s, 3 H, -O-CH3), 3.49-3.66 (m, 10 H, 2 × -O-CH2-CH2-O- + 
-O-CH2-), 4.14 (t, 2 H, Ts-CH2-, 
3JH-H = 5.75 Hz), 7.32 (d, 2 H, Ar-H, 
3JH-H = 8.25 Hz), 7.77 (d, 2 H, Ar-H, 
3JH-H = 8.25 Hz); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 144.7, 132.9, 129.7, 127.9, 71.8, 70.6, 70.5, 
70.4, 69.2, 68.6, 58.9, 21.6; ESI-MS (ion trap): m/z 337 [M+H2O+H]
+. 
2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate (7a). Purified by flash chromatography 
using DCM:Acetone 8:2 as eluent. 94 % yield as a colourless oil. 1H-NMR (250 MHz, CDCl3) δ 
(ppm): 2.41 (s, 3 H, Ar-CH3), 3.33 (s, 3 H, -O-CH3), 3.48-3.67 (m, 14 H, 3 × -O-CH2-CH2-O- + -O-CH2-), 
4.12 (t, 2 H, Ts-CH2-, 
3JH-H = 4.90 Hz), 7.30 (d, 2 H, Ar-H, 
3JH-H = 8.30 Hz), 7.76 (d, 2 H, Ar-H, 
3JH-H = 
8.00 Hz); 13C-NMR (62.9 MHz, CDCl3) δ (ppm): 144.7, 132.8, 129.7, 127.8, 71.8, 70.6, 70.4, 70.4, 
70.4, 70.3, 69.1, 68.5, 58.9, 21.5; ESI-MS (ion trap): m/z 381 [M+H2O+H]
+. 
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2,5,8,11,14,17-hexaoxanonadecan-19-yl 4-methylbenzenesulfonate (8a). Purified by flash 
chromatography using DCM:Acetone 6.5:3.5 as eluent. 98 % yield as a colourless oil. 1H-NMR (250 
MHz, CDCl3) δ (ppm): 2.35 (s, 3 H, Ar-CH3), 3.27 (s, 3 H, -O-CH3), 3.42-3.60 (m, 22 H, 2 × -O-CH2-
CH2-O- + -O-CH2-), 4.05 (t, 2 H, Ts-CH2-, 
3JH-H = 5.00 Hz), 7.25 (d, 2 H, Ar-H, 
3JH-H = 7.93 Hz), 7.70 (d, 2 
H, Ar-H, 3JH-H = 8.34 Hz); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 144.6, 132.7, 129.6, 127.7, 71.7, 70.5, 
70.4, 70.4, 70.3, 70.3, 70.3, 69.1, 68.4, 58.8, 21.4; ESI-MS (ion trap): m/z 451 [M+H]+. 
General Procedure for the preparation of methoxyoligoethylene glycol-azides (6b-8b). Sodium 
azide (10.72 g, 0.165 mol, 5.0 eq.) were added to a solution of methoxyoligoethylene glycol-p-
toluenesulfonate (6a-8a) (33 mmol, 1.0 eq.) in a water/acetone solution (1:3, 65 mL), and the 
mixture was stirred at 75 °C overnight. The mixture was then diluted in DCM (250 mL) and washed 
with water (250 mL). The aqueous layer was washed with DCM (5 × 100 mL) and all the organic 
fractions were collected, dried over MgSO4 and filtered. The solvent was evaporated under 
reduced pressure and the residue was purified by flash chromatography. 
1-azido-2-(2-(2-methoxyethoxy)ethoxy)ethane (6b). Purified by flash chromatography using 
DCM:Acetone 9:1 as eluent. 99 % yield as a colourless oil. 1H-NMR (250 MHz, CDCl3) δ (ppm): 
3.32-3.36 (m, 5 H, -O-CH3  + -O-CH2-CH2-N3), 3.48-3.58 (m, 2 H, -O-CH2-CH2-N3), 3.48-3.58 (m, 8 H, 2 
× -O-CH2-CH2-O-); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 71.7, 70.5, 70.5, 70.4, 69.9, 58.8, 50.5; ESI-
MS (ion trap): m/z 190 [M+H]+. 
13-azido-2,5,8,11-tetraoxatridecane (7b). Purified by flash chromatography using DCM:Acetone 
85:15 as eluent. 97 % yield as a colourless oil. 1H-NMR (250 MHz, CDCl3) δ (ppm): 3.32-3.36 (m, 5 
H, -O-CH3  + -O-CH2-CH2-N3), 3.48-3.52 (m, 2 H, -O-CH2-CH2-N3), 3.58-3.65 (m, 12 H, 3 × -O-CH2-CH2-
O-); 13C-NMR (62.9 MHz, CDCl3) δ (ppm): 71.8, 70.5, 70.5, 70.5, 70.4, 70.3, 69.9, 58.9, 50.5; ESI-MS 
(ion trap): m/z 234 [M+H]+. 
19-azido-2,5,8,11,14,17-hexaoxanonadecane (8b). Purified by flash chromatography using 
DCM:Acetone 8:2 as eluent. 96 % yield as a colourless oil. 1H-NMR (250 MHz, CDCl3) δ (ppm): 
3.28-3.32 (m, 5 H, -O-CH3  + -O-CH2-CH2-N3), 3.43-3.48 (m, 2 H, -O-CH2-CH2-N3), 3.53-3.61 (m, 20 H, 
5 × -O-CH2-CH2-O-); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 71.6, 70.4, 70.4, 70.3, 70.3, 70.3, 70.3, 
70.3, 70.2, 69.7, 58.7, 50.4; ESI-MS (ion trap): m/z 322 [M+H]+. 
General Procedure for the preparation of methoxyoligoethylene glycol-amines (6-8). 
Triphenylphosphine (10.88 g, 41.5 mmol, 1.25 eq.) in anhydrous THF (25 mL) was added dropwise 
to a solution of methoxyoligoethylene glycol-azide (6b-8b) (33.0 mmol, 1.0 eq.) in anhydrous THF 
(25 mL), and the solution was stirred at RT for 5 hours. Distilled water (20 mL) was then added 
and the mixture was heated under reflux (80°C) and vigorously stirred overnight. The resulting 
mixture was evaporated under reduced pressure and the residue was purified by flash 
chromatography. 
2-(2-(2-methoxyethoxy)ethoxy)ethanamine (6). Purified by flash chromatography using 
DCM:MeOH = 9:1 (+ 1% Et3N) as eluent. 97 % yield as a pale yellow oil. 
1H-NMR (250 MHz, CDCl3) 
δ (ppm): 1.57 (s, 2 H, -CH2-NH2), 2.79 (t, 2 H, 
3JH-H = 5.25 Hz, -CH2-CH2-NH2), 3.31 (s, 3 H, -O-CH3), 
3.41-3.51 (m, 4 H, -O-CH2-CH2-O- + -O-CH2-CH2-NH2), 3.52-3.63 (m, 6 H, -O-CH2-CH2-O- + -O-CH2-
CH2-O-); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 73.2, 71.6, 70.3, 70.3, 70.0, 58.8, 41.5; ESI-MS (ion 
trap): m/z 164 [M+H]+. 
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2,5,8,11-tetraoxatridecan-13-amine (7). Purified by flash chromatography using DCM:MeOH = 9:1 
(+ 1% Et3N) as eluent. 96 % yield as a pale yellow oil. 
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.54 (s, 2 
H, -CH2-NH2), 2.71 (t, 2 H, 
3JH-H = 5.25 Hz, -CH2-CH2-NH2), 3.22 (s, 3 H, -O-CH3), 3.34-3.41 (m, 4 H, -
O-CH2-CH2-O- + -O-CH2-CH2-NH2), 3.45-3.51 (m, 10 H, 2 × -O-CH2-CH2-O- + -O-CH2-CH2-O-); 
13C-
NMR (62.9 MHz, CDCl3) δ (ppm): 40.7, 39.3, 38.0, 37.9, 37.9, 37.9, 37.6, 26.4, 9.1; ESI-MS (ion 
trap): m/z 208 [M+H]+. 
2,5,8,11,14,17-hexaoxanonadecan-19-amine (8). Purified by flash chromatography using 
DCM:MeOH = 9:1 (+ 1% Et3N) as eluent. 98 % yield as a pale yellow oil. 
1H-NMR (250 MHz, CDCl3) 
δ (ppm): 1.78 (s, 2 H, -CH2-NH2), 2.76 (t, 2 H, 
3JH-H = 5.25 Hz, -CH2-CH2-NH2), 3.26 (s, 3 H, -O-CH3), 
3.39-3.46 (m, 4 H, -O-CH2-CH2-O- + -O-CH2-CH2-NH2), 3.51-3.56 (m, 18 H, 4 × -O-CH2-CH2-O- + -O-
CH2-CH2-O-); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 72.8, 71.6, 70.3, 70.3, 70.3, 70.2, 70.2, 70.2, 
70.0, 58.7, 41.4; ESI-MS (ion trap): m/z 296 [M+H]+. 
General procedure for the preparation of activated 4-nitrophenyl urethanes (2c-11c, Scheme 1). 
A solution of amine (2-8) (8.2 mmol, 1.0 eq.) and DMAP (2.00 g, 16.4 mmol, 2.0 eq.) in acetonitrile 
(15 mL) was added dropwise to a solution of bis(4-nitrophenyl) carbonate (2.74 g, 9.0 mmol, 1.1 
eq.) in acetonitrile (15 mL) and the resulting solution was stirred at 50 °C for 3 hours. The reaction 
mixture was then diluted in DCM (150 mL) and washed with 0.5 N HCl (100 mL). The aqueous 
layer was washed with DCM (5 × 100 mL) and all the organic fractions were collected, dried over 
MgSO4 and filtered. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography. 
tert-butyl 4-methyl-2-(((4-nitrophenoxy)carbonyl)amino)pentanoate (2c). Purified by flash 
chromatography using DCM:Acetone:Hexane = 8:0.5:1.5 as eluent. The first two spots were 
collected and the solvent was evaporated under reduced pressure, then the residue was absorbed 
on silica and purified by flash chromatography using Hexane:Ethyl Ether = 6.5:3.5 as eluent. 65% 
yield as a pale yellow oil. 1H-NMR (250 MHz, CDCl3) δ (ppm): 0.97-1.01 (m, 6 H, 2 × -CH-CH3), 1.49 
(s, 1 H, -CH-CH3), 1.52-1.85 (m, 11 H, 3 × -C-CH3 and -CH-CH2-), 4.27-4.36 (m, 1 H, NH-CH-), 5.56 (d, 
1 H, -CH-NH-, 3JH-H = 8.5 Hz), 7.33 (d, 2 H, Ar-H, 
3JH-H = 9.25 Hz), 8.24 (d, 2 H, Ar-H, 
3JH-H = 9.25 Hz); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 171.7, 155.8, 152.7, 125.1, 122.0, 82.5, 53.2, 42.0, 28.0, 27.9, 
24.9, 22.8, 22.0. ESI-MS (ion trap): m/z 353 [M+H]+. 
tert-butyl 3-methyl-2-(((4-nitrophenoxy)carbonyl)amino)pentanoate (3c). Purified by flash 
chromatography using DCM:Acetone:Hexane = 8:0.5:1.5. 93% yield as a pale yellow oil. 1H-NMR 
(300 MHz, CDCl3) δ (ppm): 0.95-1.38 (m, 5 H, -CH2-CH3, CH3-CH2-), 1.52 (s, 9 H, 3 × -C-CH3), 1.87-
2.04 (m, 1 H, -CH-CH2-), 4.29 (dd, 1 H, -CH-NH-, 
3JH-H = 8.7, 4.3 Hz), 5.76 (d, 1 H, -CH-NH-, 
3JH-H = 8.6 
Hz), 7.32-7.37 (d, 2 H, Ar-H, 3JH-H = 9.25 Hz), 8.22-8.28 (d, 2 H, Ar-H, 
3JH-H = 9.25 Hz); 
13C-NMR (300 
MHz, CDCl3) δ(ppm): 172.2, 157.6, 154.6, 145.5, 126.8, 123.7, 84.3, 79.2, 78.8, 78.3, 60.5, 29.8, 
26.9, 17.1, 13.4. ESI-MS (ion trap): m/z 353 [M+H]+. 
tert-butyl 3-(tert-butoxy)-2-(((4-nitrophenoxy)carbonyl)amino)butanoate (4c). Purified by flash 
chromatography using DCM:Acetone:Hexane = 8:0.5:1.5 as eluent. 93% yield as a pale yellow oil. 
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.19 (s, 9 H, 3 × C-CH3), 1.28 (d, 3 H, -CH-CH3, 
3JH-H = 6.3 Hz), 
1.49 (s, 9 H, 3 × -C-CH3), 4.05-4.17 (m, 1 H, -O-CH-), 4.22-4.33 (m, 1 H, NH-CH-), 5.94 (d, 1 H, CH-
NH-, 3JH-H= 9.5 Hz), 7.35 (d, 2 H, Ar-H, 
3JH-H = 9.25 Hz), 8.27 (d, 2 H, Ar-H, 
3JH-H = 9.25 Hz); 
13C-NMR 
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(62.9 MHz, CDCl3) δ(ppm): 169.7, 156.2, 153.8, 144.9, 125.2, 122.2, 82.5, 74.2, 67.2, 60.8, 28.9, 
28.3, 21.4. ESI-MS (ion trap): m/z 397 [M+H]+. 
tert-butyl 2-(((4-nitrophenoxy)carbonyl)amino)-3-phenylpropanoate (5c). Purified by flash 
chromatography using DCM:Acetone = 9:1 as eluent. 81 % yield as a pale yellow oil. 1H-NMR (250 
MHz, CDCl3) δ (ppm): 1.54 (s, 9 H, 3 × -C-CH3), 3.05-3.35 (m, 2 H, 2 × C-CH2), 4.70 (dd, 1 H, -NH-CH-
CH2- J = 14.7, 6.5 Hz), 6.33 (d, 1 H, -NH-, J = 8.3 Hz), 7.22-7.45 (m, 7 H, Ar-H), 8.23 (d, 2 H, Ar-H, 
3JH-
H= 15.5 Hz); 13C-NMR (62.9 MHz, CDCl3) δ (ppm): 170.4, 155.8, 152.6, 144.6, 136.0, 129.5, 128.1, 
127.5, 124.9, 121.9, 82.7, 55.6, 38.2, 27.3. ESI-MS (ion trap): m/z 387 [M+H]+. 
4-nitrophenyl (2-(2-(2-methoxyethoxy)ethoxy)ethyl)carbamate (6c). Purified by flash 
chromatography using DCM:Acetone = 9:1 as eluent. 87 % yield as a pale yellow oil. 1H-NMR (250 
MHz, CDCl3) δ (ppm): 3.31 (s, 3 H, -O-CH3), 3.37-3.43 (m, 2 H, -O-CH2-CH2-NH-), 3.49-3.63 (m, 10 H, 
2 × -O-CH2-CH2-O- + -O-CH2-CH2-NH-), 6.06 (t, 1 H, -NH-, 
3JH-H = 5 Hz), 7.25 (d, 2 H, Ar-H, 
3JH-H = 9.25 
Hz), 8.15 (d, 2 H, Ar-H, 3JH-H = 9.25 Hz); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 155.9, 153.1, 144.3, 
124.8, 121.8, 71.6, 70.2, 70.2, 69.9, 69.3, 58.7, 40.8; ESI-MS (ion trap): m/z 329 [M+H]+. 
4-nitrophenyl 2,5,8,11-tetraoxatridecan-13-ylcarbamate (7c). Purified by flash chromatography 
using DCM:Acetone = 85:15 as eluent. 85 % yield as a pale yellow oil. 1H-NMR (250 MHz, CDCl3) δ 
(ppm): 3.17 (s, 3 H, -O-CH3), 3.24-3.30 (m, 2 H, -O-CH2-CH2-NH-), 3.35-3.50 (m, 14 H, 3 × -O-CH2-
CH2-O- + -O-CH2-CH2-NH-), 6.21 (t, 1 H, -NH-, 
3JH-H = 5 Hz), 7.15 (d, 2 H, Ar-H, 
 3JH-H = 9.25 Hz), 8.03 
(d, 2 H, Ar-H,  3JH-H = 9.25 Hz); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 
13C-NMR (63 MHz, CDCl3) δ 
(ppm) 156.1, 153.2, 144.3, 124.9, 121.9, 71.7, 70.4, 70.3, 70.2, 70.1, 69.4, 58.7, 41.0; ESI-MS (ion 
trap): m/z 373 [M+H]+. 
4-nitrophenyl 2,5,8,11,14,17-hexaoxanonadecan-19-ylcarbamate (8c). Purified by flash 
chromatography using DCM:Acetone gradient from 8:2 to 6:4 as eluent. 84 % yield as a pale 
yellow oil. 1H-NMR (250 MHz, CDCl3) δ (ppm): 3.30 (s, 3 H, -O-CH3),  3.37-3.50 (m, 4 H, -O-CH2-CH2-
NH-), 3.55-3.61 (m, 20 H, 5 × -O-CH2-CH2-O-), 6.04 (t, 1 H, -NH-, 
3JH-H = 5 Hz), 7.26 (d, 2 H, Ar-H, 
 3JH-
H = 9.25 Hz), 8.17 (d, 2 H, Ar-H
 , 3JH-H = 9.25 Hz); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 125.8, 124.9, 
121.8, 115.5, 71.6, 70.3, 70.3, 70.3, 70.2, 70.0, 69.3, 58.8, 40.9; ESI-MS (ion trap): m/z 461 [M+H]+. 
General procedure for the preparation of 3,4’,5-N-monosubstituted-resveratrol carbamate esters 
(2d-8d). A solution of resveratrol (0.24 g, 1.1 mmol, 1.0 eq.) and DMAP (0.52 g, 4.2 mmol, 4.0 eq.) 
in ACN (15 mL) was added to a solution of the activated 4-nitrophenyl urethane (2c-8c) (4.8 mmol, 
4.5 eq) in ACN (5 mL) and the resulting mixture was allowed to react under vigorous stirring at 50 
°C for 24 h. The reaction mixture was diluted with methylene chloride (150 mL) and washed with 
0.5 N HCl (100 mL). The aqueous layer was washed with DCM (5 × 75 mL) and all the organic 
fractions were collected, dried over MgSO4 and filtered. The solvent was evaporated under 
reduced pressure and the residue was purified by flash chromatography. 
(E)-di-tert-butyl 2,2'-((((5-(4-(((1-(tert-butoxy)-4-methyl-1-oxopentan-2-yl)carbamoyl)oxy)styryl)-
1,3-phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(4-methylpentanoate) (2d). Purified by flash 
chromatography using CHCl3 as eluent. 55% yield as a colourless oil. 
1H-NMR (250 MHz, CDCl3) δ 
(ppm): 0.93 (m, 18 H, 6 × CH-CH3), 1.44 (s, 27 H, 9 × -C-CH3), 1.48-1.53 (m, 9 H, 3 × CH3-CH and 3 × 
-CH-CH2), 4.23-4.32 (m, 3 H, 3 × -NH-CH), 5.64 (m, 3 H, 3 × -NH-), 6.80-7.07 (m, 7 H, H-4, H-3’, H-5’, 
H-2, H-6, H-7, H-8), 7.47 (d, 2 H, 3JH-H = 8.5 Hz, H-2’, H-6’); 
13C-NMR (62.9 MHz, CDCl3
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172.1, 172.3, 154.0, 153.7, 151.4, 150.5, 139.0, 134.0, 129.2, 134.0, 129.2, 127.3, 127.0, 121.7, 
116.4, 114.2, 82.0, 53.1, 41.9, 27.9, 24.8, 22.8, 21.9. ESI-MS (ion trap): m/z 868 [M+H]+. 
(E)-di-tert-butyl 2,2'-((((5-(4-(((1-(tert-butoxy)-3-methyl-1-oxopentan-2-yl)carbamoyl)oxy)styryl)-
1,3-phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-methylpentanoate) (3d). Purified by flash 
chromatography using Hexane: EtOAc = 8:2. The first spot was separated and the remaining spots 
were collected and the solvent was evaporated under reduced pressure, then purified by flash 
chromatography using DCM:Hexane:EtOAc = 7:2:1. 60 % yield as a colourless oil. 1H-NMR (300 
MHz, CDCl3) δ (ppm): 0.87-1.05 (m, 18 H, 3 × CH2-CH3, 3 × CH-CH3), 1.12-1.33 (m, 6 H, 3 × CH-CH2-
CH3), 1.49 (s, 27 H, 9 × C-CH3), 1.87-2.00 (m, 3 H, 3 × CH-CH-CH3), 4.11 (q, 1 H, -NH-CH-CH-, 
3JH-H = 
7.1 Hz), 4.23-4.33 (m, 2 H, 2 × -NH-CH-CH-), 5.79 (d, 3 H, 3 × -NH-, 3JH-H = 8.7 Hz), 6.82-7.30 (m, 7 H, 
H-4, H-3’, H-5’, H-2, H-6, H-7, H-8), 7.43 (d, 2 H, 3JH-H = 8.5 Hz, H-2’, H-6’); 
13C-NMR (300 MHz, 
CDCl3) δ(ppm): 170.7, 170.6, 154.1, 153.7, 151.4, 150.6, 139.1, 134.0, 129.2, 127.3, 116.3, 114.2, 
82.1, 58.6, 38.2, 27.9, 25.1, 15.3, 11.6. ESI-MS (ion trap): m/z 868 [M+H]+. 
(E)-di-tert-butyl 2,2'-((((5-(4-(((1,3-di-tert-butoxy-1-oxobutan-2-yl)carbamoyl)oxy)styryl)-1,3-
phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-(tert-butoxy)butanoate) (4d). Purified by 
flash chromatography using DCM:ethyl ether = 95:5 as eluent. 58 % yield as a colourless oil. 1H-
NMR (250 MHz, CDCl3) δ (ppm): 1.15 (s, 27 H, 9 × C-CH3), 1.23 (d, 9 H, 3 × CH-CH3, 
3JH-H = 6.2 Hz), 
1.45 (s, 27 H, 9 × C-CH3), 4.04-4.25 (m, 6 H, 3 × CH3-CH and 3×NH-CH), 5.78 (d, 3 H, 3 × -NH-, 
3JH-H = 
9.5 Hz), 6.85-7.30 (m, 7 H, H-4, H-3’, H-5’, H-2, H-6, H-7, H-8), 7.43 (d, 2 H, 3JH-H = 8.5 Hz, H-2’, H-
6’); 13C-NMR (62.9 MHz, CDCl3) δ (ppm): 169.6, 154.7, 154.3, 151.4, 150.5, 139.0, 133.9, 129.1, 
127.3, 127.1, 121.6, 116.2, 114.1, 81.9, 81.8, 73.7, 66.9, 60.3, 28.5, 27.9, 20.8. ESI-MS (ion trap): 
m/z 832 [M+H]+. 
(E)-di-tert-butyl 2,2'-((((5-(4-(((1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)carbamoyl)oxy)styryl)-
1,3-phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-phenylpropanoate) (5d). Purified by flash 
chromatography using Hexane:Diethyl ether = 7:3 as eluent until the exit of 4-nitrophenol from 
the column, and Hexane:Diethyl ether:EtOAc = 5:3.5:1.5 thereafter. 57 % yield as a colourless oil. 
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.41 (s, 27 H, 3 × -C-CH3), 3.02-3.30 (m, 6 H, 3 × Ph-CH2), 4.16 
(q, 1 H, NH-CH-CH2, 
3JH-H = 7.1 Hz), 4.64 (q, 2 H, 2 × NH-CH-CH2, 
3JH-H = 6.2 Hz), 5.79 (m, 3 H, 3 × -
NH-), 6.81-7.56 (m, 24 H, Ar-H); 13C-NMR (62.9 MHz, CDCl3) δ (ppm): 170.6, 154.0, 153.7, 151.6, 
150.8, 139.4, 136.2, 128.8, 128.7, 127.7, 127.3, 122.0, 116.7, 114.5, 82.8, 55.6, 38.6, 28.2. ESI-MS 
(ion trap): m/z 970 [M+H]+. 
(E)-5-(4-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)carbamate)-1,3-phenylene bis((2-(2-(2-
methoxyethoxy)ethoxy)ethyl)carbamate) (6d). purified by flash chromatography using 
DCM:Acetone = 6.5:3.5 as eluent. 75 % yield as a pale yellow oil. 1H-NMR (250 MHz, CDCl3) δ 
(ppm): 3.08 (m, 9 H, 3 × -O-CH3), 3.39 (s, 9 H, 3 × -O-CH3) 3.42-3.69 (m, 36 H, 6 × -O-CH2-CH2-O- + 3 
× -O-CH2-CH2-NH- ), 5.80 (m, 3 H, 3 × -NH-), 6.86 (t, 1 H, 
4JH,H = 2.0 Hz, H-4), 6.90-7.12 (m, 6 H, H-2, 
H-3’, H-5’, H-6, H-7, H-8), 7.45 (d, 2 H, 3JH,H = 8.75 Hz, H-2’, H-6’); 
13C-NMR (62.9 MHz, CDCl3) δ 
(ppm): 154.6, 154.3, 151.6, 150.7, 139.1, 133.9, 129.2, 127.4, 127.1, 121.8, 116.3, 114.3, 71.8, 
70.5, 70.2, 70.2, 69.8, 59.0, 40.9; ESI-MS (ion trap): m/z 818 [M+Na]+. 
(E)-5-(4-(,5,8,11-tetraoxatridecan-13-ylcarbamate)styryl)-1,3-phenylene bis(2,5,8,11-
tetraoxatridecan-13-ylcarbamate) (7d). Purified by flash chromatography using DCM:Acetone = 
5:5 as eluent. 88% yield as a colourless oil. 1H-NMR (250 MHz, CDCl3) δ (ppm): 3.35 (s, 9 H, 3 × -O-
CH3),  3.41-3.56 (m, 12 H, 3 × -O-CH2-CH2-NH-), 3.60-3.68 (m, 36 H, 9 × -O-CH2-CH2-O-), 5.81-5.88 
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(m, 3 H, 3 × -NH-), 6.80-7.14 (m, 7 H, H-2, H-4, H-3’, H-5’, H-6, H-7, H-8), 7.44 (d, 2 H, 3JH,H = 8.75 
Hz, H-2’, H-6’); 13C-NMR (62.9 MHz, CDCl3) δ (ppm): 154.5, 154.2, 151.5, 150.6, 138.9, 133.7, 
129.1, 127.3, 126.9, 121.7, 116.2, 114.2, 71.7, 70.4, 70.3, 70.3, 70.1, 70.0, 69.6, 58.8, 40.8; ESI-MS 
(ion trap): m/z 928 [M+H]+. 
(E)-5-(4-(2,5,8,11,14,17-hexaoxanonadecan-19-ylcarbamate)styryl)-1,3-phenylene 
bis(2,5,8,11,14,17-hexaoxanonadecan-19-ylcarbamate) (8d). Purified by flash chromatography 
using DCM:Acetone from 4:6 to 2:8 as eluent. 76 % yield as a colourless oil. 1H-NMR (250 MHz, 
CDCl3) δ (ppm): 3.33 (s, 9 H, 3 × -O-CH3),  3.38-3.51 (m, 12 H, 3 × -O-CH2-CH2-NH-), 3.57-3.68 (m, 
60 H, 15 × -O-CH2-CH2-O-), 5.80-5.86 (m, 3 H, 3 × -NH-), 6.80-7.12 (m, 7 H, H-2, H-4, H-3’, H-5’, H-6, 
H-7, H-8), 7.41 (d, 2 H, 3JH,H = 8.75 Hz, H-2’, H-6’); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 154.4, 
154.1, 151.5, 150.6, 138.9, 133.8, 129.1, 127.3, 127.0, 121.7, 116.2, 114.2, 71.7, 70.4, 70.4, 70.3, 
70.3, 70.3, 70.2, 69.7, 58.8, 40.9; ESI-MS (ion trap): m/z 1193 [M+H]+. 
General procedure for the tert-butyl ester deprotection in resveratrol-amino acid carbamoyl 
conjugates (2e-5e) 
Resveratrol-amino acid carbamoyl conjugate (2d-5d) (1.12 mmol) was dissolved in 10 mL of 
dichloromethane at 0°C. 500 μL of triisopropyl silane and 10 mL of TFA were then added and the 
reaction mixture was stirred at room temperature under nitrogen steam overnight. The solvent 
and residual TFA were removed under reduced pressure. The residue was washed with toluene (3 
× 5 mL), and then solvent was evaporated under reduced pressure. The product was purified by 
preparative reverse phase HPLC. 
(E)-2,2'-((((5-(4-(((1-carboxy-3-methylbutyl)carbamoyl)oxy)styryl)-1,3-
phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(4-methylpentanoic acid) (2e). Purified using a 
reverse-phase preparative HPLC column (ACE 5AQ 150 mm × 21.2 mm from 7.5 % to 38 % of ACN 
in water in 14.5 minutes). 89 % yield as a white powder after freeze-drying. 1H-NMR (250 MHz, 
DMSO-d6) δ (ppm): 0.89-0.94 (m, 18 H, 3 × -CH(CH3)2), 1.45-1.81 (m, 9 H, 3 × -CH-CH2- and 3 × 
(CH3)2CH-), 3.98-4.07 (m, 3 H, -NH-CH-), 6.76 (t, 1 H, 
4JH-H = 2 Hz, H-4), 7.10-7.38 (m, 6 H, H-3’, H-5’, 
H-2, H-6, H-7, H-8), 7.63 (d, 2 H, H-2’, H-6’, 3JH-H = 8.7 Hz), 8.12-8.21 (m, 3 H, 3 × -NH-); 
13C-NMR 
(250 MHz, DMSO-d6) δ(ppm): 174.1, 174.0, 154.4, 154.2, 151.6, 150.7, 139.1, 133.7, 129.3, 127.6, 
126.8, 121.9, 116.3, 114.4, 52.5, 39.6, 24.4, 23.0, 21.2. ESI-MS (ion trap): m/z 700 [M+H]+. 
(E)-2,2'-((((5-(4-(((1-carboxy-2-methylbutyl)carbamoyl)oxy)styryl)-1,3-
phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-methylpentanoic acid) (3e). Purified using a 
reverse-phase preparative HPLC column (ACE 5AQ 150 mm × 21.2 mm from 40 % to 70 % of ACN 
in water in 11 minutes). 93 % yield as a white powder after freeze-drying. 1H-NMR (300 MHz, 
DMSO) δ (ppm): 0.86-0.95 (m, 18H, 3 × -CH2-CH3 and 3 × -CH-CH3), 1.21-1.55 (m, 6H, 3 × -CH-CH2), 
1.80-1.91 (m, 3 H, -CH-CH-CH3), 3.89-4.13 (m, 3 H, 3 × NH-CH-CH), 6.77 (t, 1 H, 
4JH-H = 2 Hz, H-4), 
7.06-7.37 (m, 6 H, H-3’, H-5’, H-2, H-6, H-7, H-8), 7.63 (d, 2 H, H-2’, H-6’, 3JH-H = 8.7 Hz), 8.04 (d, 1 
H, -NH-, 3JH-H = 8.4 Hz), 8.10 (d, 2 H, 2 × -NH-, 
3JH-H = 8.4 Hz); 
13C-NMR (300 MHz, DMSO) δ(ppm): 
175.1, 175.0, 156.7, 156.5, 153.8, 152.9, 141.3, 135.8, 131.5, 129.8, 124.1, 118.4, 97.3, 61.0, 38.3, 
26.9, 17.8, 13.5. ESI-MS (ion trap): m/z 700 [M+H]+.  
(E)-2,2'-((((5-(4-(((1-carboxy-2-hydroxypropyl)carbamoyl)oxy)styryl)-1,3-
phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-hydroxybutanoic acid) (4e). Purified using a 
reverse-phase preparative HPLC column (ACE 5AQ 150 mm × 21.2 mm from 7.5 % to 38 % of ACN 
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in water in 14.5 minutes). 91 % yield as a white powder after freeze-drying. 1H-NMR (250 MHz, 
DMSO-d6) δ (ppm): 1.17-1.19 (m, 9 H, 3 × -CH-CH3), 4.00-4.23 (m, 6 H, 3 × CH3-CH- and 3× NH-CH-), 
6.80 (t, 1 H, 4JH-H = 2 Hz, H-4), 7.01-7.39 (m, 6 H, H-3’, H-5’, H-2, H-6, H-7, H-8), 7.61-7.72 (m, 5 H, 3 
× -NH- and H-2’, H-6’); 13C-NMR (250 MHz, DMSO-d6) δ(ppm):172.1, 172.1, 154.8, 154.6, 151.7, 
150.8, 139.2, 133.8, 129.4, 127.7, 126.9, 122.0, 116.4, 114.6, 66.5, 60.4, 48.7, 20.5. ESI-MS (ion 
trap): m/z 664 [M+H]+. 
(E)-2,2'-((((5-(4-(((1-carboxy-2-phenylethyl)carbamoyl)oxy)styryl)-1,3-
phenylene)bis(oxy))bis(carbonyl))bis(azanediyl))bis(3-phenylpropanoic acid) (5e). Purified using a 
reverse-phase preparative HPLC column (ACE 5AQ 150 mm × 21.2 mm from 35 % to 65 % of ACN 
in water in 13 minutes). 91 % yield as a white powder after freeze-drying. 1H-NMR (250 MHz, 
DMSO-d6) δ (ppm): 2.86-3.19 (m, 6 H, 3 × Ph-CH2), 4.21-4.30 (m, 3H, 3 × -NH-CH-CH2), 6.47 (t, 1 H, 
4JH-H = 2 Hz, H-4), 6.91-7.33 (m, 21 H, Ar-H and H-3’, H-5’, H-2, H-6, H-7, H-8), 7.58 (d, 2 H, H-2’, H-
6’, 3JH-H = 8.7 Hz), 8.20-8.29 (m, 3H, 3 × -NH-); 13C-NMR (62.9 MHz, DMSO-d6) δ (ppm): 173.0, 
154.3, 154.0, 151.5, 150.7, 139.1, 137.8, 137.8, 133.6, 129.3, 128.3, 127.6, 126.6, 121.8, 116.1, 
114.2, 55.8, 55.0, 36.6; ESI-MS (ion trap): m/z 802 [M+H]+. 
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4. Synthesis and evaluation of hydrophilic carbamate ester 
analogs of resveratrol 
 
Abstract:  
Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene) is an unfulfilled promise for health care: its 
exploitation is hindered by rapid conjugative metabolism in enterocytes and hepatocytes. 
Prodrug development has the potential to improve bioavailability and to advantageously 
modify the chemico-physical properties of the compound. We report here the synthesis 
of precursors in which all or part of the hydroxyl groups are linked via an N-
monosubstituted carbamate ester group to promoieties derived from glycerol or 
galactose, conferring higher water solubility. Kinetic studies of their hydrolysis in solutions 
and in blood indicated that regeneration of resveratrol took place in an appropriate time 
frame. Hydrophilicity hindered absorption from the gastrointestinal tract, which was 
acceptable only for some of the compounds. In these cases the prodrug-derived species 
found in blood after administration of a bolus consisted mainly of partially deprotected 
molecules and of the products of their glucuronidation, thus providing proof-of-principle 
evidence of behavior as prodrugs. The soluble compounds largely reached the lower 
intestinal tract of rats. Upon administration of resveratrol, the major species to be found 
in this region is dihydroresveratrol, produced by enzymes of the intestinal flora. In 
experiments with a fully protected (trisubstituted) deoxygalactose-containing prodrug, 
the major species were the prodrug itself and partially deprotected derivatives, along 
with small amounts of dihydroresveratrol. We conclude that the N-monosubstituted 
carbamate moiety is a suitable one for the generation of prodrugs of polyphenols. The 
behavior of these prodrugs vis-à-vis absorption from the intestine is bound to depend on 
the properties of the chosen promoieties. Groups imparting a high water solubility hinder 
absorption and lead to accumulation of the prodrug and its derivatives in the lower part 
of the intestine, providing a method for the delivery of resveratrol to that organ, where it 
is thought to exert anti-inflammatory and anti-carcinogenic activities. 
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Introduction: 
The scope of resveratrol’s biomedical potentialities is vast. It is well known to the public 
as a “natural drug”, potentially useful on major health battlefields: afflictions of the 
cardiovascular system,2-4 neurodegeneration,5-8 aging,9, 10 diabetes, obesity, metabolic 
syndrome,11-13 cancer.14, 15 Reports suggest effectiveness against such conditions as, e.g., 
acne,16, 17 caries,18 H. pylori-induced pathologies,19, 20 erectile dysfunction in diabetes,21 
osteoporosis,22 noise-induced hearing loss,23, 24 hypertension,25 allergy,26 macular 
degeneration of the retina,27, 28 fatigue.29 
This multiplicity of potential biomedical effects stems from the impact resveratrol has on 
the activity of apical or key proteins in interconnected cellular signaling networks. Among 
its major effects observed in vitro, resveratrol inhibits phosphodiesterases (in particular 
PDE4), leading to an increase of cellular cAMP.30-32 Downstream events include the 
upregulation of AMPK, whose activation by resveratrol (and other phytochemicals)33 is 
clearly supported by data from several labs.34-42 AMPK is a key sensor and regulator of 
cellular energetic status with roles in many pathophysiological situations.43, 44 After much 
debate, a consensus now seems to have been reached that resveratrol also induces 
upregulation of SIRT1, an important NAD-dependent histone deacetylase.45, 46 SIRT1 
activation has actually been reported to be upstream of AMPK activation at low 
resveratrol doses.46, 47 Upregulation of AMPK activity induces mitogenesis and 
autophagy,48-50 largely through inhibition of mTORC151-53 whose activity downregulates 
these processes50 and which is also commonly upregulated in cancers.54 The cAMP-AMPK-
mTORC1 axis presumably accounts to a considerable degree for the antagonistic activity 
vs. neurodegeneration, metabolic syndrome55 and cancer.56 Activation of SIRT1 has 
pleiotropic epigenetic effects, reportedly culminating in life extension and  health 
improvement in mice when elicited by novel small molecules.57, 58 Another, interwined44, 
59, 60 major way resveratrol acts is by antagonizing inflammation.61, 62 Resveratrol 
suppresses NF-kB activation,63-65 with the attendant reduction of NO and prostaglandin 
production due to downregulation of iNOS and COX-2 expression. Chronic inflammation is 
well recognized to be a factor in carcinogenesis.66-68 A relevant example is provided by the 
frequent insurgence of polyposis and colon cancer in humans69-71 and laboratory 
animals72, 73 affected by (experimental in the latter) colitis (inflammatory bowel disease). 
Resveratrol has been reported to be beneficial in rodent models of colitis, polyposis and 
colon cancer induced by sodium dextran sulfate (DSS) or azoxymethane (AOM) + DSS.74-78  
Resveratrol is not, however, free of shortcomings. The major one is its poor 
bioavailability, due to the built-in propensity, common to all polyphenols, to undergo 
phase II metabolic conjugation to give sulfated and glucuronidated derivatives79-86 and 
reduction of the double bond plus other transformations by the colonic flora.87, 88 It has 
therefore often been pointed out89 that the results of studies carried out in vitro with 
high concentrations of unmodified resveratrol may be of little pharmacological or 
nutritional relevance. Another unfavorable characteristic of the “aglycone” is its low 
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water solubility. A variety of formulations and nano-structured delivery systems are being 
tested with the goal of overcoming these obstacles.90-93 Another approach relies on the 
construction of prodrugs, i.e. derivatives with favourable physico-chemical and 
absorption properties which can offer initial protection from metabolism and regenerate 
the active compound with appropriate kinetics.91, 94 Indeed, in view of the many-fold 
activities and possible applications of resveratrol there is a need for customized delivery 
vehicles and/or chemical elaborations to best conform to the specific task at hand. 
Returning to the example of the possible use of resveratrol against colitis and associated 
pathologies, specific delivery to the colon has been achieved using a formulation (Ca 
pectinate beads)95 and sophisticated prodrugs comprising a glucose moiety linked to 
resveratrol via a glycosidic bond and an hydrocarbon chain linked to the sugar ring by 
esterification.96 
Here we report the synthesis and characterization of mono-, di- and tri-substituted 
resveratrol derivatives incorporating promoieties imparting water solubility 
(dihydroxypropyl and 6-deoxygalactosyl moieties) linked via N-monosubstituted 
carbamate ester bonds to the phenolic oxygens of resveratrol (scheme 1). The N-
monosubstituted linkage undergoes hydrolysis more rapidly than N,N-disubstituted 
carbamates,97 and is thus suitable for use in prodrugs. The kinetics of hydrolysis to 
produce progressively de-protected species have been studied, and the fate of the 
prodrugs after oral administration to rats has been investigated. The compounds may be 
useful for all applications in which water solubility and protection from metabolism and 
oxidation are important. 
Experimental section: 
Materials and general chemistry. Resveratrol was purchased from Waseta Int. Trading 
Co. (Shangai, P.R.China). Other starting materials and reagents were purchased from 
Sigma-Aldrich, Fluka, Merck-Novabiochem, Riedel de Haen, J.T. Baker, Cambridge Isotope 
 R1 R2 R3 
2 DHP-C H H 
3 H DHP-C H 
4 DHP-C DHP-C H 
5 H DHP-C DHP-C 
6 DHP-C DHP-C DHP-C 
7 DGAL-C H H 
8 H DGAL-C H 
9 DGAL-C DGAL-C H 
10 H DGAL-C DGAL-C 
11 DGAL-C DGAL-C DGAL-C 
Scheme 1: Molecular structure of resveratrol (1, trans-
3,5,4’-trihydroxy stilbene) and its carbamate esters 
derivatives (2-11). 
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Laboratories Inc., Acros Organics, Carlo Erba and Prolabo, and were used as received. 1H 
and 13C NMR spectra were recorded with a Bruker AC250F spectrometer and a Bruker 
Avance DMX 600. Chemical shifts (δ) are given in ppm relative to the signal of the solvent. 
TLCs were run on silica gel supported on plastic (Macherey-Nagel Polygram®SIL G/UV254, 
silica thickness 0.2 mm) and visualized by UV detection, ninhydrin reaction or KMnO4 
oxidation. Flash chromatography was performed on silica gel (Macherey-Nagel 60, 230-
400 mesh granulometry (0.063-0.040 mm)) under air pressure. The solvents were 
analytical or synthetic grade and were used without further purification. Preparative HPLC 
was performed using a Shimadzu LC-8A equipped with a UV/VIS detector SPD-20A 
Prominence® and a reverse phase column (ACE 5AQ (150 × 21.2 mm)). 
Animals. Adult male Wistar rats (approximately 400 g body weight) from the facility of 
the Department of Biomedical Sciences were used for pharmacokinetic experiments. All 
experiments involving animals were performed after approval by the University of Padova 
Ethical Committee for Experimentation on Animals (CEASA) (Permit Number: 80/2011) 
and of the Italian Ministry of Health, and with the supervision of the Central Veterinary 
Service of the University of Padova, in compliance with Italian Law DL 116/92, embodying 
UE Directive 86/609.  
LogP, Solubility and TPSA. Unless otherwise indicated, the LogPow and solubility values 
reported are predictions obtained using the software ALOGPS 2.1 (available at Virtual 
Computational Chemistry Laboratory, http://www.vcclab.org). “Topological” Polar Surface 
Area98 values were predicted using the Molinspiration Property Calculator 
(www.molinspiration.com). 
HPLC-UV Analysis. Samples (2 µl) were analyzed by HPLC/UV (1290 Infinity LC System, 
Agilent Technologies) using a reverse phase column (Zorbax RRHD Eclipse Plus C18, 1.8 
µm, 50 x 2.1 mm i.d.; Agilent Technologies) and a UV diode array detector (190-500 nm). 
Solvents A and B were water containing 0.1% trifluoroacetic acid (TFA) and acetonitrile, 
respectively. The gradient for B was as follows: 2% (0.5 min), from 2% to 10% in 0.3 min, 
then from 10% to 18% in 1.7 min, then from 18% to 28% in 0.5 min, 28%  for 0.5 min then 
from 28% to100% in 1.8 min; the flow rate was 0.6 mL/min. The eluate was preferentially 
monitored at 286, 300 and 320 nm (corresponding to absorbance maxima of the internal 
standard, derivatives and resveratrol, respectively). The column compartment was 
thermostated at 35°C. 
HPLC/ESI-MS Analysis. HPLC/ESI-MS analyses and mass spectra were performed with a 
1100 Series Agilent Technologies system, equipped with binary pump (G1312A) and MSD 
SL Trap mass spectrometer (G2445D SL) with ESI source operating in full-scan positive or 
negative ion mode, with nebulizer pressure 70 psi, dry gas flow 12 L/min, dry gas 
temperature 350°C. ESI-MS positive mass spectra of reaction intermediates and final 
purified products were obtained by flow injection analysis of solutions in acetonitrile, 
eluting with a water:acetonitrile, 1:1 mixture containing 0.1% formic acid. HPLC/ESI-MS 
was also performed on selected samples from hydrolysis studies and pharmacokinetics. 
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Samples (20 µl) were analyzed using a reversed phase column (Synergi-MAX, 4 µm, 150 x 
4.6 mm i.d.; Phenomenex, Castel Maggiore (BO), Italy). Solvents A and B were water 
containing 0.1% TFA or 5 mM NH4OAc and acetonitrile, respectively. The gradient for B 
was as follows: 10% for 2 min, from 10% to 35% in 20 min, from 35% to 100% in 20 min, 
then 100% for 2 min; the flow rate was 1 mL/min. The eluate was preferentially 
monitored at 286, 300 and 320 nm. MS analysis was performed with an ESI source 
operating in full-scan positive or negative ion mode 
Hydrolysis Reactions. The chemical stability of all new compounds was tested in aqueous 
media approximating gastric (0.1 N HCl, NormaFix) and intestinal (0.1 M PBS buffer, pH 
6.8) pH values. A 5 µM solution of the compound was prepared from a 5 mM stock 
solution in DMSO, and incubated at 37°C for 24 hours; samples withdrawn at different 
times were analysed by HPLC-UV. Hydrolysis products were identified by comparison of 
chromatographic retention time with true samples. Non-linear curve fitting was 
performed using Origin 8.0 data analysis software; the hydrolysis reaction rate constants 
(k) of the starting compounds were calculated through interpolation of data with the 
equation for pseudo-first order reactions:  = 
	, where: 
[C ] : concentration of the compound 
[C ]0 : concentration of the compound at the initial time t0 
t: time. 
To evaluate the long-term stability under mildly acidic conditions, we stored compound 
11 dissolved in citrate buffer (5 mM) / sucrose (5 mM) solution, pH 5.0, at 4°C or R.T., 
following the disappearance of 11 by HPLC analysis of samples taken at intervals over a 
period of several months. 
Hydrolysis in blood. Rats were anesthetized and blood was withdrawn from the jugular 
vein, heparinized and transferred into tubes containing EDTA. Blood samples (1 mL) were 
spiked with compound (5 µM; dilution from a 5 mM stock solution in DMSO), and 
incubated at 37°C for 4 hours (the maximum period allowed by blood stability). Aliquots 
were taken after 10 min, 30 min, 1 h, 2 h and 4 h and treated as described below. Cleared 
blood samples were finally subjected to HPLC-UV analysis. 
Blood Sample Treatment and Analysis. Before starting the treatment, 4,4’-
dihydroxybiphenyl was added as internal standard to a carefully measured blood volume 
(25 µM final concentration). Blood was then stabilized with a freshly-prepared 10 mM 
solution of ascorbic acid (0.1 vol) and acidified with 0.6 M acetic acid (0.1 vol); after 
mixing, an excess of acetone (4 vol) was added, followed by sonication (2 min) and 
centrifugation (12,000 g, 7 min, 4°C). The supernatant was finally collected and stored at -
20°C. Before analysis, acetone was allowed to evaporate at room temperature using a 
Univapo 150H (UniEquip) vacuum concentrator centrifuge, and up to 40 µL of CH3CN 
were added to precipitate residual proteins. After centrifugation (12,000 g, 5 min, 4°C), 
cleared samples were directly subjected to HPLC-UV analysis.  
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Metabolites and hydrolysis products were identified by HPLC/ESI-MS analysis and/or 
comparison of chromatographic retention time with true samples. 
The recovery yields of resveratrol and its metabolites have been reported previously.99, 100 
For the new prodrugs the corresponding recoveries, expressed as ratio to the recovery of 
internal standard, were as follows: 2: 0.751 ± 0.122, 3: 0.752 ± 0.103, 4: 0.985 ± 0.083, 5: 
1.022 ± 0.035, 6: 0.855 ± 0.111; 7: 1.358 ± 0.119, 8: 1.097± 0.253, 9: 0.682 ± 0.070, 10: 
0.672 ± 0.068, 11: 0.903 ± 0.104 (N = 4 or 5 for all derivatives; mean values ± standard 
deviation). Recoveries ratios of glucuronides were approximated as follows: for the 
glucuronide of 2 (retention time 2.35 min) the ratio used was that of compound 4, which 
has the same substitution pattern; for the two glucuronides of 3 (r.t. 2.38 and 3.08 min) 
the ratio was assumed to be close to 1.0, since the recovery ratios of both isomeric 
prodrugs carrying two protecting groups (4 and 5) were not significantly different from 1. 
Knowledge or assumption of these ratios allowed us to determine the unknown amount 
of analyte in a blood sample by quantifying the recovered internal standard.101 
Pharmacokinetics Studies. Derivatives 2-11 were administered to overnight-fasted male 
rats as a single intragastric dose (88 µmol/Kg, dissolved in 250 µl DMSO). Blood samples 
were obtained by the tail bleeding technique: before drug administration, rats were 
anesthetized with isoflurane and the tip of the tail was cut off; blood samples (80-100 µL 
each) were then taken from the tail tip at different time points after drug administration. 
Blood was collected in heparinized tubes, kept in ice and treated as described below 
within 10 min.  
Intestinal accumulation and distribution. Resveratrol or 11 were chronically 
administered to rats for 48 h. The beverage for the treatments was 5mM citrate buffer 
with sucrose (5mM), pH 5, supplemented with the compound at a concentration 
calculated to provide a daily intake of approximately 220µmoles/kg × day. Preliminary 
experiments showed that this solution was well-liked  by rats, which drank an average of 
about 35 mL daily (hence, e.g., the concentration of resveratrol or derivative was 2.51 
mM for a 400-gram rat). The slightly acidic pH insured the stability of the carbamoyl 
derivative (see below). In the case of resveratrol, 2-hydroxypropyl-β-cyclodextrin (HP-β-
CD) was used to allow its solubilization: resveratrol and HP-β-CD were mixed in a 1:3 ratio 
in citrate buffer, and stirred overnight. 
At the end of the treatment, the treatment solution was replaced with tap water; 1h 
later, animals were sacrificed, and the intestine explanted and cut into 10 cm-long 
segments. The luminal content of each segment was collected, 100mg were weighed, H2O 
(1 vol) was added and the mixture was homogenized by vortexing (2 min). Samples were 
then stabilized and extracted adding 10 mM ascorbic acid (0.1 vol), 0.6 M acetic acid (0.1 
vol) and acetonitrile (3 vol), vortexed (2 min), sonicated (2 min) and centrifuged (12,000 
g, 7 min, 4°C); the supernatant was collected, concentrated, and finally analyzed via 
HPLC-UV and LC-ESI/MS. 
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Statistics. All experiments were performed at least in triplicate. Averages ± s.d. are 
presented. Significance in comparisons was assessed using the Wilcoxon Rank Test. 
Results:  
Synthesis. Syntheses were performed by Prof. C. Paradisi’s group. Derivatives 2-11 
(scheme 1) were obtained through transesterification of resveratrol (1) with the 
appropriate activated 4-nitrophenyl carbamate ester (13, 23). 
The synthesis of 2-6 is outlined in scheme 2. The starting material for the dihydroxypropyl 
carbamate (DHP-C) moiety was commercially available 2,2-Dimethyl-1,3-dioxolane-4-
methanamine (12) which was allowed to react with bis-(4-nitrophenyl) carbonate in 
presence of 4-(dimethylamino)pyridine (DMAP) to give the corresponding activated 
urethane (13) in good yield. Compound 13 was added in slight excess to resveratrol (1) in 
pyridine and in presence of DMAP and allowed to react at 70°C to obtain a mixture of all 
the possible mono-, di- and tri- substituted resveratrol derivatives (14-18). The last step 
consisted in the removal of the isopropylidene protecting groups, freeing the hydroxyl 
functions necessary to enhance the solubility in water of the final products (2-6) which 
were finally isolated by preparative reverse-phase HPLC.  
The synthesis of derivatives 7-11 (scheme 3) was less straightforward, because of the 
need to synthesize the commercially unavailable amine (22). The starting material in this 
case was 1,2:3,4-di-O-isopropylidene-α-D-galactopyranose (19), possessing one free 
hydroxyl group, which was esterified with tosyl chloride to obtain compound 20. The 
tosylate group of 20 was easily displaced in the second step by sodium azide giving the 
azide (21) in nearly quantitative yield. Azide 21 was then reduced to the desired primary 
amine (22) under Staudinger reaction conditions in excellent yield. The subsequent 
synthetic steps are equivalent to those reported above for derivatives (2-6), which consist 
in the production of the active urethane (23) followed by transesterification with 
resveratrol to give a mixture of all the possible mono-, di- and tri- substituted resveratrol 
 R1’ R2’ R3’ 
14 DDM-C H H 
15 H DDM-C H 
16 DDM-C DDM-C H 
17 H DDM-C DDM-C 
18 DDM-C DDM-C DDM-C 
Scheme 2. Synthesis of derivatives 2-6 
Reagents and conditions: (a) bis-(4-
nitrophenyl) carbonate, DMAP, THF, 
r.t., 3 h; (b) Resveratrol (1), Pyridine, 
DMAP, 70°C, 16 h; (c) trifluoroacetic 
acid : water 9:1, r.t., 1.5 h. 
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derivatives (24-28), and cleavage of the isopropylidene protecting groups to afford, after 
preparative HPLC isolation, all the desired resveratrol-6-deoxy-galactosyl carbamate ester 
conjugates (7-11).  
LogP, Solubility and TPSA. The octanol/water partition coefficient, water solubility, and 
the polar surface area were estimated for each compound (see Materials and Methods). 
The molecular polar surface area is the sum of the surfaces of polar atoms (oxygen, 
nitrogen) in a molecule.98 The ability to permeate cell membranes is considered to be 
inversely related to this parameter, which is instead positively linked to water solubility. 
 R1’ R2’ R3’ 
24 DIG-C H H 
25 H DIG-C H 
26 DIG-C DIG-C H 
27 H DIG-C DIG-C 
28 DIG-C DIG-C DIG-C 
Scheme 3. Synthesis of 
derivatives 7-11 
Reagents and conditions: (i) Tosyl 
chloride, Pyridine, DMAP, from 
0°C to r.t., 5 h; (ii) Sodium azide, 
DMSO, 160°C, 1.5 h; (iii) 
Triphenylphosphine, THF, r.t., 4 h; 
(iv) Water, reflux, 16 h; (a) bis-(4-
nitrophenyl) carbonate, DMAP, 
THF, r.t., 3 h; (b) Resveratrol (1), 
Pyridine, DMAP, 70°C, 16 h; (c) 
trifluoroacetic acid : water 9:1, 
r.t., 1.5 h. 
Compound Log Pow PSA (Å
2) Solubility (g/L) 
Resveratrol (1) 2.69 ± 0.12 (b) 60.68 0.039 ± 0.009 (b) 
2 1.57 119.24 0.049 
3 1.57 119.24 0.054 
4 0.15 177.80 0.12 
5 0.15 177.80 0.13 
6 -1.27 236.36 0.20 
7 0.52 168.93 1.38 
8 0.52 168.93 1.51 
9 -1.94 277.18 2.53 
10 -1.94 277.18 2.80 
11 -4.34 385.43 > 4.22 (b) 
(b)
 Experimental value; see1 
Table 1. LogP
ow
, water solubility and topological PSA values of resveratrol and 
of its carbamate ester derivatives. Algorithm-predicted values unless 
indicated. 
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Hydrolysis in Acid and Near-Neutral Solution. All the compounds proved to be stable 
over a 24 h period in acid solution (0.1 N HCl, 37°C). On the other hand, derivatives 
underwent hydrolysis of the carbamoyl bond in 0.1 M PBS buffer, pH 6.8, 37°C (fig 1). 
Table 2 shows the pseudo 1st order hydrolysis rate costants (k) of the starting compounds, 
and fig 1 presents the kinetic plots and fits for the dihydroxylpropyl derivatives. Kinetics 
were very similar for dihydroxypropyl and 6-deoxygalactosyl carbamate ester derivatives 
(cf. 2 vs. 7, 3 vs. 8, 4 vs. 9, 5 vs 10, 6 vs. 11 in table 2). 
The different reactivity of the two di-substituted isomers (3,4’- vs 3,5-; i.e. 4 vs. 5, 9 vs. 
10) suggests that the simultaneous presence of two carbamoyl moieties in positions 3 and 
5 accelerates the hydrolysis process at these positions. This hypothesis is supported by 
the hydrolysis behaviour of the tri-substituted derivatives 6 and 11, which generate 
mainly the 3,4’- isomers 4 and 9. The 3,5-disubstituted isomers 5 and 10 were detected 
only in very low amounts, because of the higher hydrolysis rate at position 3- in 
Figure 1. Hydrolysis of Resveratrol 
dihydroxypropyl carbamate ester 
derivatives (2-6) in PBS 0.1 M, pH 6.8, 37°C. 
Data are expressed as % of the initially 
loaded compound. The fit is for pseudo-
first order kinetics. 
b 
c 
e 
d 
a 
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comparison to position 4’- when all the three OH’s of resveratrol are carbamoylated, and 
because of the higher hydrolysis rate of the 3,5-disubstituted derivatives compared to the 
3,4’-disubstituted ones. When only one carbamoyl function is present in the molecule, 
the rate of its hydrolysis is not affected by the position occupied (similar reactivity of 4’- 
and 3- monosubstituted derivatives, cf. 2 vs 3, 7 vs 8 in table 2).  
To verify whether these derivatives would withstand long-term storage in liquid form we 
followed the hydrolysis of compound 11 in citrate buffer (5 mM each) at pH 5.0 or 6.0, 
4°C or R.T., over several months. The results (fig 2) indicate that indeed hydrolysis is very 
slow under these conditions.  
Hydrolysis in Blood. Hydrolysis in blood (fig 3) was faster than in PBS pH 6.8. Reaction 
rates were similar for dihydroxypropyl and 6-deoxygalactosyl carbamate ester derivatives. 
As in PBS, hydrolysis was accelerated/promoted by the presence of two carbamoyl groups 
in positions 3- and 5-. When only one carbamoyl moiety was present in the molecule (i.e., 
with mono-substituted derivatives), the rate of hydrolysis depended on the substitution 
2 3 4 5 6 7 8 9 10 11
k (h
-1
)
0.0366 ± 
0.0008
0.0362 ± 
0.0003
0.087 ± 
0.001
0.2063 ± 
0.0009
0.3072 ± 
0.0008
0.0369 ± 
0.0009
0.0315 ± 
0.0003
0.088 ± 
0.001
0.238 ± 
0.007
0.329 ± 
0.003
Table 2. Hydrolysis reaction rate costants (k) in PBS 0.1M, pH 6.8, 37°C. 
pH 5, RT 
pH 5, 4°C 
pH 6, RT pH 6, 4°C 
Figure 2. Kinetics of hydrolysis of 11 under the specified conditions. 
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position, with the compound substituted in 4’- reacting markedly more rapidly than the 3-
substituted isomer (see fig 3 and table 3). This indicates the involvement of a 
regioselective (enzymatic) hydrolysis mechanism, since in PBS the kinetics are similar in 
the two cases. Plasma albumin has carbamoyl esterase activity102, 103 and it has been 
reported to be the main component of plasma catalyzing hydrolysis of phenolic 
carbamate esters.104 
b 
c 
e 
d 
a 
Figure 3. Hydrolysis of resveratrol 
dihydroxypropyl carbamates (2-6)  in 
blood. Data are expressed as % of the 
initially loaded compound. 
2 3 4 5 6 7 8 9 10 11
k (h
-1
)
0.35 ± 
0.03
0.081 ± 
0.003
0.36 ± 
0.02
1.36 ± 
0.04
1.4 ± 
0.1
0.70 ± 
0.06
0.114 ± 
0.009
0.34 ± 
0.02
1.1 ± 
0.2
3.9 ± 
0.5
Table  3. Pseudo 1st order hydrolysis rate costants (k) in rat blood, 37°C 
Chapter 4 
94 
 
Pharmacokinetic Studies. In vitro stability studies thus indicated that the rate of 
hydrolysis of the carbamoyl bond in our derivatives is of the correct order of magnitude 
for our intended applications as prodrugs. We therefore proceeded to investigate the 
behaviour of our compounds in pharmacokinetics studies in vivo. 
Dihydroxypropyl carbamate ester derivatives 
Following administration of a single intragastric bolus, the mono-substituted derivatives 
were readily absorbed, but also extensively metabolized: low concentrations of the 
unmodified derivative were detected in blood, together with considerably higher 
amounts of metabolite(s) (fig 4). The mono-substituted derivative 3 produced two 
different metabolites, while the 4’-isomer 2 produced only one. Maximum concentration 
was reached approximately 1 hour after administration (fig 5, d-e). The two isomers 
differed however in their kinetic profile: both 2 and its metabolite persisted in the 
bloodstream for a longer time than 3 and its metabolites.  
HPLC-UV-ESI/MS analysis showed that the metabolites were the products of 
glucuronidation of the mono-substituted derivatives, still bearing the protective 
carbamoyl group (fig 4 shows a representative analysis).  
It was not possible to definitely associate each of the two peaks observed in HPLC and 
HPLC-MS chromatograms to one or the other of the two isomeric glucuronides formed 
from 3. They are referred to below by their chromatographic retention times under our 
standard analysis protocol, 2.38 and 3.08 min respectively. We note however that the r.t. 
of 2.38 min is very similar to the r.t. of 2.35 min characteristic of the single mono-
glucuronidated metabolite formed from 2, which necessarily carries the carbamoyl 
promoiety in position 4’ and the glucuronide group in 3. It is likely that the compound 
with r.t. 2.38 min, which is carbamoylated in position 3, has a similar structure, i.e., that it 
0 2 4 6 8 10 12 14 16 18 Time [min]
0
5
10
15
20
Intens.
mAU
UV Chromatogram, 298-302 nm
BiPh 
2 glucuronide 
a 
279.2
346.1
522.1
692.4
807.6 970.3
+MS, 11.9min #420, Background Subtracted
0.0
0.2
0.4
0.6
0.8
5x10
Intens.
200 300 400 500 600 700 800 900 m/z
385.0
520.1
656.0
785.9
-MS, 11.9min #419, Background Subtracted
0.0
0.2
0.4
0.6
0.8
1.0
5x10
Intens.
200 300 400 500 600 700 800 900 m/z
b 
c 
Figure 4. LC-MS analysis of a blood sample taken 2h after administration of 2. a) UV 
chromatogram, 300 nm; “BiPh” is the internal standard. b, c) ESI mass spectra of the 
metabolite, acquired in the positive (b) and negative (c) ion current mode, 
respectively. 
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carries the glucuronic acid moiety in position 4’. It follows that in the metabolite with r.t. 
3.08 the two substituents probably occupy positions 3 and 5. 
The tri- and di-substituted derivatives (4-6) were poorly absorbed. The relative amount of 
non-conjugated vs. conjugated (glucuronidated) derivatives in the bloodstream was 
inversely correlated to the fraction (1/3, 2/3, 3/3) of protected hydroxyls in the original 
prodrug.  
When 6 was administered, the intact derivative rapidly reached the bloodstream, and 
underwent hydrolysis to the 3,4’-disubstituted derivative (4) (position 3/5- is more prone 
to hydrolysis than position 4’; see “Stability in PBS and blood”). The 3-glucuronide of 2 
and the glucuronide with r.t. 3.08 of 3  were also detected, and reached maximum 
concentration at later times (tmax at 8h and 2h, respectively).  
b 
c 
e 
d 
a 
Figure 5. Pharmacokinetic profiles after 
oral administration of resveratrol 
derivatives (2-6). Data represent average 
values + standard deviation. N = 3 in all 
cases 
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Absorption of disubstituted derivatives was rapid, with the unmodified prodrug peaking 
in blood about 30 minutes after gavage. Administration of the 3,4’-(dihydroxypropyl) 
derivative (4) resulted in detectable levels of two of the possible glucuronides of 2 and 3 
namely the ones with r.t. 2.35 and 2.38 min; no other intermediate products were 
detected. On the other hand, administration of the 3,5-(dihydroxypropyl) isomer (5) 
resulted in appearance of 3 and of its glucuronide with r.t. 2.38 min.  
6-Deoxygalactosyl carbamate ester derivatives 
Pharmacokinetic determinations provided no evidence of absorption for 3,4’,5- and 3,5-
derivatives (11 and 10) after oral administration.  
Fig 4 shows the pharmacokinetic profiles of 3,4’-, 3- and 4’- substituted derivatives (9, 8 
and 7 respectively). Compounds were generally poorly absorbed (fig 6, a). Absorption of 9 
was rapid, reaching 10 minutes after administration a low peak blood concentration, 
which then remained approximately constant for up to 2 hours. 8 reached an early peak 
in blood (fig 6B), with the concentration then decaying in an approximately exponential 
manner, down to undetectable levels after about 4 hours. The 4’-substituted derivative 
(7) again differed significantly from its isomer: it showed a delayed absorption with the 
maximum concentration of total species in blood reached at approximately 2 hours after 
administration. Metabolites or resveratrol could not be reliably identified in any 
pharmacokinetic run with deoxygalactosyl carbamate ester derivatives.  
Figure 6. Pharmacokinetic profiles after 
oral administration of resveratrol 6-
deoxygalactosyl derivatives 7-9. Data 
represent average values + standard 
deviation. N = 3 in all cases.  
a b 
c 
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Intestinal Levels. The highly soluble derivative 11 did not enter systemic circulation after 
oral administration.  Poor intestinal absorption may however be expected to result in high 
levels in the lumen of the lower intestinal tract, suggesting possible applications  for the 
treatment of intestinal disorders.  
After chronic administration, a striking difference was observed in the intestinal fate of 
resveratrol and 11: in the colon and caecum the former was present mainly as its 
bacterial metabolite dihydroresveratrol (fig 7), while the latter was mainly present as 
partially hydrolyzed derivatives (fig 8). Low amounts of resveratrol and dihydroresveratrol 
were also detected. 
Conclusions: 
The new resveratrol derivatives presented here proved to have a satisfactory reactivity vs. 
chemical hydrolysis. In particular, they are stable in acid solution, and can therefore 
survive the gastric stage. In near-neutral solution and blood the rate of hydrolysis is 
relatively slow. In vivo experiments they displayed satisfactory adsorption in the case of 
mono-substituted dihydroxypropyl derivatives (2, 3). Remarkably, sulphated metabolites 
were below detection limits in all cases. We were also unable to confirm formation of the 
products expected to arise from glucuronidation of di-protected species, while the 
compounds bearing only one promoiety could be acted upon by glucuronyltransferase 
activities in vivo.  
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Figure 7. Resveratrol and its 
metabolites in the lower 
intestine of rats after 
chronic administration. a) 
Amounts of resveratrol 
dihydroresveratrol and 
resveratrol sulfates in 
caecum and colon after 48h 
of chronic treatment with 
approx. 220 µmol/kg×day of 
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Derivatives comprising the 6-deoxygalactose moiety (7-11) are more hydrophilic, and thus 
less permeable than derivatives 2-6 which incorporate the dihydroxypropyl moiety. The 
trisubstituted compound 11 is the most soluble, and was not absorbed in the 
gastrointestinal tract; however, interestingly, chronic administration of this compound 
resulted in its accumulation in the intestine. The presence in colon and caecum of 
partially hydrolyzed derivatives of 11 suggests protracted gradual release of intact 
resveratrol, which would be expected to be rapidly reduced to dihydroresveratrol by 
bacterial enzymes. These findings suggest a possible use of glycosyl-resveratrol 
derivatives for the treatment of colitis and prevention of colon cancer. 
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Appendix: 
Synthesis of derivatives 2-9 
Derivatives were synthesized by the group of prof. Cristina Paradisi, Department  of Chemical 
Sciences, University of Padova. 
[N-(2,2-dimethyl-1,3-dioxolane-4-methan)-carbamoyl]-4-nitrophenol (13): Bis-4-(nitrophenyl) 
carbonate (3.47 g, 11.4 mmol, 1 eq.) in 20 mL of anhydrous THF and DMAP (2.79 g, 22.8 mmol, 2 
eq.) were mixed in a 100 mL round-bottom flask with a magnetic stirrer under N2. 2,2-dimethyl-
1,3-dioxolane-4-methanamine (12, 1.5 g, 11.4 mmol, 1 eq.) in THF (20 mL) was then added 
dropwise at RT. After three hours the mixture was taken up in EtOAc (150 mL), transferred to a 
500 mL separation funnel and washed with 0.5 M HCl (3 × 150 mL). The organic phase was then 
dried over MgSO4 and filtered. The solvent was evaporated under reduced pressure and the 
residue was purified by flash chromatography on silica gel (eluent: CH2Cl2/EtOAc, 9.5:0.5) to 
afford 13 (75% yield). 1H-NMR (250 MHz, CDCl3) δ (ppm): 1.38 (s, 3H, -CH3), 1.48 (s, 3H, -CH3), 
3.28-3.61 (m, 2H, -NH-CH2), 3.70-4.14 (m, 2H, -CH2-), 4.28-4.37 (m, 1H, -CH-), 7.32 (d, 2H, Ar-H, 
3JH-
H: 9.25 Hz), 8.25 (d, 2H, Ar-H, 
3JH-H: 9.25 Hz); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 155.7, 153.3, 
144.7, 125.1, 121.9, 109.6, 74.2, 66.5, 43.6, 26.7, 25.0; ESI-MS (ion trap): m/z 297 [M+H]+. 
(4’-mono-, 3-mono-, 3,4’-di-, 3,5-di-, 3,4’,5-tri-) [N-(2,2-dimethyl-1,3-dioxolane-4-methan)-
carbamoyl]-resveratrol (14-18): 13 (1.24 g, 4.2 mmol, 2.6 eq.) and pyridine (10 mL) were placed in 
a 100 mL round-bottom flask with magnetic stirrer and under N2. Resveratrol (1, 0.37 g, 1.6 mmol, 
1.0 eq.) and DMAP (0.79 g, 6.4 mmol, 4.0 eq.) in pyridine (10 mL) was added and the reaction was 
allowed to proceed at 70°C overnight. The mixture was then taken up with 150 mL of EtOAc, 
transferred to a separation funnel and washed with 0.5 M HCl (5 × 150 mL). The organic phase 
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was then dried over MgSO4 and filtered. The solvent was evaporated under reduced pressure. The 
resulting solid was purified by flash chromatography (eluent: CH2Cl2/Acetone, 7.5:2.5) to afford 
0.57 g of a mixture of 14-18 used as such for the subsequent synthetic step. ESI-MS (ion trap): 14, 
15: m/z 386 [M+H]+; 16, 17: m/z 543 [M+H]+; 18: m/z 700 [M+H]+. 
(4’-mono-, 3-mono-, 3,4’-di-, 3,5-di-, 3,4’,5-tri-)[N-(2,3-dihydroxypropyl)-carbamoyl]-resveratrol 
conjugates (2-6):  The mixture (14-18, 0.57 g) obtained in the previous step was added to a 
solution of TFA/water (90:10, 5 mL). The resulting mixture was vigorously stirred for 1.5 h at RT 
and then dried under vacuum. The residue was then separated by preparative HPLC (from 0% to 
40% ACN in 17 minutes) and lyophilized to afford derivatives: 2 (0.129 g, cumulative yield of the 
final two steps: 23%), 3 (0.068 g, cumulative yield of the final two steps: 12%), 4 (0.135 g, 
cumulative yield of the final two steps: 18%), 5 (0.038 g, cumulative yield of the final two steps: 
5%) and 6 (0.085 g, cumulative yield of the final two steps: 9%). 
2: 1H-NMR (250 MHz, DMSO-d6) δ (ppm): 2.95-3.25 (m, 2H, -CH2-), 3.35 (d, 2H, 
3JH-H = 5.25 Hz, -
CH2-), 3.51-3.66 (m, 1H, -CH-), 6.17 (t, 1H, 
4JH,H = 2.0 Hz, H-4), 6.45 (d, 2H, 
4JH,H = 2.0 Hz, H-2, H-6), 
7.03-7.10 (m, 4H, H-3’, H-5’, H-7, H-8), 7.57 (d, 2H, 3JH-H = 8.5 Hz, H-2’, H-6’), 7.65 (t, 1H, 
3JH-H = 5.75 
Hz, -N-H); 13C-NMR (62.9 MHz, DMSO-d6) δ (ppm): 158.5, 154.5, 150.5, 138.8, 133.8, 128.6, 127.2, 
127.1, 121.9, 104.7, 102.3, 70.3, 63.8, 44.1; ESI-MS (ion trap): m/z 346 [M+ H]+. 
3: 1H-NMR (250 MHz, DMSO-d6) δ (ppm): 2.93-3.23 (m, 2H, -CH2-), 3.34 (d, 2H, 
3JH-H = 5.25 Hz, -
CH2-), 3.52-3.61 (m, 1H, -CH-), 6.38 (t, 1H, 
4JH,H = 2.0 Hz, H-4), 6.73-6.78 (m, 4H, H-2, H-6, H-3’, H-
5’), 6.90 (d, 1H, 3JH-H = 16.5, H-7), 7.07 (d, 1H, 
3JH-H = 16.5, H-8), 7.42 (d, 2H, 
3JH-H = 8.75, H-2’, H-6’), 
7.58 (t, 2H, 3JH-H = 5.75 Hz, 2 × -N-H); 
13C-NMR (62.9 MHz, DMSO-d6) δ (ppm): 158.0, 157.4, 154.5, 
152.2, 139.3, 128.9, 128.0, 127.8, 124.6, 115.5, 110.0, 109.7, 107.8, 70.3, 63.8, 44.0; ESI-MS (ion 
trap): m/z 346 [M+ H]+. 
4: 1H-NMR (250 MHz, DMSO-d6) δ (ppm): 
1H-NMR (250 MHz, DMSO-d6) δ (ppm): 2.95-3.25 (m, 4H, 
2 × -CH2-), 3.36 (d, 4H, 
3JH-H = 5.25 Hz, 2 × -CH2-), 3.53-3.62 (m, 2H, -CH-), 6.41-6.43 (m, 1H, H-4), 
6.77-6.80 (m, 2H, H-2, H-6), 7.02-7.19 (m, 4H, H-3’, H-5’, H-7, H-8), 7.52-7.61 (m, 4H, 2 × -NH-, H-
2’, H-6’); 13C-NMR (62.9 MHz, DMSO-d6) δ (ppm): 158.1, 154.5, 154.4, 152.2, 150.6, 138.7, 133.6, 
128.0, 127.6, 127.3, 121.9, 110.3, 110.1, 108.4, 70.2, 70.3, 63.7, 44.0; ESI-MS (ion trap): m/z 463 
[M+H]+. 
5: 1H-NMR (250 MHz, CDCl3) δ (ppm): 
1H-NMR (250 MHz, DMSO-d6) δ (ppm): 2.96-3.25 (m, 4H, 2 × 
-CH2-), 3.36 (d, 4H, 
3JH-H = 5.25 Hz, 2 × -CH2-), 3.54-3.63 (m, 2H, 2 × -CH-), 6.64-6.80 (m, 3H, H-4, H-
2, H-6), 6.97-7.24 (m, 4H, H-3’, H-5’, H-7, H-8), 7.40 (d, 2H, 3JH-H = 8.5 Hz, H-2’, H-6’), 7.70 (t, 2H, 
3JH-
H = 5.75 Hz, 2 × -N-H); 
13C-NMR (62.9 MHz, DMSO-d6) δ (ppm): 157.6, 154.3, 151.8, 139.4, 130.0, 
128.2, 127.7, 123.7, 115.8, 115.6, 114.0, 70.3, 63.8, 44.2; ESI-MS (ion trap): m/z 463 [M+H]+. 
6: 1H-NMR (250 MHz, CDCl3) δ (ppm): 
1H-NMR (250 MHz DMSO-d6) δ (ppm): 2.94-3.25 (m, 6H, 3 × 
-CH2-), 3.35 (d, 6H, 
3JH-H = 5.25 Hz, 3 × -CH2-), 3.53-3.62 (m, 3H, 3 × -CH-), 6.78 (t, 1H, 
4JH,H = 2.0 Hz, 
H-4), 7.10-7.36 (m, 6H, H-2, H-6, H-3’, H-5’, H-7, H-8), 7.59-7.74 (m, 5H, H-2’, H-6’, 3 × -N-H); 13C-
NMR (62.9 MHz, DMSO-d6) δ (ppm): 154.4, 154.2, 151.7, 150.8, 138.8, 133.5, 129.1, 127.5, 126.7, 
122.0, 116.2, 114.6, 70.3, 63.8, 44.1; ESI-MS (ion trap): m/z 580 [M+H]+. 
(1,2:3,4-di-O-isopropylidene-6-O-(p-toluensulfonate))-α-D-galactopiranose (20): Pyridine (3.1 
mL, 38.4 mmol, 2.0 eq.) and DMAP (3.51 g, 28.7 mmol, 1.5 eq.) were added to a solution of 
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1,2:3,4-di-O-isopropylidene-α-D-galactopiranose (19, 5.0 g, 19.2 mmol, 1.0 eq.) in CH2Cl2 (20 mL), 
and the mixture was stirred at 0°C for 15 min. A solution of tosyl chloride (5.49 g, 28.7 mmol, 1.5 
eq.) in CH2Cl2 (20 mL) was then added dropwise and the mixture was stirred at room temperature 
for 5 hours. After adding H2O (30 mL), the mixture was diluted in CH2Cl2 (150 mL) and washed 
with 0.5 N HCl (5 × 100 mL). The organic layer was dried over MgSO4 and filtered. The solvent was 
evaporated under reduced pressure and the residue was purified by flash chromatography 
(eluent: CH2Cl2/EtOAc, 9:1) to afford 7.33 g of 20 (92 % yield). 
1H-NMR (250 MHz, CDCl3) δ (ppm): 
1.26 (s, 3H, -C-CH3), 1.30 (s, 3H, -C-CH3), 1.33 (s, 3H, -C-CH3), 1.49 (s, 3H, -C-CH3), 2.43 (s, 3H, Ar-
CH3), 4.00-4.20 (m, 4H, H-4, H-5, H-6), 4.28 (dd, 1H, 
3J3-2 = 2.5 Hz, 
3J3-4 = 2.5 Hz, H-3), 4.57 (dd, 1H, 
3J2-1 = 2.5 Hz, H-2), 5.44 (d, 1H, 
3J1-2 = 5 Hz, H-1), 7.32 (d, 2H, Ar-H, 
3JH-H = 10 Hz), 7.80 (d, 2H, 
3JH-H = 
7.5 Hz); 13C-NMR (62.9 MHz, CDCl3) δ (ppm): 144.7, 132.7, 129.7, 128.0, 109.5, 108.9, 96.0, 70.4, 
70.3, 70.3, 68.1, 65.8, 25.9, 25.7, 24.9, 24.3, 21.6; ESI-MS (ion trap): m/z 415 [M+H]+. 
(1,2:3,4-di-O-isopropylidene-6-deoxy-azido)-α-D-galactopiranose (21): Sodium azide (5.84 g, 89.8 
mmol, 5.0 eq.) was added to a solution of 20 (7.22 g, 17.4 mmol, 1.0 eq.) in DMSO (40 mL), and 
the mixture was stirred at 160 °C for 1.5 hours under nitrogen. The resulting mixture was poured 
into ice water (500 mL), and extracted with EtOAc (2 × 250 mL). The organic layer was dried over 
MgSO4 and filtered. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography (eluent: CH2Cl2/EtOAc, 97:3) to afford 4.60 g of 11 (93 % yield). 
1H-NMR (250 MHz, CDCl3) δ (ppm): 1.33 (s, 6H, 2 × -C-CH3), 1.44 (s, 3H, -C-CH3), 1.53 (s, 3H, -C-
CH3), 3.34 (dd, 1H, 
2J6*-6 = 12.5 Hz, 
3J6*-5 = 5 Hz, H-6*), 3.50 (dd, 1H, 
2J6-6* = 12.5 Hz, 
3J6-5 = 7.5 Hz, H-
6), 3.87-3.93 (m, 1H, H-5), 4.18 (dd, 1H, 3J4-3 = 2.5 Hz, 
3J4-5 = 7.5 Hz, H-4), 4.31 (dd, 1H, 
3J3-2 = 2.5 Hz, 
3J3-4 = 2.5 Hz, H-3), 4.61 (dd, 1H, 
3J2-1 = 7.5 Hz, 
3J2-3 = 2.5 Hz, H-2), 5.53 (d, 1H, 
3J1-2 = 5 Hz, H-1); 
13C-
NMR (62.9 MHz, CDCl3) δ (ppm): 109.5, 108.7, 96.3, 71.0, 70.7, 70.3, 66.9, 50.6, 25.9, 25.9, 24.8, 
24.3; ESI-MS (ion trap): m/z 286 [M+H]+. 
(1,2:3,4-di-O-isopropylidene-6-deoxy-amino)-α-D-galactopiranose (22): A solution of 
triphenylphosphine (5.49 g, 20.9 mmol, 1.3 eq.) in THF (35 mL) was added dropwise to a solution 
of 21 (4.60 g, 16.1 mmol, 1.0 eq.) in THF (60 mL), and the mixture was stirred at RT for 4 hours 
under nitrogen. Distilled water (25 mL) was then added and the resulting mixture was heated to 
reflux and vigorously stirred for 15 hours. Solvents were removed under vacuum and the residue 
was purified by flash chromatography (eluent: CH2Cl2/MeOH, 95:5 + 1% of triethylamine) to afford 
4.05 g of 22 (97 % yield). 1H-NMR (250 MHz, CDCl3) δ (ppm): 1.32 (s, 6H, 2 × -C-CH3), 1.34 (s, 2H, -
NH2), 1.43 (s, 3H, -C-CH3), 1.51 (s, 3H, -C-CH3), 2.82 (dd, 1H, 
2J6*6 = 15 Hz, 
3J6*-5 = 5 Hz, H-6*), 2.95 
(dd, 1H, 2J6-6* = 12.5 Hz, 
3J6-5 = 7.5 Hz, H-6), 3.65-3.71 (m, 1H, H-5), 4.21 (dd, 1H, 
3J4-3 = 7.5 Hz, 
3J4-5 = 
2.5 Hz, H-4), 4.30 (dd, 1H, 3J3-2 = 5 Hz 
3J3-4 = 2.5Hz, H-3), 4.58 (dd, 1H, 
3J2-1 = 10 Hz, 
3J2-3 = 2.5 Hz, H-
2), 5.53 (d, 1H, 3J1-2 = 2.5Hz, H-1); 
13C-NMR (62.9 MHz, CDCl3) δ (ppm): 109.1, 108.4, 96.3, 71.7, 
70.7, 70.5, 69.4, 42.3, 26.0, 25.9, 24.9, 24.3; ESI-MS (ion trap): m/z 260 [M+H]+. 
[N-(1,2:3,4-di-O-isopropylidene-6-deoxy-α-D-galactopyranosyl)-carbamoyl]-4-nitrophenol (23): 
A solution of 22 (1.0 g, 3.9 mmol, 1.0 eq.) in THF (15 mL) was added dropwise to a solution of bis 
(4-nitrophenyl) carbonate (1.17 g, 3.9 mmol, 1.0 eq.) and DMAP (1.01 g, 7.8 mmol, 2.0 eq.) in THF 
(20 mL) and the mixture was stirred at RT for 5 hours. The resulting mixture was diluted in EtOAc 
(150 mL) and washed with 0.5 N HCl (3 × 100 mL). The organic layer was dried over MgSO4 and 
filtered. The solvent was evaporated under reduced pressure and the residue was purified by 
flash chromatography (eluent: CH2Cl2/Hexane, 75:25) to afford 1.27 g of 23 (78 % yield). 
1H-NMR 
(250 MHz, CDCl3) δ (ppm): 1.34 (s, 3H, -C-CH3), 1.35 (s, 3H, -C-CH3), 1.46 (s, 3H, -C-CH3), 1.51 (s, 
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3H, -C-CH3), 3.34-3.44 (m, 1H, H-6*), 3.55-3.65 (m, 1H, H-6), 3.95-4.01 (m, 1H, H-5), 4.23 (dd, 1H, 
3J4-3 = 10 Hz, 
3J4-5 = 2.5 Hz, H-4), 4.34 (dd, 1H, 
3J3-2 = 2.5 Hz, 
3J3-4 = 5 Hz, H-3), 4.63 (dd, 1H, 
3J2-1 = 7.5 
Hz, 3J2-3 = 2.5 Hz, H-2), 5.55 (d, 1H, 
3J1-2 = 5 Hz, H-1), 5.60 (dd, 1H, 
3JNH-6* = 7.5 Hz, JNH-6 = 5 Hz, -NH), 
7.28-7.32 (m, 2H, H-2’, H-6’), 8.21-8-25 (m, 2H, H-3’, H-5’); 13C-NMR (250 MHz, CDCl3) δ (ppm): 
155.9, 153.3, 144.7, 125.0, 121.9, 109.5, 108.8, 96.3, 71.5, 70.7, 70.4, 66.0, 41.8, 26.0, 25.9, 24.9, 
24.3; ESI-MS (ion trap): m/z 425 [M+H]+. 
(4’-mono-, 3-mono-, 3,4’-di-, 3,5-di-, 3,4’,5-tri-)-[N-(1,2:3,4-di-O-isopropylidene-6-deoxy-α-D-
galactopyranosyl)-carbamoyl]-resveratrol (24-28): A solution of resveratrol (0.15 g, 0.66 mmol, 
1.0 eq.) and DMAP (0.32 g, 2.64 mmol, 4.0 eq.) in pyridine (10 mL) was added to a solution of 23 
(1.13 g, 2.7 mmol, 4.0 eq.) in pyridine (10 mL) and the resulting mixture was allowed to react 
under vigorous stirring at 70°C for 16 hours. The reaction mixture was then diluted in EtOAc (200 
mL) and washed with 0.5 N HCl (5 × 150 mL). The organic layer was dried over MgSO4 and filtered. 
The solvent was evaporated under reduced pressure and the residue was purified by flash 
chromatography using EtOAc:Hexane 5.5:4.5 as eluent to afford 0.39 g of a mixture of 24-28 used 
as such for the subsequent synthetic step. ESI-MS (ion trap): 24, 25: m/z 514 [M+H]+; 26, 27: m/z 
799 [M+H]+; 28: m/z 1084 [M+H]+. 
(4’-mono-, 3-mono-, 3,4’-di-, 3,5-di-, 3,4’,5-tri-)-[N-(6-deoxy-galactosyl)-carbamoyl]-resveratrol 
(7-11) 
The mixture (24-28, 0.39 g) obtained in the previous step was added to a solution of TFA/water 
(90:10, 3 mL) and vigorously stirred at RT. After 1.5 hours the resulting mixture was precipitated 
with 40 mL of diethyl ether, the material was centrifuged and the solvent was decanted. The 
white powder obtained was then washed with diethyl ether three more times to eliminate traces 
of TFA. The residue was then dried under vacuum, separated by preparative HPLC (from 0% to 
38% ACN in 17 minutes) and lyophilized to afford derivatives: 7 (0.040 g, cumulative yield of the 
final two steps: 14%), 8 (0.023 g, cumulative yield of the final two steps: 8%), 9 (0.093 g, 
cumulative yield of the final two steps: 22%), 10 (0.025 g, cumulative yield of the final two steps: 
6%) and 11 (0.094 g, cumulative yield of the final two steps: 17%). 
7: 1H-NMR (600 MHz, DMSO-d6) δ(ppm): 8.00 (t, 1H, JNH-6*= JNH-6 = 6 Hz, -NH-), 7.56 (d, 2H, J2’’-3’’ = 
12 Hz, H-2’’, 6’’), 7.07 (d, 2H, J3’’-2’’ = 6 Hz, H-3’’, 5’’ ), 7.10-7.31 (m, 2H, H-8, 9), 6.43 (s, 2H, H-2’, 6’), 
6.15 (s, 1H, H-4’), 4.89-5.00 (m, 1H, H-1), 4.24-3.17 (m, 12H, H-2, 3, 4, 5, 6, 6*, 6 OH); 13C-NMR 
(151 MHz, DMSO-d6) δ (ppm): 158.6, 154.5, 150.5, 138.8, 133.9, 128.7, 127.3, 127.1, 121.9, 104.7, 
102.4, 97.6, 92.7, 73.3, 72.4, 71.9, 69.5, 69.2, 68.9, 68.6, 68.0, 41.8, 41.6; ESI-MS (ion trap): m/z 
434 [M+H]+. 
8: 1H-NMR (600 MHz, DMSO-d6) δ (ppm): 7.68 (t, 1H, JNH-6*= JNH-6 = 6 Hz, -NH- ), 7.41 (d, 2H, J2’’-3’’= 6 
Hz, H-2’’, 6’’), 6.16-7.08 (m, 7H, H-3’’,5’’, 2’, 4’, 6’, 8, 9), 3.17-4.95(m, 13H, H-1, 2, 3, 4, 5, 6, 6*,6 
OH); 13C-NMR (151 MHz, DMSO-d6) δ (ppm): 158.5, 157.9, 154.9, 152.6, 139.8, 129.4, 128.4, 
128.3, 125.0, 115.9, 115.5, 115.1, 114.8, 110.4, 110.2, 108.2, 97.9, 93.1, 73.7, 72.8, 72.3, 69.9, 
69.6, 69.3, 69.0, 68.5, 42.1, 42.0; ESI-MS (ion trap): m/z 434 [M+H]+. 
9: 1H-NMR (600 MHz, DMSO-d6) δ (ppm): 7.71 (m, 2H, -NH-), 7.58 (d, 2H, J2’’-3’’= 6 Hz, H-2’’, 6’’), 
7.08-7.18 (m, 4H, H-3’’5’’, 8, 9), 6.81 (s, 1H, H-2’), 6.79 (s, 1H, H-4’), 6.41 (s, 1H, H-6’), 4.94-5.01 
(m, 2H, 2 × H-1), 3.18-4.26 (m, 22H, 2 × H-1, 2, 3, 4, 5, 6, 6*, 8 OH); 13C-NMR (151 MHz, DMSO-d6) 
δ (ppm): 158.2, 154.5, 154.5, 152.3, 150.6, 138.9, 133.7, 128.2, 127.7, 127.4, 121.9, 110.4, 110.2, 
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108.4, 101.7, 97.5, 97.5, 92.7, 82.6, 82.2, 76.2, 73.3, 73.3, 72.4, 72.4, 72.0, 71.9, 69.5, 69.2, 68.9, 
68.6, 68.1, 68.0, 41.7, 41.6; ESI-MS (ion trap): m/z 639 [M+H]+. 
10: 1H-NMR (600 MHz, DMSO-d6) δ (ppm): 7.74 (t, 2H, JNH-6*= JNH-6 = 6 Hz, -NH-), 7.42 (d, 2H, J2’’-3’’= 
6 Hz, H-2’’, 6’’), 6.97-7.18 (m, 4H, H-3’’5’’, 8, 9), 6.79 (s, 1H, H-2’), 6.76(s, 1H, H-4’), 3.07-4.24 (m, 
23H, H-6’, 2 × H-1, 2, 3, 4, 5, 6, 6*, 8 OH); 13C-NMR (151 MHz, DMSO-d6) δ (ppm): 157.6, 154.3, 
154.2, 151.7, 151.7, 130.1, 130.0, 128.2, 127.8, 115.6, 115.3, 97.5, 97.5, 92.7, 73.3, 73.3, 72.4, 
71.9, 71.9, 69.4, 69.3, 68.9, 68.8, 68.6, 68.0, 41.8, 41.7, 41.6. ESI-MS (ion trap): m/z 639 [M+H]+. 
11: 1H-NMR (600 MHz, DMSO-d6) δ (ppm): 7.68-7.81 (m, 3H, -NH-), 7.60 (d, 2H, J2’’-3’’= 6 Hz, H-2’’, 
6’’), 7.11-7.33 (m, 6H, H-3’’5’’, 8, 9, 2’, 6’), 6.78 (s, 1H, H-4’), 2.98-4.95 (m, 33H, 3 × H-1, 2, 3, 4, 5, 
6, 6*, 12 OH); 13C-NMR (151 MHz, DMSO-d6) δ (ppm): 154.4, 154.2, 151.7, 150.8, 138.9, 134.5, 
133.5, 129.2, 127.5, 126.7, 122.0, 116.3, 101.7, 97.5, 92.7, 82.6, 82.1, 76.1, 73.3, 72.4, 71.9, 69.4, 
69.2, 68.9, 68.6, 68.0, 68.0, 41.8, 41.7. ESI-MS (ion trap): m/z 845 [M+H]+. 
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Synthesis of pterostilbene-4’-sulfate (Pt-S) 
Chlorosulfonic acid (0.128 g, 1.10 mmol, 5.0 eq.) in acetonitrile (0.5 mL) was added 
dropwise to a vigorously stirred solution of pterostilbene (Pt, 0.056 g, 0.22 mmol, 1.0 eq.) 
and pyridine (0.5 mL) in acetonitrile (2.0 mL) in a 50 mL conical centrifugation tube 
(FalconTM type) at -20 °C. The reaction mixture was allowed to warm to room temperature. 
After 16 h the resulting reaction mixture was concentrated to about 1.5 mL under a weak 
nitrogen stream and solutes were precipitated with diethyl ether (40 mL). The slurry was 
then centrifuged (2200 rpm, 5 minutes) and the solvent decanted. The residue (a pale 
yellow gel) was dissolved in the minimum amount of acetonitrile and precipitation was 
repeated. The resulting solid was dissolved in 2 mL of water/methanol 1:1 and applied to a 
column (1.5 cm × 15.0 cm) of cation-exchange resin (Dowex 50WX8, K+ form, 10 g) and 
eluted with water. Fractions containing the desired product (identified by UV-detection on 
TLC) were combined and purified by reverse phase preparative HPLC using an ACE 5 AQ 
(150 mm × 21.2 mm) column and a flow rate of 17 mL/min (eluents: ACN and H2O; from 
10 to 60% ACN in 20 minutes; detection at 300 nm). Fractions containing the desired 
product were lyophilized to afford Pt-S as a bright white solid (0.062 g, 75%).  
Purity (HPLC/UV) ≥ 99%. 
1H NMR (500 MHz, DMSO) δ 7.50 (d, J = 8.6 Hz, 2H), 7.23 (d, J = 16.4 Hz, 1H), 7.18 (d, 
J = 8.6 Hz, 2H), 7.06 (d, J = 16.4 Hz, 1H), 6.76 (d, J = 2.0 Hz, 2H), 6.39 (t, J = 2.0 Hz, 
1H), 3.78 (s, 6H). 13C NMR (126 MHz, DMSO) δ 161.11, 153.79, 139.79, 132.23, 129.04, 
127.50, 127.47, 120.97, 104.70, 100.19, 55.65.  
HRMS (ESI-): m/z 335.0589 [M-H]-, calcd for C16H15O6S:.335.0595. 
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Quantification of analytes in blood and tissue samples 
The concentration of Pt or Pt-S in the original sample [A] was determined as follows: 
 
Where:  
• [A]m and [IS]m are the concentrations of analyte (A) or internal standard (IS), 
respectively, measured in the final/treated sample; 
• [IS]spike is the known concentration of IS in a solution of H2O:ACN, 1:1 spiked with 
the same amount of IS as in the sample before treatment; 
• AreaA,m and AreaIS,m are the HPLC peak area of the analyte or internal standard, 
respectively, measured in the final/treated sample; 
• AreaIS,spike is the HPLC peak area of IS, measured in the spiked H2O:ACN solution; 
• αA and αIS are the slopes of the calibration curves for A or IS, respectively, which 
correlates HPLC peak area with concentrations; 
• RA/IS is the ratio of recovery yields of A and IS, previously determined from 
samples spiked with known amounts of both A and IS (see below and Table 1). 
 
We can arguably assume that 1 g of tissue corresponds to 1 mL volume, and thus the 
concentration of analyte per gram of tissue lysate (nmol/g) can be approximated to 
concentration in µM units (i.e., nomol/mL). 
 
 
[A] = [A]m[IS]m
[IS]spike
1  
RA/IS
× ×
Recovery IS 
Recovery A =
AreaA,m
αA
= ×
αIS
AreaIS,m
AreaIS,spike
αIS
× × =
1  
RA/IS
AreaA,m
αA
= ×
AreaIS,spike
AreaIS,m
×
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Recovery yields 
To establish the recovery yields of Pt and Pt-S from blood and organs, the protocols for the 
treatment of blood or tissues were applied to samples spiked with a known amount of Pt or 
Pt-S.  
Recoveries of Pt, Pt-S and internal standard were determined as follows: 
 
Where: 
• [A]spike is the known concentration of the analyte (A) in a solution of H2O:ACN, 
1:1 spiked with the same amount of A as in the sample before treatment; 
• AreaA,spike is HPLC peak area of A, measured in the spiked H2O:ACN solution. 
All the other abbreviations are the same as described for analyte quantification in blood 
and tissue samples (see above).  
 
Recovery A 
Recovery IS
Area A,m
Area A,spike
Area IS,spike
Area IS,m
RA/IS =
AreaA,m
αA
αA
AreaA,spike×
AreaIS,m
αIS
αIS
AreaIS,spike×
=
=
=
×
=
[A]m
[A]spike
[IS]m
[IS]spike
Final volume
Initial volume×
Final volume
Initial volume =×
=
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Supporting Information Table 1. Comparison of pharmacokinetic data for resveratrol 
(Resv) and pterostilbene (Pt).  
a)
 some data were deduced from published graphs. 
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6. Boosting pterostilbene’s effects: a prodrug approach 
 
Abstract:  
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene, Pt) is the di-methylated analogue 
of Resveratrol (Rv). The methyl groups in positions 3 and 5 increase lipophilicity, 
bioavailability and efficacy. Pt is under investigation for its activity against metabolic 
disorders, neurodegenerative and cardiovascular diseases, inflammation, cancer. 
The bioavailability of Pt, while higher than that of Rv, is negatively affected by the free –
OH group in position 4’ which is an ideal target for the conjugative enzymes of phase II 
metabolism. As shown in Azzolini et al.,1 after an oral administration of Pt to fasted rats Pt 
sulphate was the major species in blood and organs. 
We thus aimed to lessen this problem by protecting the free –OH group of Pt. Our group 
has developed prodrug tools to reversibly protect the free phenolic functionalities of Rv 
(e.g. chapters 3 and 4). Here we present a series of Pt derivatives in which the hydroxyl is 
protected via a carbamoyl linkage to a natural aminoacid. The carbamoyl bond presents 
the stability characteristics required for prodrugs, and amino acids might a priori be 
recognized and used by amino acid transporters, thus boosting Pt absorption. 
Administration of derivatives of non-polar amino acids led to the best results. Absorption 
of the derivatives was high (blood concentrations in the range of 100 µM) and the release 
of Pt was important when isoleucine or β-alanine were used as promoiety. The Pt prodrug 
incorporating isoleucine was then used for further analysis, and the distribution in several 
organs of prodrug, Pt and Pt-sulfate was studied as a function of time after oral 
administration.  
The results indicate that in comparison to administration of Pt as such the prodrug 
affords: 
1. Increased absorption of the molecule 
2. Considerable reduction of metabolism 
3. Higher concentrations of pterostilbene, sustained for several hours, in most of the 
organs examined  
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Introduction: 
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene, Pt) is a di-methylated form of 
Resveratrol (3, 5, 4’-trihydroxy-trans-stilbene, Rv) found in blueberries and grapes. While 
Rv has been intensively studied because of its potential multi-faceted usefulness in many 
areas of human health care, Pt has only recently emerged as a therapeutic compound. 
The literature suggests that, apart from the structure, Rv and Pt share also many 
beneficial properties. Rv was addressed to be effective against type 2 diabetes2-5 and 
metabolic disease,6-8 cardiovascular diseases,9-11 inflammation,12-14 neurodegenerative 
disorders15-17 and cancer.18-23 Pt now is under intensive investigation for the same 
targets.24-27  
The mechanisms behind this multi-targeted activity of Pt are not fully understood, but the 
effects are in part ascribable to modulation of Nrf2/Keap1 signaling,28-30 inhibition of the 
NF-kB pathway31-34 and perhaps to regulation of gene expression through the 
MTA1/NuRD complex.35 
Pt was found to possess a higher efficacy compared to Rv in various investigations,36-38 a 
superiority possibly due to a higher bioavailability. Nutakul et al.38 have found that, in 
vitro, intracellular levels of Pt were 2-4 fold higher than those of Rv after an equimolar 
dose treatment. The presence of the two methyl groups indeed renders Pt more 
lipophylic than Resveratrol. Its greater lipophylicity may provide the explanation for its in 
vitro potency, attributable to an efficient permeation of membranes and/or interaction 
with target proteins. In vivo data agrees with those obtained in vitro: Pterostilbene shows 
a greater bioavailability compared to Resveratrol when orally administered.39  
However, the presence of the hydroxyl group in position 4’ renders Pt a good substrate 
for phase II metabolism enzymes. Depending on the model used, the major phase II 
metabolites found after Pt oral administration are sulfates and glucuronides. In our 
previous work1 we have demonstrated that, except for the brain, the main species found 
in major rat organs after an oral administration of Pt is the sulfate. Literature in general 
focuses on the activity of the aglicones, while attention for metabolites is very recent.40 In 
the following chapter we show that Pt and Rv can induce autophagy. Metabolites were 
also investigated for their role in autophagy. While the main species found in the colon, 
namely dihydro-Rv and dihydro-Pt, showed high efficacy in the induction of autophagy, 
similar to that of the corresponding aglicones, sulfates were in general less effective. 
Moreover, phase II metabolites are expected to be rapidly excreted and to be confined to 
aqueous compartments, thus excluding themselves from important sites of action such as 
the brain or adipose tissue. 
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Prodrugs might be a convenient tool to reduce Pt phase II metabolism and slow down its 
clearance, thus increasing its in vivo efficacy. Previous work by my research group has 
identified the carbamoyl bond as the most convenient linkage for prodrugs of Rv 
(chapters 3 and 4). The carbamoyl group in fact presents an elevated stability in an acid 
environment similar to that of the gastric mucosae, it is fairly stable at neutral pH, similar 
 
Isoleucine (Ile, 2) 
Leucine (Leu, 3) 
β-alanine (betaAla, 4) 
Valine (Val, 5) 
Aliphatics 
 
Aspartic acid (Asp, 9) 
Acidic ( - ) 
 
Arginine (Arg, 10) 
Basic ( + ) 
 
Phenylalanine (Phe, 6) 
Aromatic 
 
Asparagine (Asn, 7) 
Threonine (Thr, 8) 
Hydrophilic 
Fig 1: Pt (1) was protected at the hydroxyl group by chemical derivatization. The aminoacids 
shown were attached to the stilbenoid structure via a carbamoyl bond linking the α-amino 
group and the phenolic oxygen, producing the corresponding derivatives 2-10 
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to that of the intestinal mucosae, and it is hydrolyzed with opportune kinetics in blood. 
However, we have noticed that a multiple substituent pattern may be an obstacle for the 
permeation of derivatives through the intestinal walls.  
In chapter 4 indeed we obtained the best results (sum of prodrugs + phase II metabolites) 
when we administered mono-substituted derivatives. In so doing unfortunately two of 
the three hydroxyl’s groups of Rv were exposed to phase II enzymes. Pt carries only one 
free hydroxyl group, so in a carbamate prodrug the obstacle to absorption should be 
limited. We have also previously tested several substituent groups (chapters 3 and 4). 
Natural amino acids can be considered the most convenient: they are indeed safe, 
present several transporters that might enhance the absorption of our derivatives and 
their structure facilitates the chemical synthesis of derivatives comprising the carbamoyl 
bond. 
Here we present the synthesis and the characterization of a series of derivatives of Pt 
comprising the carbamoyl bond system and an amino acid (fig 1).  
Materials and Methods: 
Chemicals and general chemistry procedures. Pterostilbene was purchased from Waseta 
Int. Trading Co. (Shangai, P.R.China). Other starting materials and solvents were obtained 
from Wonda Science, Sigma Aldrich, Fluka & Riedel-de Haen, Carlo Erba Reagenti, Iris 
Biotech, Cambridge Isotope Laboratories Inc., Acros Organics, Prolabo, Merck-
Novabiochem, J.T. Baker,  and were used as received. 
TLCs were run on silica gel supported on plastic (Macherey-Nagel Polygram ® SIL 
G/UV254, silica thickness 0.2 mm) and visualized by UV detection using a Spectroline 
NMS-240 lamp. Purifications were performed by flash chromatography on silica gel 
(Macherey-Nagel 60, 230-400 mesh granulometry 0.063-0.0040 mm) under air pressure 
or by the automated chromatography system BÜCHI Sepacore® flash system X10 or by 
preparative HPCL using a Shimadzu LC-8A with UV-Vis spectrophotometric detection and 
an inverse phase column (C18-functionalized silica) ACE 5 AQ, 150x21,2 mm. 
Mass spectrometry analyses were performed by Agilent Technologies MSD SL Trap with 
an electrospray source and ion trap analyzer. A Phenomenex® Gemini 3u 110A column 
was used for HPLC-ESI/MS separations. 
NMR spectra were recorded with a Bruker AC 200F spectrometer operating at 200 MHz 
(for 1H-NMR) and 50 MHz (for 13C-NMR), or a Bruker AV300 FT-NMR UltraShield operating 
at 300 MHz (for 1H-NMR) and 75 MHz (for 13C-NMR), or a Bruker AVII500 UltraShield 
operating at 500 MHz (for 1H-NMR) and 126 MHz (for 13C-NMR).  
Syntheses were carried out by the group of Prof. C. Paradisi (Dept. of Chemical Sciences) 
and are described in the Appendix. 
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Animals. Adult male Wistar rats (approximately 400 g body weight) from the facility of 
the Department of Biomedical Sciences were used for pharmacokinetic experiments. All 
experiments involving animals were performed after approval by the University of Padova 
Ethical Committee for Experimentation on Animals (CEASA) (Permit Number: 80/2011) 
and by the Italian Ministry of Health, and with the supervision of the Central Veterinary 
Service of the University of Padova, in compliance with Italian Law DL 116/92, embodying 
UE Directive 86/609.  
HPLC-UV Analysis. Samples (2 µl) were analyzed by HPLC/UV (1290 Infinity LC System, 
Agilent Technologies) using a reverse phase column (Zorbax RRHD Eclipse Plus C18, 1.8 
µm, 50 x 2.1 mm i.d.; Agilent Technologies) and a UV diode array detector (190-500 nm). 
Solvents A and B were water containing 0.1% trifluoroacetic acid (TFA) and acetonitrile, 
respectively. The gradient for B was as follows: 10% (0.5 min) then from 10% to 100% in 5 
min; the flow rate was 0.6 mL/min. The eluate was preferentially monitored at 286, 300 
and 320 nm (corresponding to absorbance maxima of the internal standard, 
derivatives/metabolites and pterostilbene, respectively). The column compartment was 
maintained at 35°C.  
Hydrolysis Reactions. The chemical stability of all new compounds was tested in aqueous 
media approximating gastric (0.1 N HCl, NormaFix) and intestinal (0.1 M PBS buffer, pH 
6.8) pH values. A 5 µM solution of the compound was prepared from a 5 mM stock 
solution in DMSO, and incubated at 37°C for 24 hours; samples withdrawn at different 
times were analyzed by HPLC-UV. Hydrolysis products were identified by comparison of 
chromatographic retention time with true samples. Non-linear curve fitting was 
performed using Origin 8.0 data analysis software; the hydrolysis reaction rate constants 
(k) of the starting compounds were calculated through interpolation of data with the 
equation for pseudo-first order reactions:  = 
	, where: 
[C ] : concentration of the compound 
[C ]0 : concentration of the compound at the initial time t0 
t: time. 
Hydrolysis in blood. Rats were anesthetized and blood was withdrawn from the jugular 
vein, heparinized and transferred into tubes containing EDTA. Blood samples (1 mL) were 
spiked with compound (5 µM; dilution from a 5 mM stock solution in DMSO), and 
incubated at 37°C for 4 hours (the maximum period allowed by blood stability). Aliquots 
were taken after 10 min, 30 min, 1 h, 2 h and 4 h and treated as described below. Cleared 
blood samples were finally subjected to HPLC-UV analysis. 
Blood Sample Treatment and Analysis. Before starting the treatment, 4,4’-
dihydroxybiphenyl was added as internal standard to a carefully measured blood volume 
(25 µM final concentration). Blood was then stabilized with a freshly-prepared 10 mM 
solution of ascorbic acid (0.1 vol) and acidified with 0.6 M acetic acid (0.1 vol); after 
mixing, an excess of acetone (4 vol) was added, followed by sonication (2 min) and 
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centrifugation (12,000 g, 7 min, 4°C). The supernatant was finally collected and stored at -
20°C. Before analysis, acetone was allowed to evaporate at room temperature using a 
Univapo 150H (UniEquip) vacuum concentrator centrifuge, and up to 40 µL of CH3CN 
were added to precipitate residual proteins. After centrifugation (12,000 g, 5 min, 4°C), 
cleared samples were directly subjected to HPLC-UV analysis.  
Metabolites and hydrolysis products were identified by comparison of chromatographic 
retention time with true samples. 
The recovery yields of pterostilbene and its metabolite have been reported previously.1 
The recovery yields of the new prodrugs were obtained following the same protocol and 
are listed in table 1. Briefly, the recovery yield of each analyte was calculated as the ratio 
of the amount recovered to that of recovered internal standard. Knowledge of these 
ratios allowed us to determine the amount of analyte in a blood/organ sample by 
measuring the recovery of the internal standard (see 41). 
Pharmacokinetics Studies:  
Blood. Derivatives 2-10 were administered to overnight-fasted male rats as a single 
intragastric dose (88 µmol/Kg, dissolved in 250 µl DMSO). Blood samples were obtained 
by the tail bleeding technique: before drug administration, rats were anesthetized with 
isoflurane and the tip of the tail was cut off; blood samples (80-100 µL each) were then 
taken from the tail tip at different time points after drug administration. Blood was 
collected in heparinized tubes, kept in ice and treated as described above (blood sample 
treatment and analysis) within 10 min.  
Organ distribution. The organ distribution profile of derivative 2 was determined as 
described in Azzolini et al.1 Briefly, after a single intragastric oral administration of the 
derivative (same procedure as for blood pharmacokinetic determinations) animals were 
anesthetized with isoflurane and sacrificed (N = 3 or 4 for each time point). Blood was 
collected in heparinized tubes, kept in ice and treated as described above within 10 min. 
Brain, lungs, heart, liver, kidneys, testes and skeletal muscles (soleus, gastroctemius and 
anterior tibialis) were explanted, weighed and immediately frozen in liquid nitrogen.  1 g 
of thawed tissue was mixed with 1 mL of D-PBS (Euroclone), and homogenized with a 
motorized polypropylene pestel (Sigma, for brain and testes) or with an Ultra-Turrax T25 
homogenizer (Janke & Kunkel, for all other tissues). 200 mg of tissue homogenate were 
transferred into a vial and spiked with the internal standard (4,4’-dihydroxybiphenyl, 
dilution from a 50× stock solution in acetonitrile, 25 nmol/g tissue final concentration). 10 
µL of a freshly-prepared 10 mM solution of ascorbic acid, 10 µL of 4.35 M acetic acid, and 
500 µL of acetone were added. Samples were vortexed (2 min), sonicated (2 min) and 
then centrifuged (12,000 g, 7 min, 4°C). An accurately measured portion of the 
supernatant was finally collected and stored at -20°C. Further processing and analysis was 
carried out as described above for blood samples. The Area Under the Curve (AUC) values 
were calculated using the trapezoidal rule.  
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Recovery yields of 1 and 1-sulfate from the organs are those reported in Azzolini et al.1 
The recovery yield of 2 from the organs was determined following the same procedure 
adopted for 1 and 1-sulfate. Briefly, 1 g of tissue (from an untreated animal) was mixed 
with 1 mL of PBS containing 5 nmoles of 2 (dilution from a 100× stock solution in DMSO), 
and homogenized. 200 mg aliquots of the homogenate were then taken and processed as 
described above. Recoveries of 2 from the organs are listed in table 2. 
Results: 
Hydrolysis in media mimicking gastric and intestinal pH: 
Apart from an easy absorption from the intestine, prodrug candidates should also 
regenerate the parent compound with opportune kinetics. In agreement with previous 
results (chapters 3 and 4) the carbamoyl bond turned out to be stable in acidic media (pH 
= 1; 24h, 37°C) in these compounds. At near-neutral pH (6.8), the derivatives underwent 
hydrolysis, whose rate depended on the substituent group (figure 1), but was generally 
low. Derivatives 7 and 8 hydrolyzed most rapidly, while reaction rates were slowest for 
derivatives 3, 6 and 9 (see table 1). 
 
 
Table 1: Recovery ratios and hydrolysis constants of derivatives 2-10. Recovery ratio  
(analyte/internal standard) from blood are given as mean values  ± standard deviation. N 
≥ 4 for each condition. Pseudo-first-order rate constant were calculated as best fit of the 
experimental points using the first order exponential equation: [C] = [C
0
]*exp(-kt) 
Substituent Recovery ratio K (h
-1
) in PBS pH 6,8 K (h
-1
) in rat 
blood 
2 Isoleucine 1.124 ± 0.088 0.00547 ± 0.00008 0.28 ± 0.01 
3 Leucine 0.759 ± 0.068 0.00465 ± 0.00005 0.059 ± 0.004 
4 β-alanine 0.697 ± 0.033 0.0070 ± 0.0006 0.96 ± 0.05 
5 Valine 0.892 ± 0.077 0.0065 ± 0.0002 0.114 ± 0.007 
6 Phenylalanine 0.854 ± 0.029 0.0050 ± 0.0004 0.025 ± 0.002 
7 Asparagine 0.712 ± 0.058 0.0114 ± 0.0006 0.174 ± 0.005 
8 Threonine 0.714 ± 0.063 0.01320 ± 0.00007 0.131 ± 0.005 
9 Aspartic acid 0.884 ± 0.048 0.0034 ± 0.0004 0.034 ± 0.003 
10 Arginine 0.778 ± 0.035 0.0099 ± 0.0002 0.31 ± 0.03 
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Hydrolysis in blood:  
Fresh blood from the jugular vein of a rat was thermostatically kept at 37°C and spiked 
with a known amount of the derivatives. Due to the limited stability of blood outside the 
body, the experiments were terminated after 4 hours. 
The higher pH of blood in comparison to that of our PBS solution (7.4 vs. 6.8) and the 
presence of esterase activities in blood (for a discussion please see chapter 3) make 
hydrolysis in blood faster than in PBS. k values in blood are indeed in most cases higher by 
a factor of at least 10 compared to those obtained in PBS solution (see table 1). Derivative 
4 (with β-alanine) regenerated 1 with the fastest kinetics, while derivatives 3, 6 and 9 
exhibited the lowest rates. Derivative 6 (with phenylalanine) was affected the least by the 
presence of an higher pH and hydrolytic enzymes (fig 3).  
Blood pharmacokinetics: 
In vitro (pH = 1 and pH = 6.8) and ex vivo (blood) stability profiles of derivatives 2-10 
indicated their suitability for use as prodrugs of pterostilbene. We therefore proceeded to 
determine the pharmacokinetic profile of each of them.  
Fig 2: Hydrolysis of derivatives 2-10 in PBS 0.1M, pH 6.8, 37°C. Data are expressed as % of the initially 
loaded compound. The fit is for pseudo-first order kinetics. 
Isoleucine β-alanine Leucine 
Asparagine Phenylalanine Valine 
Threonine Aspartic acid Arginine 
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Here the results are presented by class of 
substituent group. Graphs are identified by 
the number of the derivative administered 
(see legends, black line) 
1. Derivatives with aliphatic amino acids as 
promoieties (2-5):  
Derivatives 2-5 when orally administered 
were rapidly and extensively absorbed by 
the intestine (fig 4), reaching very high 
concentrations in blood. As reported in table 
2, compounds 2, 3 and 5 peaked at values 
around 100 µM (94 ± 49 µM, 113 ± 86 µM 
and 202 ± 36 µM, respectively). The 
maximum concentration of compound 4 was 
also high, but less so than for the other 3 
derivatives (50 ± 11 µM). 
Fig 3: Hydrolysis or derivatives 2-10 in blood. Data are expressed as % of the initially loaded compound. 
The fit is for pseudo-first order kinetics. 
Isoleucine β-alanine Leucine 
Asparagine Phenylalanine Valine 
Threonine Aspartic acid Arginine 
Table 2: Blood pharmacokinetics C
max
 and t
max
 
parameters of derivatives 2-10. N ≥ 3 for each 
condition. Mean values ± standard deviation 
are shown. 
 
Cmax (µM) tmax (h) 
2 94.07 ± 49.19 2 
3 112.71 ± 85.52 2 
4 49.86 ± 10.96 1/2 
5 102.60 ± 36.03 4 
6 40.40 ± 50.44 2 
7 0.83 ± 0.32 1 
8 5.74 ± 8.86 1/6 
9 1.42  ± 2.02 1/6 
10 0.73 ± 0.32 2 
 
Chapter 6 
134 
 
Compounds 2, 3 and 5 reached their maximum concentration in blood 2 hours after 
administration and their level was sustained until the 8th hour, then it slowly dropped to 
almost complete clearance at 24h (fig 4, 2 and 3). Pterostilbene (1), the hydrolysis 
product, as well as its major metabolite, 1-sulfate, were formed in all cases. After the 
administration of 3 and 5 other minor metabolites were detected, but due to their low 
amount it was not possible to identify them. 
Derivative 4 plateaued in the interval from 30 min to 2 hours after administration, then it 
rapidly decreased (fig 4, 4). The high rate of hydrolysis (fig 3, 4) and the rapid and 
consistent formation of 1-sulfate suggest that this compound is also well absorbed, but it 
rapidly hydrolyzes to produce 1 which is subsequently sulfated. Unidentified metabolites 
were present also in this case (fig 4, 4). 
2. Derivative with an aromatic amino acid promoiety (6): 
Derivative 6 is also lipophilic, and analogously to derivatives 2-5 it also reached an 
elevated concentration in blood, sustained for several hours after its oral administration 
(fig 5, 6). However its high stability in blood limited the release of 1. Levels of 1 were low, 
but phase II metabolite 1-sulfate was present, indicating a certain degree of hydrolysis of 
the parent compound under physiological condition. 6 peaked at 2 hours and 1-sulfate at 
8 hours. 
 
Fig 4: Pharmacokinetic profiles after oral administration of derivatives 2-5. Data 
represent average values ± standard deviation. N ≥ 3 in all cases. 
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3. Derivatives with hydrophilic amino acid  promoieties (7 and 8):  
Compared to previously discussed molecules, the concentrations attained by these two 
derivatives in blood were very low. 7 reached a disappointing 0.8 µM after 30 minutes, 
while 8 peaked at 5.7 µM after 10 minutes and then rapidly dropped. In the case of 7 no 
other species were detected, while 8 yielded traces of 1-sulfate. 
4. Derivatives with charged amino acid promoieties (9, acidic and 10, basic):  
Administration of 9 and 10 led to very low concentrations of the derivatives in blood (1.4 
µM after 10 minutes and 0.7 µM after 2 hours, respectively, in the case of 9). 1 and 1-
sulfate were detected only after administration of 9, and as mere traces. 
This pharmacokinetics analysis clearly indicates that compounds bearing aliphatic and 
aromatic amino acid promoieties (2-6) give the best results. We intend prodrugs as a tool 
to increase the levels of the parent compound in the body. Blood cannot be considered as 
Fig 5: Pharmacokinetic profiles after oral 
administration of derivatives 6-10. 6 
bears an aromatic amino acid, 7 and 8 an 
hydrophilic amino acid and 9 and 10 a 
charged amino acid. Data represent 
average values ± standard deviation. N ≥ 
3 in all cases. 
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fully representative of the body in terms of the levels of 1, 1-sulfate and of our 
derivatives. Its aqueous character renders the blood much more attractive for hydrophilic 
compounds than for lipophilic ones, as previously mentioned in Azzolini et al.1 (chapter 
5). However a complete organ distribution study of each derivative is time- and energy-
expensive. Blood pharmacokinetics are therefore a useful way to separate those 
compounds which have no chance to function as prodrugs from those presenting 
desirable  characteristics.  
The Area Under the Curve (AUC0-24) parameter gives a quantitative idea of the results 
obtained in blood pharmacokinetics. The AUC0-24 of the total amount of pterostilbene-
derived species after administration of derivatives 2 to 6 was definitely higher compared 
to that resulting from administration of 1 as such (fig 6, a).  
a b 
c d 
e Fig 6: a, AUC
0-24
 of the total circulating species 
derived from 1-6 after oral administration of 
equimolar doses of 1-6. b, AUC
0-24
 of the 
derivatives 2-6. c, AUC
0-24
 of 1-sulfate. d, AUC
0-
24
 of 1 after the administration of the indicated 
compound. Panel e shows the pharmacokinetic 
profile of 1 when it is administered as such and 
when it is released by hydrolysis of the 
prodrugs. Error bars represent standard 
deviation. 
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AUC0-24 values are provided in fig 6 for the three species contributing to the total: the 
unchanged prodrugs (fig 6, b), 1-sulfate (fig 6, c) and 1 (fig 6, d). While the AUC0-24 of 1-
sulfate is similar in all cases (fig 6, c), the relative contribution of 1 and the derivatives is 
quite different depending on what was administered. 
Derivatives 2, 3 and 5 afforded the highest values of overall AUC0-24. The highest AUC0-24 
for 1 was produced instead upon administration of 2 (the isoleucine derivative) and 4 (the 
β-alanine derivative). 
The data indicate that all the derivatives when orally administered had a better AUC0-24 
compared to the oral administration of 1 as such, but at the same time they also indicate 
that for our purposes derivatives 3, 5 and 6 are not convenient prodrugs of Pt. In fig 6, d 
and 6, e indeed it is possible to appreciate that only derivatives 2 and 4 were able to 
boost the AUC0-24 of 1 to very high values. 
We finally decided to proceed with a detailed analysis of the organ distribution of the 
compounds of interest after a single oral administration, using compound 2. 
Distribution of derivative 2 into major organs: 
The recovery ratio of 2 was satisfactory for all the organs examined (see table 3). The time 
points at which we performed the analysis differ from those of the blood 
pharmacokinetics. Samplings at 10 minutes, 1 hour and 24 hours were replaced with 
analyses carried out at 12 and 16 hours. This was done to better cover the period in which 
the levels of prodrug and its derivatives in the body were high. In the blood 
pharmacokinetics study with 2 we detected only the prodrug itself, 1 and 1-sulfate (fig 4, 
2). In liver and kidneys also other minor unidentified metabolites were present, which are 
not further mentioned here because of their low concentration.  
Blood analysis was repeated as a control for the 
experiment. Levels of 2, 1 and 1-sulfate were 
comparable to those observed in the blood 
pharmacokinetics study (fig 7, blood).   
2 was the major species observed in most of the 
organs examined, exceptions being the brain and 
skeletal muscle. 1 and 1-sulfate concentrations 
varied depending on the properties of the tissue 
examined.  
1 was the predominant species in the brain, 
reaching 20 nmoles/g 8 hours after the 
administration of the prodrug. Notably, in brain 
the levels of 1 remained above 10 nmoles/g for 
several hours, from the 4th to the 10th. 1 was also 
 
Organs Recovery ratio of 2 
Brain 0.933 ± 0.089 
Lungs 0.887 ± 0.111 
Heart 0.909 ± 0.087 
Liver 0.830 ± 0.063 
Kidneys 0.678 ± 0.082 
Testes 0.866 ± 0.091 
Muscles 0.958 ± 0.064 
Table 3: Recovery of 2 from tissues. 
N ≥ 4 for each condition. Mean 
values ± standard error  are shown. 
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present at appreciable levels in the other organs, with concentrations comprised between 
10 and 20 nmoles/g in most of cases (except blood), peaking at the 8th hour.  
Testes Skeletal 
muscle 
Fig 7: Concentration versus time profiles of derivative 2, 1 and 1-sulfate in blood and 
tissues. A single intragastric dose of 2 (88 µmoles/kg body weight) was administered to rats 
at time 0. Reported are mean values ± standard deviation. N ≥ 3. 
Liver Kidneys 
Lungs Heart 
Blood Brain 
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1-sulfate was present at high levels in the liver and kidneys (Cmax approximately 60 and 25 
nmoles/g, respectively) while in the brain, testes and skeletal muscle its levels were low 
(Cmax approximately 0.5, 3 and 2 nmoles/g, respectively). 
Our previous article, “Pharmacokinetics and tissue distribution of pterostilbene in the rat” 
(1, chapter 5) can be considered as a control for this part of the work. Figure 8 compares 
the AUC values for pterostilbene (1; panel a) and its sulfate (1-sulfate; panel b) obtained 
integrating the curves of the organ pharmacokinetics after the administration of 2 (black 
bars) and those from that work (grey bars). 2 was administered to fasted animals with the 
same molar dose used in Azzolini et al.1 (chapter 5). 
AUC comparison indicates that by administering prodrug 2 we obtained a consistent 
increase in the AUC of 1 in most of the organs examined. Minor differences were found in 
the kidneys, lungs and blood, while the AUC doubled in the brain, heart, testes and 
skeletal muscle. In the liver the AUC of 1 was similar in the two cases. 
When orally administered, compounds are absorbed by the intestine and funneled 
through the systemic circulation to the liver. This might explain why administration of 2 
results in a lower AUC of 1-sulfate in the liver: while by administering 1 all the absorbed 
phenol is filtered in the hepatocyte network (and much remains entrapped in the tissue), 
by administering 2 hepatic clearance concerns to a large extent the prodrug. 1 will reach 
the liver only after being generated by hydrolysis of 2, which is distributed in the body.  
As previously seen (fig 6, c), the AUC of 1-sulfate in blood does not differ when 1 or 2 are 
administered. In testes, skeletal muscle and brain its dependence on the specie 
administered is minor, while differences are more important in lungs, heart, liver and 
kidneys. In particular in the heart, skeletal muscle, testes and in the kidneys the 
administration of 2 reduced overall levels of 1-sulfate by a factor of 2, while in liver and 
a b 
Fig 8: AUC
0-16h
’s comparison between results obtained in Azzolini et al.1 (grey bars) and those 
obtained in this work (black bars). a, AUC
0-16
 of 1 after the administration of the indicated 
compound. b, AUC
0-16
 of 1-sulfate after the administration of the indicated compound. Error 
bars represent standard deviation. 
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lungs the difference was even larger. This presumably reflects the elimination of part of 
the prodrug as such (unaltered). 
Conclusions: 
Carbamoyl bond-based prodrugs of pterostilbene have been shown to be effective in 
increasing its bioavailability. 
The stability in media mimicking gastric and intestinal pH of all the derivatives is high. At 
the same time derivatives 2-10 undergo hydrolysis at a moderate rate in blood. From a 
practical point of view this means that the derivatives, when orally administered, can pass 
intact through the stomach and the intestine, be distributed in the body through the 
blood and finally regenerate the natural compound in the organs. 
All the derivatives were screened through blood pharmacokinetics. Compounds bearing 
aliphatic and aromatic amino acids gave the best results. Derivatives 2-6 were able to 
reach blood concentrations in the range of 50-100 µM. Among these derivatives, 2 and 4 
afforded the highest levels of Pterostilbene. 
2 was selected for further analysis. We have previously reported the distribution in major 
organs of pterostilbene following administration of pterostilbene itself; compound 2 was 
studied under the same conditions in order to compare the results obtained in the two 
experiments. By administering the prodrug we obtained: 
1. Increased absorption of the molecule 
2. Consistent reduction of metabolism 
3. Higher concentrations of pterostilbene, sustained for several hours, in most of the 
organs examined  
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Appendix:  
Synthesis of derivatives 2-10:  
Derivatives were synthesized by the group of prof. Cristina Paradisi, Department of Chemical 
Sciences, University of Padova. 
4’-[N-(isoleucinyl)-carbamoyl]-pterostilbene (Pt-CP-Ile, 2): 
1. 4’-[N-(isoleucinyl-tert-butyl)]-pterostilbene 
A solution of L-isoleucine tert butyl ester hydrochloride (0.5005 g, MW = 223.74 g/mol, n = 2.23 
10-3 mol, 1 eq) and DMAP (1.0883 g, MW = 122.17 g/mol, 8.91 10-3 mol, 4 eq) in DCM dry (7 mL) 
was added dropwise to a solution of bis-(4-nitrophenyl) carbonate (0.7142 g, MW = 304.21 g/mol, 
n = 2.35 10-3 mol, 1.05 eq) in DCM dry (4.5 mL). The resulting mixture was stirred at 50°C for 4 
hours. Then, pterostilbene (0.7523 g, MW = 256.3 g/mol, n = 2.93 10-3 mol, 1.3 eq) was added to 
the solution. The resulting mixture was stirred at 50°C overnight, and then it was diluted in DCM 
(100 mL) and extracted with HCl 0.5 M (2 × 100 mL). The organic layer was dried over with MgSO4 
and filtered. The solvent was evaporated under reduced pressure and the product was purified 
from PNP, and Pt by flash chromatography using petroleum ether/DCM/ethylic ether (5/4/1) as 
eluent, and from Ile-OtBu-PNPC by flash chromatography using petroleum ether/Et2O (7/3) as 
eluent, to afford Pt-CP-Ile-OtBu as a colourless oil (0.7803 g, MW = 469.25 g/mol, n = 1.66 10-3 
mol, 74.3 % yield). 
MS-ESI (ion trap) = 470 m/z [M+H+]  
1H NMR (200 MHz, CDCl3) δ (ppm) = 7.48 (d, J = 8.4 Hz, 2H), 7.19 – 6.82 (m, 4H), 6.66 (d, J = 2.0 Hz, 
2H), 6.39 (m, 1H), 5.62 (m, 1H), 4.29 (m, 1H), 3.83 (s, 6H), 1.95 (m, 1H), 1.50 (m, 11H), 0.97 (m, 
6H). 
13C NMR (50 MHz, CDCl3) δ(ppm) = 170.91, 161.20, 154.31, 150.64, 139.40, 134.54, 128.45, 
127.50, 121.90, 104.66, 100.17, 82.40, 58.82, 55.49, 38.50, 28.21, 25.30, 15.54, 11.88. 
2. 4’-[N-(isoleucinyl)-carbamoyl]-pterostilbene 
TFA (2.5 mL, MW = 114.02 g/mol, n = 3.26 10-2 mol, 40.25 eq) was added to a solution of Pt-CP-Ile-
OtBu (0.3798 g, MW = 469.25 g/mol, n = 8.1 10-4 mol, 1 eq) and TIPS (0.625 mL, 5 % v/v) in DCM 
dry (10 mL). The mixture was stirred at 0°C overnight. The TFA and the solvent were evaporated 
under reduced pressure. The product was titrated with toluene (2 × 5 mL) and purified by flash 
chromatography using petroleum ether/acetone (7/3) as eluent, to afford Pt-CP-Ile-OH as a white 
solid (0.2537 g, MW = 413.18 g/mol, n = 6.14 10-4 mol, 76 % yield).  
MS-ESI (ion trap) = 413 m/z, 434 m/z [M+Na]+ 
1H NMR (200 MHz, CDCl3) δ (ppm) = 8.06-8.03 (m, 1H) 7.49 (d, J = 8.5 Hz, 2H), 7.04 (m, 4H), 6.66 
(d, J = 1.9 Hz, 2H), 6.40 (m, 1H), 4.46 (m, 1H), 3.83 (s, 6H), 1.86 (m, 1H)1.53-1.21 (m, 1H) 0.94-0.85 
(m, 1H), 1.03 (m, 6H). 
13C NMR (50 MHz, CDCl3) δ (ppm) = 176.02, 160.66, 154.11, 150.02, 138.93, 134.31, 128.42, 
127.93, 127.11, 121.42, 104.27, 99.77, 58.05, 55.07, 37.53, 24.60, 15.25, 11.32. 
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4’-[N-(leucinyl)-carbamoyl]-pterostilbene (Pt-CP-Leu, 3) 
1. [N-(tert-butyl-leucinyl)-carbamoyl]-p-nitrophenol (PNPC-Leu-OtBu). 
Leucine tert butyl ester hydrocloride (1.5997 g, MW = 223.74 g/mol, n = 7.15·10-3 mol, 1 eq) was 
dissolved in 35 mL of acetonitrile. DMAP (1.7590 g, MW = 122.17 g/mol, n = 1.44·10-2 mol, 2 eq) 
and bis(4-nitrophenyl)carbonate (2.1766g, MW = 304.21 g, n = 7.15·10-3 mol, 1 eq) were added at 
the previous solution. The reaction mixture was stirred at room temperature for 3 hours and then 
was warmed up to 50°C and stirred for another hour. The resulting mixture was diluted in DCM 
(200 mL), washed with 0,5 N HCl (150 mL) and extracted with 2 × 100 mL of dichloromethane. The 
organic layer was dried over MgSO4 and filtred. The solvent was evaporated under reduced 
pressure and the residue was purified by flash chromatography using Petroleum Ether:Ethyl 
Ether=6,5:3,5 as eluent. Solvent was evaporated under reduced pressure to afford 1.9800 g of 
product (78.6% yield). 
1H NMR (CDCl3, 300 MHz) δ (ppm): 8.205 (d, 2H, aromatic meta position, 
3JH-H = 9 Hz), 7.295 (d, 
2H, aromatic ortho position, 3JH-H = 9 Hz), 5.735 (d, 1H, CH-NH, 
3JH-H = 9 Hz), 4.26-4.34 (m, 1H, NH-
CH), 1.52-1.83 (m, 3H, NH-CH-CH2 and CH3-CH-CH3), 1.48 (s, 9H, 3 × C-CH3), 0.97 (d, 6H, 2 × CH-
CH3, 
3JH-H = 9 Hz); 
13C NMR (CDCl3, 300 MHz) δ (ppm): 171.72, 155.76, 152.69, 144.76, 125.10, 121.96, 82.50, 53.23, 
41.99, 27.98, 24.89, 22.81, 21.98. 
2. [N-(tert-butyl-leucinyl)-carbamoyl]-pterostilbene (Pt-CP-Leu-OtBu). 
A solution of pterostilbene (0.5015 g, MW = 256.3 g/mol, n = 1.96·10-3 mol, 1 eq) in 20 mL of 
acetonitrile was prepared. PNPC-Leu-OtBu (1.3791 g, MW = 396.43 g/mol, n = 3.91·10-3 mol, 2 eq) 
and DMAP (0.4723 g, MW = 122,17 g/mol, n = 3,86·10-3 mol, 2 eq) were added to the previous 
solution. The mixture was stirred at 50°C under nitrogen stream overnight. The reaction progress 
was checked by TLC. The resulting mixture was diluted in DCM (100 mL), washed with 0,5 N HCl 
(100 mL) and extracted with 2 × 100 mL of DCM. The organic layer was collected and dried over 
MgSO4. The solvent was evaporated under reduced pressure and the residue was purified from 4-
nitrophenol by flash chromatography using Petroleum Ether:Dichloromethane:Ethyl Ether=5:4:1, 
and from the residual PNPC-Leu-OtBu  by flash chromatography using Petroleum Ether:Ethyl 
Ether=7:3. The solvent was evaporated under reduced pressure to afford 0.8902 g of product 
(86.2% yield). 
1H NMR (CDCl3, 500 MHz) δ (ppm): 8,01 (d, 1H, O-(C=O)-NH, 
3JH-H = 10 Hz), 7.465 (d, 2H, H-2' and 
6', 3JH-H = 5 Hz), 7.13 (d, 2H, H-3' and 5', 
3JH-H = 10 Hz), 6.93-7.06 (d+d, 2H, H-7 and 8), 6.66 (d, 2H, 
H-2 and 6, 4JH-H = 2 Hz), 6.40 (t, 1H, H-4, 
4JH-H = 2 Hz), 4.32-4.36 (m 1H, Leu Cα-H), 3.80 (s, 6H, O-
CH3), 1.75-1,83 (m, 1H, Leu Cγ-H), 1.55-1.70 (m, 2H, Leu Cβ-H2), 1.50 (s, 9H, (C=O)-O-C(CH3)3 ), 0.98-
1.00 (dd, 6H, Leu Cδ-H3 and Leu Cε-H3). 
13C NMR (CDCl3, 500 MHz) δ (ppm): 172.12, 160.94, 154.17, 150.47, 139.22, 134.37, 128.55, 
128..22, 127.33, 121.75, 104.52, 100.00, 82.03, 55.27, 41.90, 27.97, 24.86, 22.82, 21.99. 
3. [N-(leucinyl)-carbamoyl]-pterostilbene (Pt-CP-Leu-OH). 
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Pt-CP-Leu-OtBu ( 0.7958 g, MW = 469.57 g/mol, n = 1.69·10-3 mol, 1 eq) was dissolved in 25 mL of 
anhydrous dichloromethane and 5 mL of TFA ( MW = 114.02 g/mol, n = 6.53·10-2 mol, 42.7 eq) 
were added to the solution. The mixture was stirred at room temperature for 3 hours under 
nitrogen stream. The reaction progress was checked by TLC. After 3 hours the solvent and the 
residual TFA were evaporated under reduced pressure. The residue was titrated with toluene (2 × 
5 mL), and then solvent was evaporated under reduced pressure. The product was purified by 
automated chromatography system using Petroleum ether:Acetone=7:3. Solvent was evaporated 
under reduced pressure to afford 0.5103 g of product (73.0% yield). 
1H NMR (CDCl3, 500 MHz) δ (ppm): 7.47 (d, 2H, H-2' and 6', 
3JH-H = 10 Hz), 7.13 (d, 2H, H-3' and 5', 
3JH-H = 10 Hz), 6.94-7.06 (d+d, 2H, H-7 and 8), 6.655 (d, 2H, H-2 and 6, 
4JH-H = 2 Hz), 6.40 (t, 1H, H-4, 
4JH-H = 2 Hz), 4.43-4.48 (m 1H, Leu Cα-H), 3.82 (s, 6H, O-CH3), 1.72-1.84 (m, 2H, Leu Cβ-H2), 1.61-
1.67 (m, 1H, Leu Cγ-H), 0.98-1.00 (dd, 6H, Leu Cδ-H3 and Leu Cε-H3). 
13C NMR (CDCl3, 300 MHz) δ (ppm): 172.12, 160.94, 154.17, 150.47, 139.22, 134.37, 128.55, 
128..22, 127.33, 121.75, 104.52, 100.00, 82.03, 55.27, 41.90, 27.97, 24.86, 22.82, 21.99. 
ESI-MS:825 m/z [2(Pt CP-Leu-OH)]- 
4’-[N-(β-alanin)-carbamoyl]-pterostilbene (Pt-CP-betaAla, 4): 
1. [N-(β-alanin-tert-butyl)]-p-nitro-phenylcarbamate 
A solution of β-alanine-tert-butyl ester (0.5048 g, MW = 181.66 g/mol, n = 2.78 10-3 mol, 1 eq) and 
4-(dimethylamino)pyridine (0.6828 g, MW =122.17 g/mol, n = 5.59 10-3 mol, 2 eq) in ACN (5 mL) 
was added dropwise to a solution of bis(4-nitrophenyl) carbonate (0.8253 g, MW = 304.21 g/mol, 
n = 2.71 10-3 mol, 1 eq) in ACN (20 mL). The resulting mixture was stirred at 50°C overnight. The 
solution was diluted in DCM (150 mL) and washed with HCl (2 × 100 mL). The organic layer was 
dried with MgSO4 and filtered. The solvent was evaporated under reduced pressure. The product 
was purified by flash chromatography using CHCl3/acetone (99/1) as eluent, to afford β-Ala-OtBu-
PNPC as a colourless oil (0.5693 g, MW = 310.3, n = 1.83 10-3 mol, 65.3 % yield). 
MS-ESI (ion trap) = 333 m/z [M+Na]+  
1H NMR (300 MHz, CDCl3) δ (ppm) = 8.24 (d, J = 9.1 Hz, 2H), 7.32 (d, J = 9.1 Hz, 2H), 5.81 (s, 1H), 
3.52 (m, 2H), 2.54 (t, J = 5.9 Hz, 2H), 1.48 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 171.97, 156.26, 153.40, 145.11, 125.46, 122.26, 81.82, 37.31, 
35.41, 28.36. 
2. 4’-[N-(β-alanin-tert butyl ester)-carbamoyl]-pterostilbene 
A solution of DMAP (0.5482 g, MW = 122.17 g/mol, n = 4.49 10-3 mol, 2 eq) and pterostilbene 
(0.7246 g, MW = 256.3 g/mol, n = 2.83 10-3 mol, 1.3 eq) in DCM dry (5 mL) was added to a solution 
of β-Ala-OtBu-PNPC (0.6685 g, MW = 310.3 g/mol, n = 2.15 10-3 mol, 1 eq) in DCM dry (6 mL). The 
mixture was stirred at 50°C overnight. The solvent was evaporated under reduced pressure and 
the product was purified by flash chromatography using CHCl3/Et2O/petroleum ether (5/1.5/3.5) 
as eluent, to afford Pt-CP--Ala-OtBu as a colourless oil(0.8322 g, MW = 427.20 g/mol, n = 1.95 
10-3 mol, 90.4 % yield). 
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MS-ESI (ion trap) = 428 m/z [M+H+]  
1H NMR (500 MHz, CDCl3) δ (ppm) = 7.50 (d, J = 8.5 Hz, 2H), 7.18 – 6.94 (m, 4H), 6.69 (d, J = 2.2 Hz, 
2H), 6.42 (t, J = 2.1 Hz, 1H), 3.85 (s, 6H), 3.53 (m, 2H), 2.55 (t, J = 6.0 Hz, 2H), 1.51 (s, 9H).  
13C NMR (126 MHz, CDCl3) δ (ppm) = 171.73, 160.99, 154.46, 150.57, 139.29, 134.37, 128.59, 
128.33, 127.40, 121.79, 104.55, 100.03, 81.27, 55.37, 36.92, 35.34, 28.14. 
3. 4’-[N-(β-alanin)-carbamoyl]-pterostilbene 
TFA (5 mL, MW = 114.02 g/mol, n = 6.53 10-2 mol, 33.5 eq) and TIPS (5 % v/v) were added to a 
solution of Pt-CP-β-Ala-OtBu (0.8322 g, MW = 427.20 g/mol, n = 1.95 10-3 mol, 1 eq) in DCM dry (5 
mL). The mixture was stirred at 0°C overnight and then the TFA and the solvent were evaporated 
under reduced pressure. The product was titrated with toluene (2 × 5 mL) and purified by flash 
chromatography using CHCl3/acetone (7/3) as eluent, to afford Pt-CP-β-Ala-OH as a white solid 
(0.5989 g, MW = 371.14 g/mol, n = 1.61 10-3 mol, 82.5 % yield).  
ESI+-MS (ion trap): 371 m/z 
1H NMR (500 MHz, DMSO) δ (ppm) = 7.60 (d, J = 8.6 Hz, 2H), 7.20 (m, 4H), 6.79 (d, J = 2.1 Hz, 2H), 
6.43 (t, J = 2.1 Hz, 1H), 3.79 (s, 6H), 3.31 (m, 2H), 2.49 (t, J = 7.0 Hz, 2H) 
13C-NMR (126 MHz, DMSO) δ (ppm) = 172.72, 160.70, 154.21, 150.58, 139.11, 133.83, 128.14, 
127.32, 121.98, 104.47, 99.90, 55.22, 39.52, 36.73, 33.97. 
4’- [N-(valinyl)-carbamoyl]-pterostilbene (Pt-CP-Val, 5) 
1. 4’-[N-(tert-butyl-valinyl)-carbamoyl]-p-nitrophenol (PNPC-Val-OtBu). 
Valine tert butyl ester hydrocloride (0.9967 g, MW = 209.71 g/mol, n = 4.75·10-3 mol, 1 eq) was 
dissolved in 35 mL of acetonitrile. DMAP (1.1696 g, MW = 122.17 g/mol, n = 9,57·10-3 mol, 2 eq) 
and bis(4-nitrophenyl)carbonate (1.4672 g, MW = 304.21 g, n = 4.82·10-3 mol, 1 eq) were added at 
the previous solution. The reaction mixture was stirred at room temperature for 4 hours at 50°C 
under nitrogen stream. The resulting mixture was diluted in DCM (200 mL), washed with 0.5 N HCl 
(150 mL) and extracted with 2 addition of 100 mL of dichloromethane. The organic layer was dried 
over MgSO4 and filtred. The solvent was evaporated under reduced pressure and the residue was 
purified by flash chromatography using Petroleum Ether:Ethyl Ether = 7:3 as eluent. Solvent was 
evaporated under reduced pressure to afford the product as a yellow oil (1.2316 g, 76.6% yield). 
1H NMR (CDCl3, 500 MHz) δ (ppm): 8.16 (d, 2H, aromatic meta position, 
3JH-H = 10 Hz), 7.29 (d, 2H, 
aromatic ortho position, 3JH-H = 10 Hz), 6.02 (d, 1H, CH-NH, 
3JH-H = 10 Hz), 4.19-4.21 (m, 1H, Val Cα-
H), 2.16-2.23 (m, 1H, Val Cβ-H ), 1.45 (s, 9H, 3 × C-CH3), 0.975 (d, 3H, 
3JH-H = 5 Hz, CH-CγH3), 0.91(d, 
3H, 3JH-H = 10 Hz, CH-CγH3); 
13C NMR (CDCl3, 500 MHz) δ (ppm): 170.70, 155.88, 153.11, 144.65, 124.97, 121.90, 82.44, 59.57, 
31.38, 27.94, 18.87, 17.30. 
2. 4’- [N-(tert-butyl-valinyl)-carbamoyl]-pterostilbene (Pt-CP-Val-OtBu). 
A solution of Pt (0.7479 g, MW = 256.3 g/mol, n = 2,92·10-3 mol, 1 eq) in 30 mL of acetonitrile was 
prepared. PNPC-Val-OtBu (1.4820 g, MW = 338.36 g/mol, n = 4.38·10-3 mol, 1.5 eq) and DMAP 
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(0.7139g, MW = 122.17 g/mol, n = 5.84·10-3 mol, 2 eq) were added to the previous solution. The 
mixture was stirred at 50°C under nitrogen stream overnight. The reaction progress was checked 
by TLC. The resulting mixture was diluted in DCM (100 mL), washed with 0.06 N HCl (100 mL) and 
extracted with 2 × 100 mL of DCM. The organic layer was collected and dried with MgSO4. The 
solvent was evaporated under reduced pressure and the residue was purified from PNPC-Val-
OtBu by flash chromatography using Petroleum Ether:Acetone:Ethyl Ether = 7:1:2. The fraction 
collected was purified from the residual 4-nitrophenol  by flash chromatography using Petroleum 
Ether:Dichloromethane:Acetone = 5:4:1, the solvent was evaporated under reduced pressure to 
afford the product as a pale yellow oil (1.0492 g , 86,2% yield). 
1H NMR (CDCl3, 500 MHz) δ (ppm): 7.455 (d, 2H, H-2' and 6', 
3JH-H = 9 Hz), 7.14 (d, 2H, H-3' and 5', 
3JH-H = 10 Hz), 6.92-7.05 (dd, 2H, H-7 and 8), 6.655 (d, 2H, H-2 and 6, 
4JH-H = 3 Hz), 6.40 (t, 1H, H-4, 
4JH-H = 3 Hz), 5,91 (t, 1H, O-(C=O)-NH), 4.27-4.30 (q, 1H, Val Cα-H), 3.78 (s, 6H, O-CH3), 2.20-2.06 
(m, 1H, Val Cβ-H), 1.50 (s, 9H, (C=O)-O-C(CH3)3 ), 1.035 (d, 3H, Val CH-Cγ-H3), 0.965 (d, 3H, Val CH-
Cγ-H3). 
13C NMR (CDCl3, 500 MHz) δ (ppm): 170.86, 160.85, 154.36, 150.44, 139.12, 134.23, 128.43, 
128.09, 127.22, 121.64, 104.43, 99.87, 81.96, 59.41, 55.11, 31.36, 27.89, 18.85, 17.34. 
3. 4’- [N-(valinyl)-carbamoyl]-pterostilbene (Pt-CP-Val-OH). 
Pt-CP-Val-OtBu ( 0.7196g, MW = 455.54 g/mol, n = 1,58·10-3 mol, 1 eq) was dissolved in 25 mL of 
anhydrous dichloromethane and 5 mL of TFA ( MW = 114.02 g/mol, n = 6.53·10-2 mol, 42.7 eq) 
were added to the solution. The mixture was stirred at room temperature for 3 hours under 
nitrogen stream. The reaction progress was checked by TLC. After 3 hours the solvent and the 
residual TFA were evaporated under reduced pressure. The residue was titrated with toluene (3 × 
5 mL), and then solvent was evaporated under reduced pressure. The product was purified by 
automated chromatography system using Petroleum ether:Acetone = 6:4 to afford 0.4504g of 
product (71.5% yield). 
1H NMR (CDCl3, 500 MHz) δ (ppm): 7.49 (d, 2H, H-2' and 6', 
3JH-H = 10 Hz), 7.14 (d, 2H, H-3' and 5', 
3JH-H = 10 Hz), 6.95-7.07 (dd, 2H, H-7 and 8), 6.66 (d, 2H, H-2 and 6, 
4JH-H = 3 Hz), 6.40 (t, 1H, H-4, 
4JH-H = 3 Hz), 5.57 (d, 1H, O-(C=O)-NH, 
3JH-H = 10Hz), 4.41-4.44 (q, 1H, Val Cα-H), 3.83 (s, 6H, O-CH3), 
2,29-2,35 (m, 1H, Val Cβ-H), 1.085 (d, 3H, Val CH-Cγ-H3), 1.015 (d, 3H, Val CH-Cγ-H3); 
13C NMR (CDCl3, 500 MHz) δ (ppm): 176.44, 161.10, 154.82, 150.40, 139.36, 134.81, 128.91, 
128.35, 127.27, 121.86, 104.72, 100.22, 59.14, 55.53, 31.23, 19.20 17.52. 
ESI-MS: 797 m/z [2(Pstb CP-Val-OH)]- 
4’-[N-(phenylalanin)-carbamoyl]-pterostilbene (Pt-CP-Phe, 6) 
1. 4’-[N-(phenylalanin tert-butyl ester)-carbamoyl]-pterostilbene 
A solution of L-phenylalanine tert butyl ester hydrochloride (0.5062 g, MW = 257.8 g/mol, n = 1.96 
10-3 mol, 1 eq) and DMAP (1.0417 g, MW = 122.17 g/mol, 8.53 10-3 mol, 4.3 eq) in DCM dry (4 mL) 
was added dropwise to a solution of bis-(4-nitrophenyl) carbonate (0.6333 g, MW = 304.21 g/mol, 
n = 2.1 10-3 mol, 1.06 eq) in DCM dry (5 mL). The resulting mixture was stirred at 50°C for 4 hours. 
Then, pterostilbene (0.6651 g, MW = 256.3 g/mol, n = 2.59 10-3 mol, 1.3 eq) was added to the 
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solution. The resulting mixture was stirred at 50°C overnight, and then it was diluted in DCM (100 
mL) and extracted with HCl 0.5 M (3 × 100 mL). The organic layer was dried over MgSO4 and 
filtered. The solvent was evaporated under reduced pressure and the product was purified by 
flash chromatography using CHCl3/EtOAc (99.5/0.5) as eluent to afford Pt-CP-Phe-OtBu as a 
colourless oil (0.6350 g, MW = 503.58 g/mol, n = 1.26 10-3 mol, 66 % yield) 
MS-ESI (ion trap): 504 m/z [M+H]+ 
1H NMR (200 MHz, CDCl3) δ (ppm) = 7.52 (d, J = 8.6 Hz, 2H), 7.33 (m, 5H), 7.09 (m, 4H), 6.70 (d, J = 
2.1 Hz, 2H), 6.44 (t, J = 2.1 Hz, 1H), 5.61 (m, 1H), 4.63 (m, 1H), 3.87 (s, 6H), 3.20 (m, 2H), 1.48 (s, 
9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 170.46, 161.12, 153.87, 150.54, 139.39, 136.08, 134.61, 
129.68, 128.78, 128.61, 128.41, 127.50, 127.21, 121.87, 104.69, 100.18, 82.71, 55.49, 38.48, 
31.01, 28.05. 
2. 4’-[N-(phenylalanin)-carbamoyl]-pterostilbene 
TFA (4.5 mL, MW = 114.02 g/mol, n = 5.87 10-2 mol, 54 eq) and TIPS (0.450 mL, 5 % v/v) were 
added to a solution of Pt-CP-Phe-OtBu (0.6350 g, MW = 503.58 g/mol, n = 1.3 10-3 mol, 1 eq) in 
DCM dry (4.5 mL). The mixture was stirred at 0°C overnight. The TFA and the solvent were 
evaporated under reduced pressure. The product was titrated with toluene (2 × 5 mL) and 
purified by flash chromatography using DCM/acetone (97/3) + 1% AcOH as eluent. The product 
was dissolved in acetonitrile and water and it was lyophilized to afford Pt-CP-Phe-OH as a white 
solid (0.380 g, MW = 447.4 g/mol, n = 8.49 10-4 mol, 67.4 % yield). 
MS-ESI (ion trap): 447 m/z 
1H NMR (500 MHz, DMSO) δ(ppm) = 8.31 (s, 1H), 8.19 (m, 1H), 7.57 (d, J = 8.6 Hz, 2H), 7.29 (m, 
5H), 7.06 (m, 4H), 6.77 (d, J = 2.2 Hz, 2H), 6.41 (t, J = 2.2 Hz, 1H), 4.25 (m, 1H), 3.77 (s, 6H), 3.15 
(m, 1H), 2.92 (m, 1H). 
13C NMR (126 MHz, DMSO) δ (ppm) = 173.42, 161.13, 154.68, 150.85, 139.52, 138.23, 134.34, 
129.65, 128.72, 128.52, 127.78, 126.96, 122.19, 104.91, 100.37, 79.65, 56.16, 55.67, 36.97. 
4’-[N-(asparagin)-carbamoyl]-pterostilbene (Pt-CP-Asn, 7) 
1. 4’-[N-(asparagin tert-butyl ester)-carbamoyl]-pterostilbene 
A solution of L-asparagine tert butyl ester hydrochloride (0.4048 g, MW = 224.68 g/mol, n = 1.8 
10-3 mol, 1 eq) and DMAP (0.8922 g, MW = 122.17 g/mol, n = 7.3 10-3 mol, 4 eq) in ACN dry (6 mL) 
and DCM dry (7 mL) was added dropwise to a solution of bis-(4-nitrophenyl) carbonate (0.5659 g, 
MW = 304.21 g/mol, n = 1.86 10-3 mol, 1.03 eq) in ACN dry (5 mL). The resulting mixture was 
stirred at -15°C for 15 minutes. Then, pterostilbene (0.6019 g, MW = 256.3 g/mol, n = 2.35 10-3 
mol, 1.3 eq) was added to the solution. The resulting mixture was stirred at -15 °C and it reached 
r.t. overnight. The mixture was diluted in DCM (10 mL) and extracted with HCl 0.5 M (10 mL) and 
DCM (3 × 10 mL). The organic layer was dried over MgSO4 and filtered. The solvent was 
evaporated under reduced pressure and the product was purified by flash chromatography using 
EtOAc/petroleum ether(8/2) as eluent to afford Pt-CP-Asn-OtBu as a colourless oil (0.5824 g, MW 
= 470.5 g/mol, n = 1.24 10-3 mol, 68.7 % yield) 
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MS-ESI = 493 m/z [M+Na]+ 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.47 (d, J = 8.5 Hz, 2H), 7.15 – 6.84 (m, 4H), 6.65 (d, J = 1.9 Hz, 
2H), 6.39 (m, 2H), 5.87 (m, 2H) 4.49 (m,1H), 3.82 (s, 6H), 2.83 (m, 2H), 1.48 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 172.50, 169.86, 161.10, 154.64, 150.53, 139.35, 134.65, 
128.83, 128.35, 127.50, 121.92, 104.69, 100.19, 82.79, 77.16, 55.48, 51.51, 37.29, 27.99. 
2. 4’-[N-(asparagin)-carbamoyl]-pterostilbene 
A solution of Pt-CP-Asn-OtBu (0.7599 g, MW = 470.5 g/mol, n = 1.6154 10-3 mol, 1 eq) in DCM dry 
(6.2 mL) and TIPS (0.62 mL) (5 % v/v) was stirred at -15 °C. TFA (6.2 mL, MW = 114.02 g/mol, n = 8 
10-2 mol, 50 eq) at -15 °C was added dropwise to the previous solution. The mixture is stirred at 
room temperature for 4 hours. TFA and the solvent were evaporated under reduced pressure. 
The product was titrated with toluene (2 × 3 mL) and purified by flash chromatography using 
DCM/MeOH (97.5/2.5) + 1% AcOH, to afford Pt-CP-Asn-OH as a white solid (0.5115 g, MW = 414.4 
g/mol, n = 1.23 10-3 mol, 76.4 % yield) 
MS-ESI (ion trap) = 415 m/z [M+H]+ 
1H NMR (300 MHz, DMSO) δ (ppm) = 7.98 (m, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.34 – 6.88 (m, 4H), 
6.78 (d, J = 1.7 Hz, 2H), 6.42 (m, 1H), 4.40 (m, 1H), 3.78 (s, 6H), 2.75 – 2.53 (m, 2H). 
13C NMR (75 MHz, DMSO) δ (ppm) = 172.90, 171.16, 160.68, 153.98, 150.47, 139.08, 133.89, 
128.28, 128.09, 127.34, 121.79, 104.47, 99.92, 55.21, 50.84, 39.52, 36.66. 
4’-[N-(threonyl)-carbamoyl]-pterostilbene (Pt-CP-Thr, 8)  
1. [N-(tert-butyl-threonyl-tert-butyl)-carbamoyl]-p-nitrophenol (PNPC-Thr(OtBu)-OtBu). 
A solution of tert-butyl ester threonine tert-butyl ester (1.59 g, MW = 231.34 g/mol, n = 6.89·10-3 
mol, 1 eq) and DMAP (1.7032 g, MW = 122.17 g/mol, 1.39·10-2 mol, 2 eq) in THF (20 mL) was 
added dropwise to a solution of bis (4-nitrophenyl) carbonate (2.13 g, MW = 304.21 g/mol, n = 
7.00·10-3 mol, 1 eq) in THF (15 mL), and the mixture was stirred at room temperature for 3 hours. 
The resulting mixture was diluted in DCM (200 mL) and washed with 0.5 N HCl (3 additions of 100 
mL). The organic phase was dried over MgSO4 and filtred. The solvent was evaporated under 
reduced pressure and the residue was purified by flash chromatography using 
CH2Cl2:Acetone:Petroleum Ether = 8:0.5:1.5 as eluent, to afford 2.4842 g of product (91.0 % yield). 
1H NMR (CDCl3, 300 MHz) δ (ppm): 8.255 (d, 2H, aromatic meta position, 
3JH-H = 9 Hz), 7,365 (d, 
2H, aromatic ortho position, 3JH-H = 9 Hz), 5,895 (d, 1H, CH-NH, 
3JH-H = 9 Hz), 4,24-4,31 (m, 1H, NH-
CH), 4.09-4.13 (m, 1H, tBuO-CH), 1.50 (s, 9H, 3 × C-CH3), 1,285 (d, 3H, CH-CH3, 
3JH-H = 9 Hz), 1.20 (s, 
9H, 3 × CH3); 
13C NMR (CDCl3, 300 MHz) δ (ppm): 169.45, 155.95, 153.60, 144.74, 125.04, 121.94, 82.37, 74.02, 
66.96, 60.60, 28.69, 28.06, 21.18. 
2. [N-(tert-butyl-threonyl-tert-butyl)-carbamoyl]-pterostilbene (Pt-CP-Thr(OtBu)-OtBu). 
A solution of pterostilbene (0.5027 g, MW = 256.3 g/mol, n = 1,96·10-3 mol, 1 eq) in 20 mL of 
acetonitrile was prepared. PNPC-Thr(OtBu)-OtBu (1.5470 g, MW = 396.43 g/mol, n = 3.92·10-3 mol, 
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2 eq) and DMAP (0.4784 g, MW = 122.17 g/mol, n = 3,92·10-3 mol, 2 eq) were added to the 
previous solution. The mixture was stirred at 50°C under nitrogen stream overnight. The reaction 
progress was checked by TLC. The resulting mixture was diluted in DCM (3 × 100 mL) and washed 
with 0.05 N HCl (100 mL). The organic layer was collected and dried over MgSO4. The solvent was 
evaporated under reduced pressure and the residue was purified by flash chromatography using 
Petroleum Ether:Acetone:Ethyl Ether = 8:1:1. The solvent was evaporated under reduced 
pressure. The product was obtained as an oil (0.8862 g, 90.3% yield). 
1H NMR (CDCl3, 300 MHz) δ (ppm): 7.47 (d, 2H, H-2' and 6', 
3JH-H = 6 Hz), 7.155 (d, 2H, H-3' and 5', 
3JH-H = 9 Hz), 6.92-7.07 (d+d, 2H, H-7 and H-8), 6.645 (d, 2H, H-2 and 6, 
4JH-H = 3 Hz), 6.39 (t, 1H, H-
4, 4JH-H = 3 Hz), 5,815 (d, 1H, O-(C=O)-NH, 
3JH-H = 9 Hz), 4.23-4.26 (dd, 1H, Thr Cα-H), 4,12-4,16 (dd, 
1H, Thr Cβ-H), 3.80 (s, 6H, 2 × O-CH3), 1.49 (s, 9H, (C=O)-O-C(CH3)3), 1.27 (d, 3H, Thr Cγ-H, 
3JH-H = 6 
Hz), 1.19 (s, 9H, Cβ-O-C(CH3)3). 
13C NMR (CDCl3, 300 MHz) δ (ppm): 169.85, 160.99, 154.92, 150.64, 139.27, 134.37, 128.29, 
121.78, 104.55, 100.02, 82.04, 71.88, 67.17, 60.56, 55.28, 28.74, 28.08, 21.05 
3. [N-(threonyl)-carbamoyl]-pterostilbene (Pt CP-Thr-OH). 
Pt-CP-Thr(OtBu)-OtBu (0.8862g, MW = 499.60 g/mol, n = 1.77·10-3 mol, 1 eq) was dissolved in 25 
mL of anhydrous dichloromethane and 5 mL of TFA (MW = 114.02 g/mol, n = 6.53·10-2 mol, 36.9 
eq) were added to the solution. The mixture was stirred at room temperature for 3 hours. The 
reaction progress was checked by TLC. After 3 hours the solvent and the residual TFA were 
evaporated under reduced pressure. The residue was titrated with toluene (3 × 5 mL) , and then 
was evaporated under reduced pressure. The product was purified by automated 
chromatography system using chloroform + 1% acetic acid:methanol=9.8-9.5:0.2-0.5. Solvent was 
evaporated under reduced pressure. The residue was dissolved in 5 mL of dichloromethane and 
added to 200 mL of petroleum ether where the product was riprecipitated as a white solid. The 
precipitate was filtered by Büchner filter to afford 0.4736 g of product (68.9% yield). 
1H NMR (DMSO, 300 MHz) δ (ppm): 7.54-7.62 (m, 3H, H-2', 6' and O-(C=O)-NH), 7.06-7.31 (m, 4H, 
H-3', 5', 7 and 8), 6.78 (d, 2H, H-2 and 6, 4JH-H = 3 Hz), 6.42 (t, 1H, H-4, 
4JH-H = 3 Hz), 4.12-4.19 (m, 
1H, Thr Cα-H), 4.00-4.04 (dd, 1H, Thr Cβ-H), 3.78 (s, 6H,  2 × O-CH3), 1.16 (d, 3H, Thr Cγ-H, 
3JH-H = 6 
Hz). 
13C NMR (DMSO, 300 MHz) δ (ppm): 171.97, 160.67, 154.85, 150.50, 159.07, 133.93, 128.18, 
127.35, 121.85, 104.47, 99.92, 66.39, 60.23, 55.21, 20.42. 
ESI-MS: 801 m/z [2(Pt CP-Thr-OH)]- 
4’-[N-(aspartic acid)-carbamoyl]-pterostilbene (Pt-CP-Asp, 9) 
1. 4’-[N-(aspartic acid di-tert-butyl ester)-carbamoyl]-pterostilbene 
A solution of L-aspartic acid tert butyl ester hydrochloride (0.5025 g, MW = 281.77 g/mol, n = 1.78 
10-3 mol, 1 eq) and DMAP (0.8372 g, MW = 122.17 g/mol, 6.85 10-3 mol, 3.8 eq) in ACN dry (7 mL) 
was added dropwise to a solution of bis-(4-nitrophenyl) carbonate (0.5843 g, MW = 304.21 g/mol, 
n = 1.92 10-3 mol, 1.08 eq) in ACN dry (3 mL). The resulting mixture was stirred at 50 °C for 10 
minutes. Then, pterostilbene (0.5997 g, MW = 256.3 g/mol, n = 2.34 10-3 mol, 1.3 eq) was added 
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to the solution. The resulting mixture was stirred at 50°C for 1 hour, and then it was diluted in 
DCM (100 mL) and extracted with HCl 0.1 M (100 mL) and DCM (3 × 100 mL). The organic layer 
was dried over MgSO4 and filtered. The solvent was evaporated under reduced pressure and the 
product was purified by flash chromatography using DCM/petroleum ether/ acetone (5.5/4/0.5) 
as eluent to afford Pt-CP-Asp(tBu)-OtBu as a colourless oil (0.5824 g, MW = 527.61 g/mol, n = 
1.104 10-3 mol, 62 % yield) 
MS-ESI (ion trap) = 550 m/z [M+Na]+ 
1H NMR (300 MHz, CDCl3) δ (ppm) = 7.48 (d, J = 8.7 Hz, 2H), 7.18 – 6.88 (m, 4H), 6.66 (d, J = 2.2 Hz, 
2H), 6.39 (t, J = 2.2 Hz, 1H), 6.06 (m, 1H), 4.50 (m, 1H), 3.82 (s, 6H), 2.87 (m, 2H), 1.47 (s, 18H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 171.86, 171.28, 162.72, 155.96, 152.20, 141.00, 136.21, 
130.37, 130.03, 129.11, 123.50, 106.28, 101.78, 84.26, 83.46, 57.45, 57.08, 52.83, 39.41, 29.83, 
29.76, 29.68, 29.61. 
2. 4’-[N-(aspartic acid)-carbamoyl]-pterostilbene 
A solution of Pt-CP-Asp(tBu)-OtBu (0.5824 g, MW = 527.61 g/mol, n = 1.104 10-3 mol, 1 eq) in 3.4 
mL of DCM dry and 0.34 mL of TIPS (5 % v/v) was stirred at 0 °C. TFA (3.4 mL, MW = 114.02 g/mol, 
n = 4.4 10-2 mol, 40 eq) at -78 °C was added dropwise to the previous solution. The mixture is 
stirred at room temperature for 4 hours. TFA and the solvent were evaporated under reduced 
pressure. The product was titrated with toluene (2 × 3 mL) and purified by flash chromatography 
using CHCl3/MeOH (95/5) + 1% AcOH, to afford Pt-CP-Asp-OH as a white solid (0.3320 g, PM = 
415.4 g/mol, n = 8 10-4 mol, 72,4 % yield)  
MS-ESI (ion trap) = 416 m/z [M+H]+ 
1H NMR (300 MHz, DMSO) δ (ppm) = 8.10 (m, 2H), 7.60 (d, J = 8.2 Hz, 1H), 7.36 – 6.98 (m, 4H), 
6.78 (m, 2H), 6.39 (m, 1H), 4.39 (m, 1H), 3.78 (s, 6H), 2.72 (m, 2H). 
13C NMR (75 MHz, DMSO) δ (ppm) = 172.33, 171.61, 160.66, 154.02, 150.42, 139.05, 133.92, 
128.29, 128.06, 127.33, 121.77, 104.45, 99.91, 55.19, 50.68, 39.52, 36.06. 
4’-[N-(arginin)-carbamoyl]-pterostilbene (Pt-CP-Arg, 10) 
1. 4’-[N-(arginin-tert butyl-ester)-carbamoyl]-pterostilbene 
A solution of L-arginine tert butyl ester di-hydrochloride (0.5010 g, MW = 303.23 g/mol, n = 1.65 
10-3 mol, 1 eq) and DMAP (0.4196 g, MW = 122.17 g/mol, n = 3.43 10-3 mol, 2 eq) in DCM dry (4 
mL) was added dropwise to a solution of bis-(4-nitrophenyl) carbonate (0.5169 g, MW = 304.21 
g/mol, n = 1.7 10-3 mol, 1.03 eq) in DCM dry (3 mL). The resulting mixture was stirred at -15°C for 
5 hours. Then, a solution of pterostilbene (0.5498 g, MW = 256.3 g/mol, n = 2.145 10-3 mol, 1.3 
eq) and DMAP (0.2091 g, MW = 122.17 g/mol, n = 1.71 10-3 mol, 1 eq) in DCM dry (2 mL) was 
added to the solution. The resulting mixture was stirred at -15° C for two days. The resulting 
mixture was diluted in EtOAc (100 mL) and extracted with HCl 0.5 M (100 mL) and EtOAc (3 × 100 
mL). The organic layer was dried over MgSO4 and filtered. The solvent was evaporated under 
reduced pressure and the product was purified by flash chromatography using DCM/MeOH (9/1) 
as eluent to afford Pt-CP-Arg-OtBu as a colourless oil (0.4051 g, MW = 512.6 g/mol, n = 7.9 10-4 
mol, 48 % yield) 
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MS-ESI = 513 m/z [M+H]+ 
1H NMR (300 MHz, CDCl3) δ = 7.43 (d, J = 8.2 Hz, 2H), 7.00 (m, 7H), 6.62 (m, 2H), 6.40 (m, 1H), 6.36 
(m, 1H), 4.13 (m, 1H), 3.78 (s, 6H), 3.44 (s, 1H), 3.16 (m, 2H), 1.82 (m, 2H), 1.64 (m, 2H), 1.44 (s, 
9H). 
13C NMR (75 MHz, CDCl3) δ (ppm) = 171.27, 161.07, 157.50, 155.09, 150.38, 139.30, 134.74, 
128.95, 128.20, 127.57, 121.99, 104.74, 100.19, 82.82, 77.16, 55.45, 54.36, 41.05, 28.18, 27.99. 
2. 4’-[N-(arginin)-carbamoyl]-pterostilbene 
A solution of Pt-CP-Arg-OtBu (0.4051 g, MW = 512.6 g/mol, n = 7.9 10-4 mol, 1 eq) in DCM dry (3 
mL) and TIPS (0.3 mL) (5 % v/v) was stirred at -15 °C. TFA (3 mL, MW = 114.02 g/mol, n = 3.95 10-2 
mol, 50 eq) at -15 °C was added dropwise to the previous solution. The mixture was stirred at -15 
°C for 3 hours and then overnight at room temperature. TFA and the solvent were evaporated 
under reduced pressure. The product was titrated with toluene (2 × 3 mL) and purified by flash 
chromatography using DCM/MeOH (8/2) + 1% AcOH, to afford Pt-CP-Arg-OH as a white solid 
(0.2700 g, PM = 456.5 g/mol, n = 6 10-4 mol, 75 % yield) 
MS-ESI (ion trap) = 457 m/z [M+H]+ 
1H NMR (300 MHz, DMSO) δ (ppm) = 8.11 (m, 1H), 7.89 (m, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.36 – 
6.95 (m, 7H), 6.77 (d, J = 1.7 Hz, 2H), 6.41 (m, 1H), 4.02 (m, 1H), 3.78 (s, 6H), 3.15 (m, 2H), 1.81 (m, 
2H), 1.62 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 173.37, 160.69, 157.00, 154.34, 150.48, 139.07, 133.91, 128.29, 
128.09, 127.38, 121.83, 104.48, 99.92, 55.22, 53.76, 39.52, 25.29. 
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7. Transcription factor EB is a crucial transducer of the biomedical 
action of pterostilbene and resveratrol: work in progress 
 
Abstract: 
Polyphenols are a large and diversified class of natural compounds produced by plants 
mainly in response to stressing conditions. In our laboratory, we focus our attention on 
stilbenoids, in particular Resveratrol (trans 3-5-4’ trihydroxystilbene, Rv) and 
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene, Pt). These compounds exhibit, at 
least in vitro, a variety of activities of potential relevance for many areas of health care 
due to not only its redox properties but mainly to its ability to interact with various 
proteins. Although the beneficial effects of these two compounds are well-established, 
much remains to be learned about their molecular mechanisms of action.  
Autophagy is a cellular catabolic process activated by cells in response to stressing 
conditions. It involves lysosomes whose biogenesis and function are under the control of 
TFEB, the transcription factor activated under nutrients deprivation conditions. The 
relationship between polyphenols and autophagy is well established. In particular, a pro-
autophagic role is ascribed to Rv. 
Thus, we wanted to verify: 1) whether not only Rv but also - and perhaps more effectively 
- Pt could induce TFEB translocation into the nucleus of cells and consequently 
autophagy; 2) the efficacy in our system of Rv and Pt metabolites, the main species 
present in the body after the ingestion of polyphenols; 3) in case of a positive answer to 
the 1st point, how these two molecules trigger TFEB traslocation. 
HeLa cells overexpressing TFEB-GFP, kindly provided by Prof. Ballabio of TIGEM-Naples, 
were treated with different concentrations of Rv and Pt and with two types of 
metabolites and monitored by confocal microscopy for up to three hours. To verify the 
implication of AMPK and its upstream signaling, cells were treated also with a known 
AMPK activator (A769662). Variations of cellular cAMP levels were also measured using a 
FRET-based sensor (Dr. Giulietta Di Benedetto, IN-CNR). 
Both Rv and Pt, in our system, induce TFEB translocation into the nucleus of HeLa cells 
already at low, physiologically meaningful concentrations, but to a lesser extent than 
nutrient deprivation. Up to now, in fact, starvation remains the most potent migratory 
stimulus. Moreover, while sulfated forms phase II metabolites are almost uneffective, 
compounds resulting from the reduction of the stilbenic double bond (formed in the 
lower intestinal tract by bacterial enzymes) show an activity similar to that of the parent 
compounds. 
cAMP measurements instead show that our polyphenols induce in HeLa cells a slight 
increase in cAMP concentration. Addition of Forskolin or of IBMX (respectively a known 
potent activator of AC and a broad-spectrum inhibitor of PDE) induced in both cases a 
further increase of cAMP. 
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Finally, treatment with the AMPK activator, even though performed at the concentration 
known from the literature to efficiently up-regulate this kinase, shows a lower TFEB 
translocation into the nucleus if compared to the one induced by Rv and Pt. This leads us 
to speculate that our compounds might induce TFEB nuclear translocation also by 
modulating other signaling pathways. 
 
Introduction: 
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene, Pt) a close relative of storied 
Resveratrol (Rv), is emerging as a credible candidate for membership in plant phenolics’ 
hall of fame.3-5 The numerous biomedically relevant activities of Pterostilbene are broadly 
similar to those of Resveratrol, but the former apparently is more effective,3, 6, 7 
presumably because it is absorbed more readily8 and in most tissues it reaches higher 
levels after oral administration.9 This seems to be particularly significant in the case of the 
brain, and coherently pterostilbene improves intellectual performance in aged animals 
with greater efficacy than resveratrol.10 The (multiple) molecular mechanisms underlying 
the effects of Pterostilbene have not yet been comprehensively investigated, although 
several recent studies have dealt with aspects of its modulation of interlinked cellular 
signaling pathways (e.g.: 11-28). Given the results of these studies and the structural 
similarity of the two compounds, it is 
logical to postulate that largely the same 
cellular processes may account for the 
effects of resveratrol and pterostilbene 
(and other natural stilbenoids such as 
pinosylvin and piceatannol). The 
signaling cascade induced by resveratrol 
has been delineated in many studies 
(e.g., 1, 2, 25, 29, 30). A focal point is 
activation of AMPK which, among 
various effects, potentiates mitogenesis 
and autophagy,31-33 largely through 
inhibition of mTORC1, whose activity 
downregulates these cellular processes 
(e.g. 34-37). The antagonistic relationship 
between AMPK and mTORC1 is relevant 
in various contexts, in particular those of 
obesity and metabolic syndrome (e.g. 38-
40). Stimulation of autophagy has been 
given at least partial merit for important 
activities of resveratrol, such as 
promotion of β-amyloid disposition in 
neuronal cells,41, 42 protection against 
Fig1: A modified cartoon from Biasutto L et al.,1 
showing the signaling cascade identified by Park and 
colleagues2 and the confluent ROS-induced signaling.   
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prion protein-induced neurotoxicity43 and from oxidative damage,44-46 cardioprotection,47, 
48 anti-inflammatory action,49 lifespan extension in model organisms,50-53 amelioration of 
age-related functional decline54 and of neurodegeneration (e.g. 55-57). Indeed, resveratrol 
has been proposed as a potential treatment for diseases such as Alzheimer’s and 
Parkinson’s (e.g. 58-60). Pterostilbene has also been observed to stimulate autophagy.17, 24, 
61-64 
The master regulator of autophagy is Trascription Factor EB (TFEB) (revs.: 33, 65-67). Under 
normal circumstances TFEBp is Ser-phosphorylated by mTORC1 (at the lysosomal 
surface). Phosphorylated TFEB is complexed with the 14-3-3 protein and thereby 
constrained to the cytosol.68-70 Importantly, besides starvation which directly modulates 
the AMPK/mTOR axis, ROS are another major autophagy-stimulating factor.71, 72 The 
signaling pathway involved in this case reportedly involves the assembly of complexes on 
the surface of peroxisomes, and also leads to the downregulation of mTORC1 activity.73 
When its phosphorylation level decreases due to downregulation of the kinase, TFEB 
translocates to the nucleus where it increases its own expression (a positive feedback 
loop) as well as that of genes involved in lysosomal autophagy, lipophagy and fatty acid β-
oxidation. Thus TFEB upregulation may well help in the disposal of excess fat. A recent 
study has shown that hepatic overexpression of TFEB resulted in a lean phenotype, and 
significantly decreased both diet-induced and genetic obesity and metabolic syndrome,66, 
74 allowing hope that modulation of TFEB may permit the treatment and/ or prevention of 
these modern afflictions.75 Interestingly, and coherently with the emerging picture, 
pterostilbene has been reported to exert anti-obesity effects16, 76 as well as 
neuroprotection,10, 77 another context where autophagy is important (e.g. 59, 78-80).  
A very recent high-profile paper81 has reported the identification of a nutrient-sensing, 
autophagy-regulating axis formed by nuclear receptors FXR (farnesoid X receptor; a 
sensor of the nutrient-rich state) and CREB (cAMP response element binding protein). 
CREBp reportedly activates lipophagy and upregulates autophagy genes with the help of 
the co-activator CRCT2. This pleiotropic, crucial transcription factor is involved, among 
many other processes, in long-term memory formation, in which the cAMP-PKA-CREB-Nr4 
a genes axis has a major part,82-84 and thus its activation would help explain the cognitive 
effects of our compounds (chapter 8) as well.  
In view of the above, we tested whether pterostilbene could cause nuclear localization of 
a TFEB-GFP chimera expressed by engineered HeLa cells. Since this was the case, and a 
point of interest in polyphenol research is the relative efficacy of a given polyphenol, its 
analogs and metabolites, we extended the assay to resveratrol and some metabolites of 
both compounds. We furthermore checked that the signaling expected to be upstream of 
TFEB migration is indeed taking place, verifying whether an increase of cAMP occurred.  
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Materials and methods: 
Chemicals. Pterostilbene and Resveratrol were purchased from Waseta Int. Trading Co. 
(Shangai, P.R.China). Other starting materials for the synthesis of metabolites of Pt and Rv 
were from Wonda Science, Sigma Aldrich, Fluka & Riedel-de Haen, Carlo Erba Reagenti, 
Cambridge Isotope Laboratories Inc., Acros Organics, Prolabo, Merck-Novabiochem, J.T. 
Baker, and were used as received.  
Cell culture. in vitro experiments were conducted with the HeLa cell line. For confocal 
microscopy experiments we used HeLa overexpressing a TFEB-GFP construct, from prof. 
Andrea Ballabio’s laboratory (chimera cells were obtained as specified by Settembre C et 
al.69). Western blot and FRET experiments were performed with HeLa wild type (WT) cells, 
from dr. Giulietta Di Benedetto’s laboratory.  
HeLa WT cells were cultured in high glucose DMEM (Sigma Aldrich) supplemented with 
10% FBS (fetal bovine serum, Euroclone). HeLa TFEB-GFP were cultured in high glucose 
DMEM supplemented with 10% FBS and G418 (Sigma Aldrich, 100µg/ml).  
Confocal microscopy. A LEICA SP2 confocal microscope equipped with a Medical System 
Corporation thermostat was used. The light source was the emission from an Ar/HeNe 
laser at 488nm (25% power; gain 760, offset -0.4 for GFP fluorescence; gain 136 and 
offset -9.8 for bright field images). Images were taken through a 40X oil immersion 
objective. The thermostat was set at 37°C. 
18 hours prior to the confocal microscopy experiments, 200.000 HeLa TFEB-GFP cells 
were seeded onto round glass coverslips (24mm diameter, BDH) placed in the wells of a 6 
multiwell plate. Cells were cultured overnight in standard DMEM medium to allow 
adhesion. Before the experiment, the coverslip was mounted in an appropriate holder, 
gently rinsed with PBS (1x) and then covered with 1ml of Leibovitz’s L-15 medium 
(Invitrogen, supplemented with 10% FBS, no phenol red).  
Microscopy experiments were performed in temperature-controlled system without CO2 
superfusion. Leibovit’s L-15 medium is designed for supporting cell growth in 
environments without CO2 equilibration, thus it was preferred over DMEM. 
Drugs, media, treatments. Controls received DMSO (Sigma Aldrich) at the final 
concentration associated with addition of drugs, which was in all cases 0.1% of total 
volume. HBSS (Sigma Aldrich), starvation medium, was used as positive control. 
Pterostilbene (Pt) and Resveratrol (Rv) were used at final concentrations of 25µM, 10µM, 
1µM. Pterostilbene 4’-sulfate (Pt-S, 25µM), dihydro-pterostilbene (dihydro-Pt, 25µM), 
resveratrol 4’-sulfate (Rv-4’S, 25µM), resveratrol 3-4’-disulfate (Rv-3-4’S), dihydro-
resveratrol (dihydro-Rv, 25µM) were synthesized by Dr. A Mattarei of the Dept. of 
Chemical Sciences of the University of Padova and were of >98% purity in all cases. Other 
drugs used were: A 769662 (Abcam, 25µM), Rolipram (Abcam, 100µM, 25µM), IBMX 
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(Abcam, 100µM), PEG-SOD and PEG-CAT (Sigma Aldrich, 40u/ml and 500u/ml, 
respectively). 
Drugs were dissolved in a sterile solution of DMSO (Sigma Aldrich). Stock solution were 
prepared 1000x the desired working solution, so as to fix the final DMSO percentage at 
0.1% in all cases. TFEB migration was monitored for 3 hours after the addition of the drug. 
Images were taken every 15 minutes. 
Images were analyzed using the program ImageJ 1.48v (http://imagej.nih.gov/ij). TFEB 
migration was measured as a fluorescence ratio nucleus/cytosol. A few circular fields 
(regions of interest, ROIs) were drawn within the area of the nuclear and cytosolic cross 
sections of a given cell and their mean pixel intensity reading was used for fluorescence 
ratio determinations. For each image at least 5 cells were analyzed, and all ratios were 
combined to obtain a final average value of the TFEB-GFP nuclear/cytosolic concentration 
ratio. 
cAMP-FRET based sensor. cAMP variations were measured as described by Oliveira et 
al.85 Experiments were performed by dr. Giulietta Di Benedetto (CNR Institute of 
Neuroscience and Venetian Institute of Molecular Medicine, Padova). The EPAC1-based 
FRET sensor H30 described in Ponsioen B. et al.86 was used.  Briefly, HeLa WT cells were 
seeded onto 24-mm diameter round glass coverslips. Transfection was performed at 50-
70% of confluence with the FuGENE-6 transfection reagent according to manufacturer’s 
instructions. 1-2 µg of DNA were added to each coverslip. Imaging experiments were 
performed 24-48h after the transfection with H30. For imaging, cells were maintained in 
Hepes-buffered Ringer-modified saline (125mM NaCl, 5mM KCl, 1mM Na3PO4, 1mM 
MgSO4, 5.5mM glucose, 1mM CaCl2 and 20mM Hepes, pH 7.5) at room temperature. 
Images were taken with an inverted microscope (IX50, 60x NA 1.4 oil immersion 
objective, Olympus), acquired using custom-made software and processed using imageJ. 
FRET changes were measured as changes in the background-subtracted 480/545nm 
fluorescence emission intensities on excitation at 430nm and expressed as either R/R0, 
where R is the ratio at time t and R0 is the ratio at time = 0s, or ΔR/R0 where ΔR = R-R0.  
Western blot. Cells were lysed in RIPA buffer supplemented with fresh phosphatase 
inhibitors (Sigma Aldrich, Phosphatase inhibitor cocktail 2 n° P5726 and Phosphatase 
inhibitor cocktail 3 n° P0044) and protease inhibitors (Sigma Aldrich, Protease inhibitor 
cocktail n° P2714). The RIPA lysate was kept at ice temperature for 15min, then 
centrifuged (14000rcf, 20min, 4°C). The supernatant was collected and stored at -80°C. 
Protein content was estimated with the Bradford assay. Prior to electrophoresis, the 
lysate was supplemented with sample buffer (1X: 62.5mM Tris-HCl pH 6.8, 2% SDS, 10% 
glycerol, 50mM DTT, 0.02% bromophenol blue) and heated at 95°C for 5min. From 10 to 
20 micrograms of proteins per lane were loaded on 4-12% Bis-Tris gel (NUPAGE, 
Invitrogen). For the detection of high molecular weight proteins, 50 to 60 micrograms of 
proteins per lane were loaded on 3-8% Tris-Acetate gel (NUPAGE, Invitrogen). After 
electrophoretic separation proteins were transferred to PVDF membranes (300V-400mA-
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1h at 4°C or 30V-90mA-overnight at 4°C for high molecular weight proteins). Membranes 
were saturated with 5% BSA (Sigma Aldrich, n° A9647) in TBS 1X at room temperature for 
1h, then incubated with primary antibody (in TBS Tween 0.1%, 5% BSA) overnight at 4°C, 
washed with TBS Tween 0.1% and incubated with HRP-conjugated secondary antibody. 
Detection was performed using the ECL method (Pierce) in a ChemiDoc system (BioRad). 
Antibodies against the following proteins were used: TFEB (MBS716265 - MyBiosource, 
polyclonal, 1:1000); H3 (#9715 - Cell Signaling, polyclonal, 1:9000); β-Tubulin (sc-9104 - 
Santa Cruz, polyclonal 1:1000); LC3B (#3868 - Cell Signaling, monoclonal, 1:1000); HSP90 
(610419 - BD, monoclonal, 1:1000); Ph-CREB (#9198(Ser133) - Cell Signaling, monoclonal 
1:1000); Ph-AKT (#4060(Ser473) - Cell Signaling, monoclonal, 1:2000 - and 
#13038(Thr308) – Cell Signaling, monoclonal, 1:1000); Ph-ERK (#9101(Thr202/Tyr204) - 
Cell Signaling, polyclonal, 1:1000); Ph-AMPKα (#2535(Thr172) - Cell Signaling, monoclonal 
1:1000); Ph-ACC (#11818(Ser79) - Cell Signaling, monoclonal, 1:1000).  
Nuclear/cytosolic fractionation. The protocol was adapted from Gagnon KT et al.87 
Cultured cells were lysed in a 0.5% Triton X-100 buffer (HLB) for 10 minutes at ice 
temperature. Buffer composition was as follows: 50mM Tris-HCl, 137.5mM NaCl, 5mM 
EDTA, 0,5% Triton X-100 and 10% vol/vol glycerol, freshly added phosphatase and 
protease inhibitors. The lysate was then vortexed (5s), then centrifuged (800rcf, 8min, 
4°C). The supernatant, constituting the cytosolic fraction, was collected and stored at -
80°C. The pellet, containing nuclei, was washed twice by resuspension in HLB and 
centrifugation (200rcf, 2min, 4°C).  
Isolated nuclei were finally lysed in RIPA buffer for Western blot analysis, or preserved in 
ice-cold HBSS for spettrofotometric/FACS analysis. 
Triton X-100 was preferred over alternative detergents such as Np-40 or Igepal CA-630 
since it better preserves the endoplasmic reticulum surrounding the nucleus. TFEB is a 
small protein of 52-53 kDa. Nuclear pores are relatively permeable to small proteins, thus 
we decided to use a milder detergent and preserve as much as possible the integrity of 
the nuclear membranes in order to limit the loss of nuclear TFEB during the nuclei 
isolation procedures. 
For the isolation of nuclei from liver and brain tissues the dissected organs were promptly 
immersed in ice-cold PBS with Ca2+ and Mg2+ (D-PBS, Sigma Aldrich), and minced with 
scissors. Tissues were then homogenized with a Potter device (Teflon pestle, 3-4 strokes), 
filtered with a cell strainer (Falcon: 352360, 100µm), centrifuged at 500rcf, 10min, 4°C. 
Supernatants were discarded and pellets resuspended with ice-cold HLB. Subsequent 
steps were as described above for the isolation of nuclei from cultured cells.  
The effectiveness of the fractionation procedure was verified a posteriori by Western blot 
analysis. Histone-3 and β-tubulin were used as nuclear and cytosolic marker, respectively, 
to verify the purity of the two fractions. 
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FACS analysis of nuclei. Nuclei were obtained as described above, and kept in ice-cold 
HBSS. They were stained with Propidium Iodide (Sigma) at a final concentration of 
1µg/ml, (incubation in darkness at 37°C, 20min). A Beckton Dickinson II flow cytometer 
was used. 10000 nuclei were counted for each measurement.  
Synthesis of Pt and Rv metabolites. This part of the work was performed by the group of 
prof. Cristina Paradisi. Sulfates were synthetized as previously described in Mattarei et 
al.88 
Dihydro derivatives of resveratrol and pterostilbene were prepared by hydrogenation of 
corresponding stilbenes following the procedure reported by D.C. Rueda et al.89 with 
minor modification. Solutions of each stilbene (1.00 mmol) in absolute EtOH (15 ml) were 
stirred under H2 for 6 h in the presence of 10% Pd/C. The reaction mixtures were filtered 
over Celite to remove the catalyst, and evaporated to dryness. The resulting residues 
were purified by flash column chromatography, using a hexane/EtOAc gradient, to afford 
target dihydro compounds dihydro-Rv (92% yield) and dihydro-Pt (95% yield). The 
spectroscopic data of compounds were in agreement with the literature. 
Results and discussion: 
Pt and Rv induce nuclear translocation of TFEB: 
To test whether Pt and Rv induced TFEB translocation to the nucleus, HeLa TFEB-GFP cells 
in Leibovitz’s L-15 medium were initially treated with 25µM Pt or Rv and TFEB migration 
was followed by confocal microscopy. 0.1% DMSO was added in negative controls to 
verify that the vehicle per se did not induce migration. HBSS was used as experimental 
a b 
c Fig 2: Pt and Rv induce TFEB migration from 
the cytosol to the nucleus. (a) Representative 
images taken at 0 and 3h after DMEM-HBSS 
exchange or addition of Pt or Rv. (b)  TFEB-GFP 
migration to the nucleus was faster in HBSS-
induced starvation compared to Pt or Rv 
treatment. However, (c) at 3h nuclear/cytosol 
ratios were similar in the three cases. N = 2 or 
3, error bars represent standard deviation 
(when N = 3) or average deviation (for N = 2). 
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medium in order to “starve” the cells, thus providing the positive control. HBSS provides 
pH maintenance, osmotic balance, water and essential inorganic ions but no energy 
source. Energy deprivation leads to a decrease of ATP levels in the cell, while ADP and 
AMP levels increase, leading to the activation of AMPK.90 mTORC1, the protein 
responsible for TFEB phosphorylation, and thus for its cytoplasmatic confinement, is a 
direct target of AMPK.91 Phosphorylation by AMPK leads to inhibition of mTORC1 activity. 
The phosphorylation level of TFEB thus decreases and its migration to the nucleus is 
favored.65 
As expected, the vehicle (DMSO) does not itself induce TFEB migration (fig 2, b-c), while 
HBSS-induced starvation has a strong effect (fig 2, a-c). 
Both Pt and Rv, when supplied at 25µM in complete Leibovitz’s L-15 medium, are able to 
induce a consistent migration of TFEB to the nucleus (fig 2, a-c). However, the kinetics by 
which starvation, Pt and Rv act are different. Starvation is the most potent stimulus: 
maximal nuclear translocation of TFEB is achieved in 1 hour (fig 2, b). The effect of Pt and 
Rv instead is more progressive, and migration reaches its maximum level at the end of the 
three-hour period (fig 2, b-c).  
In vivo, concentrations of Pt and Rv in the 25µM range are however difficult to reach. 
While Pt can reach this level in organs such as liver and kidney after a moderate 
pharmacological dosage by oral administration,9 for Rv it is nearly impossible to attain 
these levels even after administration of high doses p.o. Moreover, also for Pt, in organs 
such as the brain, heart, lungs and skeletal muscle the concentrations achieved are 
considerably lower than in liver and kidney. Given in particular the reports that Pt and Rv 
a 
b 
c 
d 
Fig 3: Low doses of Pt and Rv induce TFEB migration from the cytosol to the nucleus. 10µM and 1µM Pt 
(a, b) or Rv (c, d) were as effective as 25µM in inducing TFEB migration. N = 2 or 3, error bars represent 
standard deviation or average deviation. 
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exert positive effects in ameliorating brain pathologies and dysfunctions (e.g. Alzheimer’s 
disease, Parkinson’s disease, cognitive aging; see the introduction), we sought to define 
the effects of more physiological levels (1 and 10 µM) of both molecules on TFEB 
distribution. 
As shown in fig 3, both concentrations, 1µM and 10µM, of both molecules, Pt and Rv, 
where about as effective as the higher 25µM concentration in inducing TFEB migration. 
While many investigations have demonstrated an activity of polyphenols at 
unphysiologically high concentrations (e.g. 2), this report is one of the few showing 
efficacy at physiological levels. 
Pt and Rv metabolites: 
In vivo, Rv and Pt are mostly transformed into metabolites. Several authors therefore 
propose that the effects ascribed to polyphenols may instead be accounted for by their 
major phase II metabolites (e.g. 92, 93). Polyphenols are also subjected to modification by 
the colonic flora. In another context during my thesis work (chapter 4) I administered 
chronically Rv to rats. In the caecum and colon I was able to quantify only dihydro-Rv, the 
reduced form of trans-Rv. Various authors have reported effects of Rv against colon 
cancer and Crohn disease.7, 94-97 We decided therefore to also verify the effects of Pt and 
Rv phase II sulfates and reduced forms (synthesized by the group of prof. Cristina 
Paradisi) in our experimental system. Sulfates and reduced forms of Pt and Rv are present 
at high concentration in organs and colon, respectively, after administration p.o. of 
pharmacological doses. For this reason so far we have tested these compounds only at 
25µM. 
Fig 4: Reduced forms of Pt and Rv, but not sulfate metabolites, induce TFEB migration from the nucleus 
to the cytosol. Experiments with 25µM Pt or Rv (panels a-d, blue) are shown for comparison purposes. 
Reduced forms of Pt and Rv, namely dihydro-Pt and diydro-Rv were about as effective as Pt and Rv 
themselves in inducing TFEB-GFP migration to the nucleus (a-d). Sulfates of both Pt and Rv had only a 
small or no effect. N = 2 or 3, error bars represent standard deviation or average deviation. 
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TFEB distribution was perturbed by dihydro-Pt and dihydro-RV, while the sulfates were 
almost uneffective (fig 4, a-d). In fig 4 the results obtained with 25µM Rv and Pt are 
shown for comparison purposes. Dihydro-Pt and dihydro-Rv not only led to 
nuclear/cytosolic ratios for TFEB (fig 4, a, c) similar to those observed upon administration 
of the parent compounds, but did so with comparable kinetics (fig 4, b, d). Pt-sulfate was 
poorly effective, inducing only a small shift of TFEB to the nucleus, if any. Rv-3-sulfate and 
Rv-3,4-disulfate definitely were completely inert (fig 4, c, d).  
One possible explanation of these results might be reconduced to the different ability of 
these molecules to cross the plasma membrane. While Pt and Rv, as well as the reduced 
forms (dihydro-Pt and dihydro-Rv) are relatively non polar, mostly neutral (at 
physiological pH) molecules and thus can passively diffuse through cell membranes, 
sulfate (and probably glucuronide) forms are bound to encounter difficulties. The 
negatively charged sulfate group confers an elevated hydrophilicity to the molecules, 
which remain confined outside of the cell.  
Pt and Rv, the starting point:   
Fig 5: cAMP levels after Pt or Rv  administration. Epac-based FRET sensor H30 was used. Forskolin 
(25µM) fully activates ACs while IBMX (100µM) inhibits PDEs. Pt and Rv induce an increase in 
cytosolic cAMP (a, b). The effect of Pt is more pronounced than that of Rv. Forskolin and IBMX were 
added after Pt or Rv, and led to a further increase in cAMP levels in the cytosol of HeLa cell. 100 µM 
IBMX induced TFEB-GFP migration to the nucleus, but was less effective than 25 µM Pt or Rv (c, d). N 
= 2 or 3, error bars represent average deviation or standard deviation. 
a 
d c 
b 
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The plethoric activity of Pt and Rv is presumably the consequence of interactions with 
multiple proteins. However, obviously some interactions may be more important than 
others for a given end-effect. In 2012, Park et al.,2 have proposed PDE 1, 3 and 4 as a 
major target of Rv. In particular they discovered that Rv acts as a competitive inhibitor of 
cAMP on PDEs. In view of this, we decided to first, confirm their results with an 
alternative approach, second, to verify if Pt effects may also be part of a cAMP-dependent 
signaling cascade. 
cAMP signaling is largely mediated by two proteins, protein kinase A (PKA) and cAMP-
regulated guanine nucleotide exchange factors (Epac1 and Epac2, Oliveira R.F. et al.85). 
The binding of cAMP to PKA or Epac leads to a conformational change of these proteins. 
H30-FRET-based biosensors exploit the conformational change of Epac1 protein in order 
to measure the cAMP level in a given environment.85 We thus measured the variation of 
cAMP concentration in HeLa WT cells transiently transfected with an Epac1-FRET-based 
biosensor (H30-FRET) after addition of Pt or Rv. 
H30-FRET-based experiments were performed by dr. Giulietta Di Benedetto (CNR Institute 
of Neuroscience, Venetian Institute of Molecular Medicine, Padua). 
Both Pt and Rv at 25µM dose induced an increase in cytosolic cAMP (fig 5, a, b). Pt in 
particular yielded the more pronounced increase. Forskolin (25µM) and IBMX (100µM) 
were used as controls. Forskolin potently activates Adenylate Cyclases (AC, 98) while IBMX 
is a non-specific inhibitor of PDEs.99 Both these drugs are normally used as a reference in 
cAMP-FRET measurements.  
Administration of Forskolin and IBMX after Pt/Rv induced a further increase in cAMP 
levels (fig 5, a, b). As shown by Park et al.,2 Rv does not increase cAMP by activating AC, 
but rather by inhibiting some PDE subfamilies. This can explain why by activating AC or 
completely inhibiting PDEs we were able to measure a further increase in cAMP levels (fig 
5, a, b).  
Notably, the increase in cAMP levels after Forskolin addition to cells previously treated 
with Pt or with Rv was of the same order of magnitude of that induced by the addition of 
Forskolin to untreated cells (fig 5, b). Since Rv does not act via AC, we can presume that 
this also applies to Pt. Otherwise, if part of the effect of Pt were mediated by AC 
activation, we would expect to observe a smaller change in cAMP levels when applying 
Forskolin to Pt-treated cells.  
The addition of IBMX after forskolin instead led to a similar plateau in cAMP levels 
independently of whether the cells had been previously treated with Pt, Rv, or neither 
stilbenoid (fig 5, a, b). This further confirms that Rv, and probably Pt, increases 
intracellular cAMP levels by inhibiting certain subclasses of PDEs. When all the PDE 
subfamilies are inhibited by IBMX, indeed, one cannot observe a significant difference in 
cAMP levels related to the presence of Rv or Pt (fig 5, b).  
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However, HeLa cells treated with Pt showed an higher increase in cAMP levels than HeLa 
cells treated with Rv. Assuming that in both cases the mechanism involves PDEs 
inhibition, we can hypothesize that the superior potency of Pt might be due to: 
1. Inhibition of other subclasses of PDE (besides subclasses 1, 3 and 4, as suggested by 
Park et al.2) 
2. A stronger inhibition of subclasses 1, 3 and 4.  
3. Both of the above 
We next wondered whether TFEB migration from the cytosol to the nucleus might be due 
to the observed increase in intracellular levels of cAMP. HeLa TFEB-GFP cells were thus 
treated with IBMX 100µM only. IBMX was able to induce the migration of the 
transcription factor to the nucleus, but to a lower extent than 25µM Pt or Rv (fig 5, c, d). 
Pt- and Rv-induced TFEB migration is thus probably in part downstream of effectors other 
than cAMP.  
Park et al.2 excluded PKA as a possible downstream mediator of Rv in HeLa cells, while a 
role of Epac was supported. The conclusion was based on specific silencing of PKA or Epac 
mRNAs. Briefly, Rv was able to activate AMPK when PKA was silenced, but not when Epac 
was silenced. Given the recent findings by Seok et al.81 (see Introduction), I decided to 
also consider the possibility of a role of CREBp in autophagy. CREB is phosphorylated, and 
thus activated, by PKA.100, 101 If Rv or Pt do not have PKA as a downstream effector, the 
phosphorylation status of CREB should be unaffected by them.   
Western blot analysis is still in progress. Here I report preliminary results obtained with 
HeLa cells by using an extremely high concentration of Pt or Rv (100µM). This part of the 
work is being done in preparation for a more physiological an exhaustive investigation 
which is being planned (see below). HeLa WT cell were seeded in a 6 multiwell plates 
(200.000 cells per well, as done for the TFEB migration experiments) and treated as 
described in fig 6. Pt, but not Rv, induced CREB phosphorylation, at levels comparable to 
Fig 6: Western blot analysis detecting the phosphorylated forms 
of CREB (Ph-CREB, Ser 133) or HSP90 (housekeeping). 0.1% 
DMSO, starvation (HBSS), 100µM Pt or Rv and IBMX (50µM) + 
Forskolin (25µM) were used as treatments. Cell were lysed with 
RIPA buffer 90min after the beginning of the treatment. 
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those induced by IBMX-Forskolin treatment. This result is in agreement with the findings 
by Park et al.2 Rv indeed does not induce dramatic CREB phosphorylation, thus PKA seems 
not to be involved in signaling downstream of Resveratrol. Conversely, Pt induces a strong 
phosphorylation of CREB, indicating PKA, as well as Epac, as downstream effectors of its 
activity. 
Is AMPK involved in Pt and Rv-induced TFEB migration? 
As previously shown, a rise in cAMP level is not sufficient to trigger TFEB migration in a 
manner similar to that of Pt and Rv (fig 5). As mentioned above, mTORC1 is a direct target 
of AMPK. To test and verify the hypothesis that AMPK is behind TFEB migration, we have 
adopted a double approach. First, we treated HeLa TFEB-GFP cell with a specific activator 
of AMPK, the compound A769662.102 A769662 was used at 25µM because it affords a 
near-maximal activation of AMPK and still higher concentration may lead to the inhibition 
of mitochondrial oxygen consumption and thus to an increase in AMP:ATP ratio.102 
As shown in fig 7, administration of A769662 to HeLa TFEB-GFP cells induced migration of 
TFEB to the nucleus. However the effect was relatively weak, lower than that of Rv or Pt, 
suggesting that AMPK may not be the only and obligatory intermediate in the signaling 
cascades initiated by stilbenoids.  
The second approach is based on western blot analysis. As previously mentioned, this 
part of the work is still ongoing and data are too preliminary to be showed here. 
Conclusions:  
As expected, given the cardinal role attributed to TFEB as a master regulator of 
autophagy, and the evidence that stilbenoids induce autophagy, in cultured HeLa cells Rv 
and Pt induce migration of a TFEB-GFP chimera to the nucleus, at concentrations as low 
as 1 µM.  
Dihydro-Rv and dihydro-Pt, the products of bacterial hydrogenation of the carbon-carbon 
double bond in the stilbenoid skeleton, are about as effective as Rv and Pt themselves, a 
Fig 7: 25µM A769662 induces TFEB-GFP migration to the nucleus. The results obtained with 25µM Pt 
and Rv are shown for comparison purposes. N = 2 or 3, error bars represent average or standard 
deviation. 
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significant finding strengthening the view that the metabolites of polyphenols may have 
much to do with the beneficial effects of these natural compounds. On the contrary, 
negatively charged, hydrophilic sulfates of Rv and Pt have no significant effect, likely 
because they do not enter cells.  
TFEB relocation is accompanied by an increase of cAMP levels, already observed by other 
authors and ascribed to the primary event, inhibition of members of the PDE family. 
According to the mechanistic scheme developed by Park et al.2 for resveratrol, the cAMP 
increase is upstream of AMPK activation and mTORC1 inhibition, i.e., autophagy 
induction. The signal cascade for resveratrol was found to involve the GEF Epac1, but not 
PKA. A recent report has furthermore implicated CREB in autophagy induction. 
Coherently, my preliminary results indicate that it becomes phosphorylated upon 
administration of Pt (but not resveratrol) to the cells (fig 6). CREB phosphorylation is 
executed by PKA, and thus it is also downstream of cAMP.  
There appears however to be a still-to-be-investigated difference between the modes of 
action of Rv (which does not cause massive phosphorylation of CREB) and Pt (which 
does). Furthermore, my results indicate that a cAMP increase due to PDE inhibition may 
not be sufficient to explain the induction of TFEB translocation, since upon treatment of 
the cells with IBMX, a PDE pan-inhibitor, TFEB translocation was lower than that induced 
by Rv or Pt (fig 5). 
AMPK activation also might account only partially for TFEB migration, since nearly full 
activation  by A769662 induced nuclear translocation of the TFEB-GFP chimera to a 
similar or lower extent than treatment with the stilbenoids. 
Perpectives: 
The results obtained so far in this part of the work encourage us to concentrate our 
efforts on the analysis of the mechanisms of action of Rv and Pt. Having established that 
Pt and Rv strongly induce TFEB migration, at least in vitro, we plan to investigate 
downstream and especially upstream events. 
Besides AMPK, mTORC1 activity can be regulated by other proteins such as AKT and ERK, 
the phosphorylation levels of which in the presence of stilbenoids are currently under 
investigation.  
AMPK activation by both Pt and Rv needs to be confirmed in our experimental model. 
PDEs inhibition by Rv has already been proven, but that Pt also inhibits 
phosphodiesterases remains an hypothesis. We plan to clarify this crucial event also for 
Pt. 
Pt and Rv can induce an increase in ROS levels.64, 103-105 ROS are sensed by the Nrf2/Keap1 
complex, which is activated and induces the transcription of ROS scavengers. ROS are 
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recognized as autophagy inducers.106 Through the use of cell permeant scavenger of ROS 
(namely PEG-CAT and PEG-SOD) we shall verify how important is the contribution of ROS 
in modulating Pt- and Rv-induced-TFEB localization.  
After an in vitro detailed mechanistic investigation of Pt and Rv pro-autophagy activity, 
we aim to show the same effects and the involvement of the same pathways also in vivo. 
A few experiments in this direction have been already performed.  
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8. Pterostilbene and cognitive performance in the aged rat model: 
preliminary findings 
 
Summary: 
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene, Pt) is a natural dietary compound 
and a major polyphenolic component of blueberries. This compound is emerging as 
potentially very beneficial for health care. Several recent papers report that it can, for 
example, contrast inflammation and cancer and improve cognitive performance and 
short-term memory impaired by old age or neurodegeneration. Pt is more bioavailable 
than its celebrated non-methylated analogue, Resveratrol (Rv), and, notably, it can cross 
the blood brain barrier. While the literature contains reports of effects of Pt in 
prevention/treatment of cognitive impairment in old individuals, no studies have 
investigated the detailed mechanisms underlying these observations.  
The intent of this study is to identify the downstream effectors of Pt treatment in aged 
rats. At this time I have completed a preliminary feasibility study. We selected from the 
literature a panel of genes and proteins that potentially might be regulated by treatment 
with Pt. These proteins and genes are suitable markers to evaluate the impact on the 
general cognitive capacity of the old treated animal (BDNF and Psd95, two proteins that 
directly correlate with the functionality of neurons and synapses), the autophagy status 
(TFEB, the recently discovered master regulator of autophagy) and the modulation of 
protein and genes expression (RbAp48 and Rest). 
The cognitive capacity of two groups of 4 aged (18 months) rats was evaluated through 
behavioral tests. One of the two groups then received Pt p.o. for 20 consecutive days, and 
the cognitive assessment was repeated. VentroMedial Prefrontal cortex (PFc), Perirhinal 
cortex (PRNLc), Dentate Gyrus (DG) and the rest of Hippocampus (HIP) were then 
collected and analyzed by RT-qPCR or western blot. 
The inadequate numerosity of the experimental groups in this preliminary experiment 
prevents, as expected, the achievement of statistical significance of the results. 
Nonetheless, trends can be detected and the basis has been set for further work which is 
expected to lead to reliable conclusions. Data indicates that after Pt administration the 
treated group presented a consistent improvement in memory and learning tests 
administered 24 hours after the training session. Gene expression analysis indicates that 
in general the DG is the area most solicited by the treatment with Pt. bdnf gene 
expression seems to be unaffected by Pt treatment while rbbp4 (the gene of RbAp48), 
tfeb, dlg4 (the gene of Psd95) and rest tend to be up-regulated in the treated animal 
group.  
Our data, although preliminary, confirm that chronic administration of pharmacological 
amounts of Pt has positive effects at a behavioral level in old animals. Gene and protein 
analysis suggests that behavioral improvement may be related to: 1. a rearrangement in 
the synaptic architecture (Psd95), 2. change in the acetylation level of histones (RbAp48) 
and 3. an increase in autophagy (TFEB).  
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Introduction: 
A number of papers report that assuming plant-derived foods or juices rich in 
antioxidants enhances the intellectual performance of rodents afflicted by age or 
neurodegeneration.2-14 Similar effects can be observed also in young15 and middle-aged16 
rats and aged humans.17-19 These foods contain a number of putative active ingredients, 
such as flavonoids, anthocyanins and resveratrol, which may have synergic action. While 
resveratrol itself has been reported to positively affect memory and cognition (e.g. 20-30), 
this study focuses on pterostilbene, i.e. 3,5-dimethylresveratrol, which is emerging as a 
possibly more effective antagonist of age in the modulation of intellectual function31-34 
and in mice reportedly protects against inflammation-linked learning and memory 
impairment35 and has anxiolytic action.36 The question arises of the mechanisms of action 
of active food constituents. Considerable work to clarify these fundamental aspects has 
been carried out with flavonoids37-49 and resveratrol.50 The protective effects of the latter 
may be partly ascribed to its anti-inflammatory action. Neuroinflammatory processes are 
believed to play a crucial role in the development of neurodegenerative diseases, due in 
part to an increased production of reactive oxygen species (ROS) (e.g. 51-53). Resveratrol is 
able to counteract ROS production by antagonizing NADPH oxidase (e.g. 54-56) and by 
accelerating mitochondrial O2
-  detoxification through upregulation of SOD2 (e.g. 57, 58). In 
addition resveratrol (as well as ROS and pterostilbene) can induce the expression of other 
antioxidant enzymes such as NAD(P)H quinone oxidoreductase 1 (NQO1), heme 
oxygenase 1 (HMOX1), glutamate-cysteine ligase (GCL) and glutathione S transferases 
(GSTs) through the upregulation of Nrf2 signaling.59-61 The transcription factor Nrf2 is 
tightly bound to Keap1, which facilitates ubiquitin-mediated degradation of the 
transcription factor. Upon oxidative stress the Nrf2/Keap1 complex is disrupted and Nrf2 
can translocate to the nucleus where it promotes the transcription of ARE-targeted genes 
(e.g. 62-64). Resveratrol also contrasts inflammation through the inhibition of nuclear 
factor kappa B (NFkB) (e.g. 65-67) via inhibition of upstream IKK kinase (e.g. 68-70) and via 
SIRT1-mediated deacetylation of NFkB itself (e.g. 71, 72). NFkB targets many pro-
inflammatory genes, such as cytokines and chemokines (e.g. 73-78). Resveratrol and anti-
inflammatory action are recognized to have beneficial effects also on the vascular and 
micro-vascular system (e.g. 25, 30, 54, 79-82). NADPH oxidases are one of the possible 
pharmacological targets (e.g. 83), and resveratrol can act at this level, again through 
SIRT1.54, 55 Age- or disease-related circulation deficits can contribute heavily to cognitive 
impairment84-88 (see also below).  
Unsurprisingly, given the structural similarity, the effects of Pt are in line with those 
ascribed to resveratrol,33, 34, 89 but its efficacy seems to be higher.31 We have determined 
the pharmacokinetics of Pt and its major metabolite, the sulfate, in various organs after 
administration of a bolus.90 The brain differs from other organs in that Pt as such is the 
major specie, presumably due to its lipophilicity. The levels it reaches are considerably 
higher than those of resveratrol after administration of an equimolar dose; this may 
account, at least in part, for its greater effectiveness. 
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In particular, Pt improved performance in spatial learning and memory tests (radial arm, 
water maze),31 implying effects on spatial memory. Thus, the hippocampus and perirhinal 
cortex may be affected. A question arising is therefore that of the molecular mechanisms 
of Pt action. Memory formation and its deterioration with aging are complex processes 
which are not known in full detail (rev.: 91, 92). It is clear however that memory is linked to 
the strengthening, de novo formation and remodeling of connections between nervous 
cells, the spines, thus upregulation of proteins and activities involved in these processes 
may be expected.  
In the early 1970’s Nobel prize winner Eric Kandel and coworkers hypothesized that there 
may be a connection between short-memory formation and cAMP-mediated signaling.93, 
94 They observed that neurotransmitters such as serotonin and dopamine could increase 
levels of cAMP. This discovery was followed by the observation that long-term memory 
formation involved the migration of PKA and MAPK (downstream effectors of cAMP) to 
the nucleus, activation of the transcription factor CREB-1 (cAMP Response Element 
Binding Protein-1) and consequent increased expression of a set of genes leading to the 
growth of new synaptic connections.95-99 Aging-related cognitive decline affects, among 
many other functions, long-term memory formation.100 Given the importance of the 
cAMP/CREB pathway in the formation of such memory, efforts are under way to find a 
pharmacological approach for the modulation of memory formation.100-102 Particularly 
interesting in this context is the role of Phosphodiesterases (PDEs). PDEs are a vast class 
of proteins (more than 100) classified in 11 groups, which can hydrolyze the 
phosphodiester bond of cAMP and cGMP. These protein are in some cases selective for 
cAMP or cGMP and they can be ubiquitously expressed or selectively expressed in certain 
areas. What is now clear is that their pharmacological regulation can be important for 
intervention on several dysfunctions. Rolipram, an inhibitor of PDE4, has already been 
tested for boosting long-term memory formation.101 While Resveratrol was shown by 
Park et al.103 to be an inhibitor of PDE class 1, 3 and 4, Pt activity in this respect is still not 
characterized. In our laboratory we have addressed the question of whether Pt can cause 
an increase of cellular [cAMP]. Pt turns out to be more potent than Resveratrol in this 
respect, thus presumably activating PKA and ultimately the CREB/CBP pathway. Part of 
our future efforts will aim to define the interaction of Pt with PDEs.  
Epigenetic modifications of neural cells are recognized to underlie memory consolidation 
and learning and conversely to play a role in cognitive decline and neurodegeneration 
(e.g. 104-113). Modulation of histone acetylation may be one of the mechanisms.114-116 
Epigenetic effects may well be responsible for a considerable portion of Pt action. Gene 
expression is strongly regulated by modifications such as DNA and histone 
acetylation/methylation. Activation of the cAMP/CREB/CBP pathway can be irrelevant if 
the target genes are not accessible to the transcription factor. Histone 
acetylation/deacetylation in particular leads to an alteration of the accessibility of the 
DNA to proteins. Histone tail acetylation causes a relaxation of the chromatin structure. 
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Acetyl group indeed masks the positive charge of lysine residues on the tail of histones 
that are important for the interaction with the negative charge of the DNA backbone.  
In 2013 it was discovered that a protein, Retino Blastoma Associated Protein 48 (RbAp48), 
is downregulated in the dentate gyrus of senescent individuals (human and mice) and 
that its restoration (in a mouse model, through AAV carriers) leads to recovery of 
cognitive capacity in old animals.117 This protein is part of a large complex called NuRD 
(Nucleosomal Remodeling and Deacetylase complex) where it directly interacts with the 
protein MTA-1 (among others). In general, NuRD consists of several proteins whose 
coordinated function is to repress gene transcription.118-122 However, this is not the only 
way by which RbAp48 acts in the modulation of the gene transcriptions. Another pathway 
(fig 1) relies on the interaction of RbAp48 with CBP (CREB Binding Protein). CBP in 
particular is recruited by the phosphorylated form of CREB, which is formed downstream 
of an increase of intracellular cAMP levels. CBP is an acetyltransferase (HAT) which uses 
acetyl-coenzyme A as an acetyl group donor to transfer an acetyl group to the ε-amino 
group of lysine residues in the N-terminal tails of the four core histones. As previously 
anticipated this acetylation results in DNA relaxation, thus exposure of promoter 
sequences to transcription factors (e.g. 123). Zhang and coworkers124 demonstrated that 
the interaction of RbAp48 with CBP induces an increase in the acetyl-transferase activity 
of this protein, leading to an increase in the transcription of genes under the control of 
the CREB promoter. 
Aging is also a matter of impaired renewal. Autophagy, in its various declinations, is the 
process that provides the turnover of cellular content. Dysfunctional proteins and 
Fig 1: Schematic representation 
of cAMP/PKA/CREB pathway   
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organelles, as well as pathogens, can be recycled and constituent (mainly amino acids and 
lipids) reused by the cell. Recently a transcription factor (EB) has been identified as 
coordinator of the expression of autophagic proteins and lysosomal biogenesis.125-129 
Transcription factor EB (TFEB) under basal conditions is kept in the cytosolic compartment 
in a phosphorylated form. Autophagic stimuli, such as starvation, induce the translocation 
of this factor to the nucleus where it can bind CLEAR-box sequences (5’-GTCACGTGAC-3’) 
inducing the transcription of the relative genes. Dysfunctional neurons often present 
dysfunctional organelles and stockpiles of unfolded protein.130, 131 In chapter 7 I have 
reported that Pt induces the translocation of TFEB to the nucleus, thus enhancing 
autophagy in HeLa cells. 
Given this chart of Pt’s potentialities in the treatment of cognitive aging, we decided to 
investigate in a rat model the real effectiveness of Pt treatment and the possible 
involvement of autophagy (TFEB) and of the epigenetic modulator RbAp48 in its effects. 
For a fuller picture of Pt activity in cognitive aging we also looked at two common markers 
of synaptic plasticity, BDNF and Psd-95, and to another protein that is emerging as an 
important regulator for gene expression in old animals/humans, Rest. 
The Repressor Element-1 Silencing Transcription factor (Rest) is a zinc finger repressor 
protein that triggers gene silencing. Rest activity is crucial during neural differentiation 
and in STEM cells.132, 133 Its expression drops to very low levels after differentiation. Rest 
is increased again in the aged brain; its role is under investigation since recent work 
indicates a central role in tumorigenesis. However Rest activity is still poorly characterized 
and it may well be involved in cognitive aging. 
The two common markers of synaptic plasticity previously mentioned are the Brain 
Derived Neurotropic Factor (BDNF) and the Post Synaptic Density protein-95 (Psd-95). 
Synaptic plasticity includes the strengthening or weakening of synaptic connections. 
Regulation can take place at the pre-synaptic site by modulating the release of 
neurotransmitter molecules or post-synaptically by changing the number, types, or 
properties of neurotransmitter receptor.134 BDNF is a member of the neurotrophin (NT) 
family, it binds the tropomyosin-related kinase receptor B (TrkB) and their interaction 
leads to the activation of the Mitogen-Activated Protein Kinase (MAPK), Phospholipase Cγ 
(PLCγ), and Phosphatidylinositol 3-kinase (PI3K) pathways.135-138 Psd-95 is a scaffold 
protein that interacts with cytoskeleton components as well as receptors, ion channels 
and cell adhesion molecules. Psd-95 exerts structural functions and its levels are directly 
correlated with synaptic plasticity.139, 140 
Here is presented a pilot study, still incomplete at this point, whose results and 
perspective will be discussed in the conclusions. Part of this work is done in collaboration 
with the groups of prof. Nicoletta Berardi and dr. Alessandro Sale, IN-CNR of Pisa. 
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Materials and methods: 
Animals and ethics statements. All procedures complied with Italian Ministry of Health 
(Law 116/92) and European Community Council (Directive 86/609/EEC) guidelines. 
4 males and 4 females Sprague Dawley rats, 18 months old, were housed in an animal 
room with a 12h/12h light/dark cycle, with food and water available ad libitum. For two 
weeks before the experiments the rats were handled daily. All experimental procedures 
were carried out during the light phase. 
Animals were subdivided in two groups, treated and untreated. Females and males were 
equally distributed among experimental groups (50%). Treated animals received twice a 
day (8 am – 8 pm) for 20 consecutive days a 22.5mg/kg dose of Pt (Waseta Int. Trading 
Co., Shangai, P.R. China) (the molar equivalent of 20 mg/kg of resveratrol) in a palatable 
jelly (prepared as described by Zhang Lei (141; materials were from commercial shops), 
while the untreated group received “unloaded” jelly.  
Palatable jelly was preferred over incorporation in food or drinking water as a route of 
administration. As reported by Zhang141, it ensures both low stress to the animal and a 
controlled administration of the compound. Jellies were administered as a food 
supplement and were prepared as follows: 
- 2.8gr of dried jelly (PaneAngeli) was re-hydrated with 20ml of citrate buffer 
(10mM, pH 5) at room temperature for 10 minutes. 
- the solution was heated at 55-60°C under stirring for 30 minutes. 
- 4 drops of sweetener were added (Diete.tic, Eridania) as well as 400µl of chocolate 
flavoring (Estratti Bertolini). The preparate was further stirred and aliquoted into a 
48 well-plate (500µl) and kept at -20°C. Pt was added to the jellies for the treated 
group, immediately after the sweetener and the flavoring. Each single loaded jelly 
contained the dose of 22.5mg/kg of Pt. During the preparation the different 
weight of male and female animals was considered. 
To avoid initial prudence towards novel foods animals were initially trained to overcome 
neophobia. Training was performed as specified by Zhang141. All the animals were 
voluntary eating the jelly after the training. 
As sketched in fig 2, animals were evaluated for their cognitive performances before and 
after the jelly administration. T maze test, object recognition test and object in context 
test (described below) were performed. Given the long duration of the behavioral 
assessment, we decided to protract the jelly administration (loaded or unloaded) during 
the entire period of the memory and learning evaluation post-treatment, at the end of 
which animals were sacrificed under deep anesthesia (Isoflurane). Brain was collected 
and ventromedial prefrontal cortex, perirhinal cortex, dentate gyrus and hippocampus 
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were dissected and rapidly frozen by immersion of a sealed vial in a bath of isopentane 
and dry ice. Samples were stored at -80°C until use. Lungs, heart, liver, kidneys, skeletal 
muscle (gastrocnemius, tibialis anterior and soleus), testes (males) and the remaining 
brain were also removed and frozen. Blood was collected at decapitation and 
immediately processed as described below.  
T-maze. The T-maze protocol was adapted from Dominguez G et al.142 Briefly, animals 
were placed for ten successive trails separated by 90-s inter-trial intervals at the starting 
point of the T-maze cage. An alternation response was considered each time the subject 
entered the arm opposite to the one visited on the immediately previous trial. Alternation 
rate was calculated taking into account the nine successive trials, and expressed as the 
mean of the arm alternation. To avoid olfactory cues, the apparatus was washed with 
water/EtOH after each trial.  
Object recognition (ORT). The ORT protocol was previously described by Silingardi, et 
al.143 Briefly, the apparatus consisted of a square arena constructed in PVC with black 
walls and white floor. The objects were three-dimensional plastic cubes (15 cm wide) 
made of transparent Plexiglas that differed for the visual patterns lining the walls. Box 
and objects were cleaned up between trials to stop the build-up of olfactory cues.1 
The experimental protocol was modified from Ennaceur and Delacour.144 Briefly, rats 
received one session of 5 min duration in the empty arena to help them habituate to the 
apparatus and test room (habituation phase). Twenty-four hours later, each rat was 
placed in the arena and exposed to two identical objects (sample phase) for 5 min and 
returned to its cage. After a delay of 1h or 24h, rats were placed back in the arena and 
exposed to a familiar object (object identical to those in sample phase) and to a novel 
object for 5 min (test phase). Objects were placed in the same locations as in sample 
phase. The time spent exploring each object was recorded for each animal and for each 
condition, and a discrimination index was calculated (described below in the 
“measurements and statistics” section). 
memory and 
learning baseline 
memory and 
learning evaluation 
day 0 day 20 
pterostilbene administration Fig 2: Experimental scheme 
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For each retention time interval, the new object for half of the animals, treated or 
untreated, was the familiar object for the other half; also the position of the novel and 
the familiar object (left–right) was balanced. For the two test sessions, 1h or 24h, 
different pairs of object were used. At least 5 days separated the two tests. When 
different groups of animals performed the same ORT test we used the same pairs of 
objects. 
Object in context test (OCT). The OCT protocol was previously described by De Rosa et 
al.1 and adapted with minor modifications. Briefly, two open field arenas made of 
poly(vinyl chloride) were used. Each arena constituted a different experimental condition 
(A and B). In condition A, horizontal white stripes were applied on the black walls of the 
arena. The floor was covered with rough Plexiglas (fig. 3a). In condition B, the arena had 
gray walls, and the floor was made of Plexiglas (fig. 3a). The particular object for a given 
test was randomly determined, but each object was used for only one experimental 
condition. The OCT was used to determine whether rats were sensitive to a change in 
context for a given object. Thus, previous familiarization with the two environments was 
fundamental. The habituation phase started 2 days before the block of tests and 
consisted of two sessions. In each session, treated and untreated rats were exposed to 
both conditions (A and B) for 5 min. The OCT was divided into four sample phases and a 
test phase, each lasting 3 min (fig. 3b). The retention interval within the sample phases 
was 3 min. There was a 5 min interval between the last sample phase and the test phase. 
In the sample phase, two objects were placed in adjacent corners of the arena; phases 1 
and 4 comprised objects A1 and A2 in environment A, and phases 2 and 3 comprised 
Fig 3: (a) Three-dimensional representation of conditions A (Left) and B (Right) in 
OCT. (b) Schematic representation of sample/test conditions in OCT. Condition A is 
represented by the shaded box, and condition B is shown by the plain box. Objects are 
represented by the symbols. Image modified from De Rosa et al.1 
Chapter 8 
 
183 
 
objects B1 and B2 in environment B (fig. 3b). The test phase was in the same environment 
as sample phase 4, but one of the objects (A2) was replaced by B2. In this way, one object 
was in the same environment as in the sample phase, and the other object was in a 
different environment from the sample phase (fig. 3b). To avoid the eventual preference 
for one of two environments, half of the rats began the sample phase in environment A 
with object A1 and A2 and finished with the same environment with object A1 and B2 and 
vice versa. 
Measurements and Statistics. The standard measure for the statistical analysis in the 
ORTs was the time spent exploring the two objects. The exploration of an object was 
defined as directing the nose to the object at a distance of <2 cm and touching it with the 
nose. Turning around, climbing over, or sitting on the object were not included. In the 
sample phase, if the exploration time was <3 sec, the rat were discarded from the sample. 
Rats also were excluded from the sample if they spent <1 sec exploring both new and 
familiar objects in the test phase. In the sample phase, the total time spent exploring each 
object was recorded and compared across different treatments with Student’s t test. For 
OCT, two-way ANOVA was used. In the test phase, comparisons between time spent 
exploring the new and old objects were performed within groups (analysis performed by 
using paired t tests). A discrimination index (DI) was calculated as the difference between 
the time spent exploring new and old object divided by the total time spent exploring the 
objects [(n - f)/(f + n), where n represents new and f represents familiar]. DIs were 
compared across treatments with a t test. For the T-maze, performance in discriminating 
side (sx versus dx) was compared across treatments with a t test. 
Tissue treatments and HPLC analysis. HPLC analysis, tissues and blood treatment were 
performed as previously described in chapter 5.90  
Quantitative real Time-PCR (qPCR). Total RNA was obtained from dentate gyrus, 
hippocampus, ventromedial prefrontal cortex and perirhinal cortex of both, treated and 
untreated animals. RNA was extracted following TRIzol® (Invitrogen) extraction methods, 
according to manufacturer’s instructions. RNA was eluted in RNase-free water and stored 
at -80°C until use. The concentration and quality of each sample were measured by 
NanoDrop (Thermo Scientific). 100ng of RNA were converted to cDNA using Superscript® 
VILO™ (Invitrogen) following the manufacturer’s instructions. Reverse transcription was 
performed in a thermal cycler (Hybaid Touchdown Thermal Cycle): 25°C for 10 min, 42°C 
for 120 min, 85 °C for 5 min. All RNA samples were simultaneously converted to cDNA to 
minimize experimental variability. Superscript® VILO™ does not require initial 
denaturation of RNA, as indicated by manufacturer’s instructions. Specific primers were 
either designed using Primer3input (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) or 
Primer Blast NCBI (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) or taken from 
already published sequences (for actb: 145; for gapdh and bdnf: 146). Thermodynamic 
specificity was determined using BLAST sequence alignment (NCBI: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi; Integrated DNA Technologies (IDT): 
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http://eu.idtdna.com/calc/analyzer). All primers were purchased from Sigma Aldrich. 
Primer sequences were as follows: 
Glyceraldehyde 3-phosphate dehydrogenase (gapdh): fw ATCACCATCTTCCAGGAGCG rv 
GATGGCATGGACTGTGGTCA 
Actin beta (actb): fw CCGCGAGTACAACCTTCTTG rv GCAGCGATATCGTCATCCAT 
Meis homeobox 1 (meis1): fw GCACAGGTGACGATGATGAC rv GAAGGATGGTGAGTCCCGTA 
Tryptofan 2,3-dioxygenase (tdo2): fw AGAAAGAGGTGCTGCTCTGC rv GAGGTCAGCAACTGGAAAGG 
TYRO 3 protein tyrosine kinase (tyro3): fw CCCTTTACTTGCTTGCTTCG rv AATGGCGTGGAAATTCTGAG    
Desmoplakin (dsp): fw CACTCCCAGTCTTCACAGCA rv TTTCTCCAGGTCCCACAATC 
Discs, large homolog 4 (dlg4): fw GAGTGCTTCTCAGCCATCGT rv ATGTAGGGGCCTGAGAGGTC 
Retinoblastoma binding protein 4 (rbbp4): fw GCTCCCTAATGACGATGCTC rv ATGATGCAAGGGTTCTGAGG 
RE1-silencing transcription factor (rest): fw AACTCACACAGGAGAACGCC rv TGTGAACCTGTCTTGCGTGT 
Transcription factor EB (tfeb): fw GGGCTACATCAACCCCGAAA rv CCGGCTCTCAGCATCTGTTA 
Brain-derived neurotrophic factor (bdnf): fw ATAGGAGACCCTCCGCAA rv CTGCCATGCATGAAACACTT   
Quantitative PCR was performed in duplicate in a 96-well IQ5 Thermal Cycler (BioRad) 
using SYBR green chemistry. gapdh and actb were tested as putative reference genes. 
gapdh turned out to provide the most reproducible output, and was used to normalize 
cycle threshold (CT) values. All samples were run simultaneously with RNA- and RT-
negative controls. The efficiency of each run was determined by a standard curve 
obtained through a serial dilution of cDNAs from a pool of the analyzed sample. 
Normalization was performed by the ΔCT method. Data are expressed as means ± SEM (n 
= 4). Comparisons were made using the t-test (p < 0.05). 
Results:  
Behavioral tests: 
Before the training session animals were handled and habituated to eat jelly (vehicle 
only). In order to overcome the initial neophobia animals were subjected to short starving 
intervals (e.g. 4-6 h) during the light phase. Calorie restriction (CR) is known to attenuate 
age-related deficits (e.g. 147-151). In order to exclude the possibility of a CR-induced 
improvement in the cognitive performance of the animals, the jelly training phase was 
performed one month before the beginning of the experiments. Short starving intervals 
were limited to the strictly necessary (2 or 3 session for each animal). The animals 
received vehicle jelly weekly during the baseline assessment period in order to maintain 
their interest for the flavor of the jelly. 
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Baseline evaluation of the cognitive status of the old animals indicated that the whole 
cohort of animals was homogeneous and presented age-related impairment in 
performing the tasks (data not shown). 
Behavioral tests were selected to probe different areas and different functions of the 
brain. Aging impairs, among many other functions, memory formation and 
consolidation.152 Given the nature of this pilot study, we decided to adopt a broad 
approach to detect any possible effect of Pt in memory. 
ORT mainly reflects the activity of the perirhinal cortex. This area of the brain is heavily 
involved in the identification of environmental stimuli and object recognition.143, 153-155 
OCT evaluates preferentially hippocampus activity. Hippocampus among other functions 
is largely responsible for processes such as consolidation of short term memory to long 
term memory, memory retrival and spatial navigation.155-160 T-maze exists in many 
different variants developed in order to evaluate different aspect of brain function. 
Forced alternation and left-right discrimination tasks using the T-maze is widely used to 
assess working memory and reference memory in rodents, and it also depends on 
hippocampal function.161, 162  
Object recognition test: 
Object recognition test was performed twice, in order to evaluate the spatial memory of 
the animals treated and untreated 1h or 24h after the training session. Each time 
different objects were used avoiding reminding of the previous test. 
Treated and untreated animals had a similar performance in recognizing the new object 
when the test was performed 1h after the training session (fig 4-a, index ctrl = 0.337 ± 
0.044, index Pt = 0.215 ± 0.039). However, the treated group had a definitely improved 
index score in comparison with the untreated group when the test was performed 24 
hours after the training session (fig 4-b, index ctrl = -0.120 ± 0.130, index Pt = 0.158 ± 
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Fig 4: Object recognition memory. Tests were performed 1h (a) and 24h (b) after the training session. 
Discrimination index (Index) was calculated with the following formula: (n – f)/(n + f), where n 
represents new and f represents familiar object. a: untreated (Ctrl) and treated (Pt) animals did not 
significantly differ in recognizing the new object 1h after the training phase. b: treated animals (Pt) tend 
to explore the new object more than untreated animals 24h after the training phase  (t-test, p = 0,088). 
Error bars represent SEM 
a b 
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0.044). Even though the difference is not statistically significant (p = 0.088) due to the low 
numerosity, the results obtained in the 24h test suggest that Pt ameliorates the 
consolidation of spatial memory, while no improvement in short-term memory is 
suggested by the 1h test. 
Object in context test:  
As for ORT, object in context test was performed 1h and 24h after the training sessions. 
Pt treatment again was effective in the phase of memory consolidation (24h, fig 5-b), 
while Pt administration seemed to be ineffective when the assay was performed 1h after 
the training session (fig 5-a). This result confirms and supports the idea that Pt treatment 
positively affects memory, particularly in the phase of its consolidation. 
T maze: 
Working memory stimulation requires the coordinated activity of many functions and 
areas of the brain. Sensor and motor cortex, spatial orientation and short term memory 
are particularly solicited. In our experiment the animals were free to choose between left 
and right arm, with a short latency within 10 trials. Even though differences are not 
significant, treated animals seem to obtain a better score than untreated animals (fig 6).  
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Fig 6: T maze test. The index was calculated as the 
mean of the arm alternation. 
The working memory of the treated group seems to 
be more efficient than that of the untreated group 
(ctrl, p = 0,072). Error bars represent SEM 
Fig 5: Object in context test. Tests were performed 1h (a) and 24h (b) after the training sessions. The 
discrimination index (Index) was calculated as described in fig  4. The performance of treated group 
(Pt) was similar to that of untreated group (ctrl) 1h after the last training session (a). 24h after the last 
training session treated animals (Pt) were significantly better than untreated animals in performing the 
task (b, p = 0,009). Error bars represent SEM 
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HPLC: 
As a control for Pt administration the major organs of treated animals were analyzed by 
HPLC in order to verify and measure the presence of Pt and its main metabolite in rats, Pt-
sulfate (Pt-S). Animals were sacrificed at different times after the last Pt administration, 
so absorption and clearance (in addition to the normal variability) can account in part for 
the variability in the concentrations of Pt and Pt-S found among the 4 treated animals.  
Pt and Pt-S were present in all treated animals. Distribution in major organs of Pt and Pt-S 
is similar to the one previously published by our group.90 However in this work animals 
were not fasted and the administration was chronic. Liver and kidney showed the highest 
concentration of both Pt and Pt-S; Pt was the predominant specie in the brain while the 
metabolite was predominant in the liver and kidneys (fig 7). 
qPCR: 
Kandel and coworkers117 have identified the dentate gyrus as one of the areas most 
affected by age, and the area that shows decreased expression of RbAp48 upon aging.  
The dentate gyrus is wrapped up by other brain structures, mostly the hippocampus. 
Given the difficulty of the dissection we decided to perform a molecular control for our 
a b 
c d 
Fig 7: Levels of Pt and Pt-S in the organs of treated animals. Females (a, b) and males (c, d) have a 
similar amount and distribution of both species. Pt was the predominant specie in the brain (a-d) 
and in female’s skeletal muscle (a, b), while Pt-S was more abundant in liver, kidneys and blood 
(a-d). 
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dentate gyrus preparation. As suggested by Hagihara163 it is possible to verify the 
accuracy of the dentate gyrus dissection measuring by RT-qPCR the level of expression of 
certain genes that are selective for the dentate gyrus (dsp and tdo2) or for the remaining 
hippocampus (meis1 and tyro3). 
tdo2 and dsp were consistently up-regulated in the whole cohort of the DG samples, 
indicating that the isolate contains the DG. However, meis1 and tyro3 expression was 
similar in both rest-of-hippocampus and DG preparates. This indicates that during the 
dissection part of the hippocampus was dissected along with the DG, and it represents a 
significant contamination in our samples. Since the DG was identified as DG, we decided 
to proceed further with the analysis even if this contamination was present (fig 8).  
Markers of synaptic plasticity: 
RT-qPCR analysis suggested that bdnf gene expression is not significantly affected by the 
treatment with Pt in any of the areas examined.  
dlg4 (the gene of Psd-95) also seems not to be up-regulated in the treated group. 
However, in the DG of treated animals there might be a slight up-regulation of the gene.  
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Fig 8: Gene expression in the dentate gyrus (DG) and 
remaining hippocampus (HIP). gapdh was used to 
normalize gene expression. Each bar represents the 
average of 8 animals. Error bars represent SEM. 
Fig 9: Quantitative PCR analysis with a bdnf specific probe (a) and a dlg4 specific probe (b). Gene 
expression is normalized on gapdh. Each bar represents the average of 4 animals. Error bars represent 
SEM. 
0
0,5
1
1,5
2
2,5
DG HIP PFc PRNLc
R
e
la
ti
v
e
 e
x
p
re
ss
io
n
2
^
-(
d
C
T m
e
a
n
 c
tr
l -
d
C
T s
a
m
p
le
) dlg4 ctrl
Pt
0
0,5
1
1,5
2
DG HIP PFc PRNLc
R
e
la
ti
v
e
 e
x
p
re
ss
io
n
2
^
-(
d
C
T m
e
a
n
 c
tr
l -
d
C
T s
a
m
p
le
) bdnf ctrl
Pt
a b 
Chapter 8 
 
189 
 
Both bdnf and dlg4, appeared to be negatively regulated by Pt treatment in the PRNLc. 
However, this result has a particularly low significance due to the small amount of PRNLc 
material we obtained. RNA extracted from this areas was indeed very scarce, due to the 
size of this portion of the cortex and due to the age of the animals. This point will be 
discussed in the conclusions section. 
Autophagy induction: 
Since it is considered the master regulator of autophagy and lysosomal biogenesis (see 
above), we examined TFEB as a marker of Pt autophagy induction. One of the genes 
controlled by TFEB is its own.164 Its activation therefore is expected to lead to an increase 
of TFEB mRNA and protein levels (positive feedback loop). Hippocampus, pre-frontal 
cortex and perirhinal cortex TFEB levels seemed to be unaffected by Pt administration. On 
the other hand, the gene seems to respond in the DG. This outcome would be in 
agreement with the results of our previous work (chapter 7) which clearly indicates, at 
least in vitro, a correlation between Pt administration and TFEB nuclear localization.  
Epigenetics and transcription silencing: 
rbbp4 (gene of RbAp48 protein) and rest follow the same pattern seen for dlg4 and tfeb. 
In both cases gene expression seems to be up-regulated in the DG whereas the other 
areas examined apparently are not influenced by Pt administration. 
 
 
a b 
Fig 10: Quantitative PCR analysis with probes 
specific for tfeb (a), rbbp4 (b) and rest (c). 
Gene expression is normalized on gapdh. Each 
bar represents the average of 4 animals. Error 
bars represent SEM 
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Discussion: 
Taken together our preliminary data suggests the following:  
1. Behavioral results confirm that Pt ameliorates cognitive impairment in old rats, at least 
deficits concerning spatio-temporal memory. 
2. Molecular study suggests that this effect may be due to a rearrangement in the 
synaptic architecture (dlg4 increase, if any), to a change in the acetylation level of 
histones (rbbp4 increase) and to an increase in autophagy level that can exert a renewal 
of intracellular components (tfeb increase). 
3. Molecular differences in the treated group were primarily found in the dentate gyrus. 
This agrees with the fact that the DG is one of the areas most affected by the age. 
However behavioral and molecular results need to be confirmed, since our sample size is 
too small. A similar study performed by Joseph’s group32 reports, at a behavioral level, 
results similar to ours. However Joseph’s work used 14 animal per group (more than 
three times our numerosity) and a longer administration of the drug (9 weeks versus 6 
weeks). 
Also, dentate gyrus dissection ought to be improved. Most of the hippocampus seems to 
respond poorly to Pt administration: we were unable to detect any significant effect in 
any of the genes we monitored in this region (except of course the DG). Given the 
contamination of our DG isolate with part of the neighboring hippocampus tissue we can 
hypothesize that we are underestimating variation in the DG. 
The use of old animals moreover makes the work difficult. 18 month-old rats suffer from 
many deficits; two of four females (the untreated animals) had a clearly formed breast 
cancer that was discovered at the end of the experimental protocol, while the whole 
cohort of animals was suffering from a mild lack of appetite that made the administration 
of the jelly difficult. At a molecular level we noticed a consistent reduction in the yield of 
the RNA extraction and protein extraction from a given weight of wet tissue.  
Concluding, data are encouraging. At a behavioral level Pt treatment was effective, as 
previously shown in a few papers.31, 32 Molecular data, taken with the necessary caution, 
are also encouraging. Except for bdnf expression, in the other cases there was a trend of 
increased gene expression in the DG. Statistics can be improved by adding more animals 
to the experimental set and by sharpening the DG dissection.  
Interestingly, a future aspect of this work will be to find an explanation for the restricted 
effects of Pt treatment in the DG. The gene for phosphodiesterase-1b displays an 
enriched expression in the DG.165 Resveratrol inhibits PDE 1, 3 and 4.103 Currently there 
isn’t any evidence that Pt acts primarily by inhibiting PDE, but we have found (chapter 7) 
that its administration leads to an increase in the cAMP levels in cultured cells, and many 
papers report similarities between the activities of Pt and Resveratrol. This suggests that 
Chapter 8 
 
191 
 
the high expression of pde-1b and the restricted activity of Pt in the DG might be 
correlated. 
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Supplementary Figure 1. Effects of RDM-4’BTPI on intracellular O2-· generation. 
Fluorescence microscopy experiment with MitoSOXTM-loaded CT-26 cells. Representative 
images (λexc: 500-520 nm; λem>570 nm) acquired 1 minute before (A) and 30 minutes after 
(B) addition of 5 µM RDM-4’BTPI. The Regions of Interest (ROI) identified in panels A 
and B are those used to generate the fluorescence plots shown in Fig. 2D. 
 
The MitoSOXTM fluorescence increase was homogenous and took place in all cells, at 
variance with the behavior reported by the Ca2+ probe Fluo-4 (Fig. 2A-C). 
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Supplementary Figure 2. Effect of Resveratrol and known respiratory chain inhibitors on 
respiration fully stimulated by FCCP. Rates of respiration by CT-26 cells were determined 
using a Seahorse XF24. A representative experiment is shown. Compounds were added at 
the indicated concentration to cells previously treated with 0.2µM FCCP. Data were 
normalized to the initial FCCP-elicited OCR for each set of wells and are presented as % 
changes with respect to that level.  
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Supplementary Figure 3. Effects of RDM-4’BTPI on the oxygen consumption rate and 
ROS generation by isolated rat liver mitochondria. A) An exemplary polarographic trace 
illustrating the experimental protocol. In this example 5 mM succinate was the respiratory 
substrate and 2 µM rotenone was present. The bars above the trace indicate what 
segments of the trace itself were used to calculate (by linear interpolation) the slope 
coefficients shown in panels B and C. RLM: 0.5 mg.prot./mL; RDM-4’BTPI: 50 µM; ADP: 
100µM; FCCP: 100nM. See below for other details. B) and C) Plot of the average values 
± s.d. of the relative slope measured in repeat experiments (N = 3) analogous to the one in 
panel A. Blue columns: no RDM-4’BTPI addition. Red or green columns: after RDM-
4’BTPI addition. Slope values are normalized setting the slope of the state 4 (no addition 
except respiratory substrate) segment = 100. D) and E) Effects of RDM-4’BTPI on ROS 
generation by RLM. Flow cytometry experiments with H2DCF-DA -loaded RLM. 
Respiratory substrate was glutamate/malate (5mM and 2.5mM respectively; panels B and 
D) or succinate (5 mM) in the presence of 2µM rotenone (panels C and E). 
 
 
Rate of respiration by isolated RLM. The rate of respiration by RLM was measured in 
polarographic assays using a Clark electrode inserted in a thermostatted (25 °C) and stirred 
enclosed chamber with an airtight injection port. The electrode was controlled by an 
HansaTech CB1D control box and interfaced with a personal computer by a Microlink 751 
digitizer. The standard medium contained 250 mM sucrose, 20 mM 3-[N-
morpholino]butanesulfonic acid (MOPS), 10 mM Tris-Base, 1 mM Pi/K+, 0.5 mM Mg2+, 
pH 7.0. RLM were used at a concentration of 0.5 mg prot./mL. The relative rate of oxygen 
consumption under the various conditions was obtained as the slope of the interpolation 
(best linear fit) of the relevant segment of the polarograph output (dimensions: mV/min) 
divided by the slope of the best linear fit of the output in the presence of mitochondria and 
respiratory substrate only. 
Flow cytometry with RLM. ROS generation in isolated RLM was measured in flow 
cytometry experiments using the fluorescent probe dichlorofluorescein (DCF), as described 
in [38]. Briefly, RLM were resuspended in the assay buffer (250 mM sucrose, 20 mM 3-
[N-morpholino]butanesulfonic acid (MOPS), 10 mM Tris-Base, 1 mM Pi/K+, 0.5 mM 
Mg2+, pH 7.0) at a concentration of 0.5 mg prot./mL, and loaded with 2’,7’-
dichlorodihydrofluorescein-diacetate (H2DCF-DA, 10 µM) in the presence of Cyclosporin 
A (CsA; 1 µM) (25°C, 10 min). 5 mM glutamate plus 2.5 mM malate or 5 mM succinate 
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plus 2 µM rotenone were added to allow respiration via complex I or complex II, 
respectively. After loading, RLM were divided into identical aliquots. At time zero the 
various compounds were added and data were collected after the desired incubation times 
(50,000 counts for each measurement). A Beckton Dickinson Canto II flow cytometer was 
used. Excitation was at 488 nm and fluorescence was collected in the 506-540 nm interval. 
To exclude debris and aggregates, samples were gated based on light-scattering properties 
in the side scatter and forward scatter modes, as determined in preliminary experiments 
with RLM stained with NAO or TMRM. Data were analyzed using the BD VISTA 
software. Averages ± s.d. of the medians of RLM fluorescence distribution histograms are 
plotted, normalized to the value measured immediately after addition of the compounds 
(time = 0). 
 
Chapter 11 
236 
 
 
Supplementary Figure 4. The decline of “recovered” respiration at high concentrations of 
oligomycin is not significantly affected by permeant Catalase (PEG-CAT) at 
concentrations (500 U/ml) shown to strongly reduce cell death (Sassi N., et al. Curr Pharm 
Des 2014). The plots show rates of respiration by CT-26 cells as determined using 
Seahorse XF24. Representative experiments are shown. 5 µM (final concentration) of the 
indicated derivative was added to cells after inhibition of ATP synthase activity with 
oligomycin 1 µg/mL (OL 1) or 10 µg/mL (OL 10).  
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Supplementary Figure 5. Impact of CsA on cytotoxicity induced by mitochondriotropic 
resveratrol derivatives. MTT assay readout. CT-26 cells were grown for 3 days in the 
presence of the specified compounds. Experiments were performed as described below. 
 
Cell growth/viability (MTT) assays. CT-26 cells were seeded in standard 96-well plates 
and allowed to grow overnight in DMEM + 10% FBS (200 µL) to insure their attachment. 
Initial density was 3000 cells/well. After cell attachment, the growth medium was replaced 
with DMEM + 10% FBS containing the desired compounds. Final DMSO concentration 
was 0.1% in all cases (including controls). Cells were incubated with the compounds for 72 
h; every 24 h the medium was substituted by a fresh aliquot (with compounds). At the end 
of the incubation period the medium was removed and 100 µL of PBS containing 10% 
CellTiter 96® AQUEOUS One solution (Promega) were added into each well. After 1 h of 
color development at 37°C, absorbance at 490 nm was measured using a Packard Spectra 
Count 96-well plate reader. All measurements were performed in quadruplicate in each 
experiment. 
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Supplementary Figure 6. Effects of acetylated and methylated resveratrol derivatives on 
the extracellular acidification rate (ECAR). ECAR was determined using Seahorse XF24. 
Representative experiments are shown. 5 µM R-BTPIs (A), RDA-BTPIs (B) or RDM-BTPIs 
(C) were added to CT-26 cells when indicated. 
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Abbreviations: 
AC: adenylate cyclase 
ACN: acetonitrile (CH3CN) 
AMP: 5'-adenosine monophosphate 
AMPK: 5'-adenosine monophosphate (AMP)-activated protein kinase 
AOM: azoxymethane 
ARE: antioxidant response element 
AUC: area under the curve 
BDNF: brain-derived neurotrophic factor 
BSA: bovine serum albumin 
cAMP: cyclic AMP 
CBP: CREB binding protein (also called CREBBP) 
CREB: cAMP response element-binding protein 
Cmax: maximal concentration 
COX: cyclooxygenase 
D-PBS: Dulbecco’s phosphate buffered saline 
DG: dentate gyrus 
DHP-C: dihydroxypropyl carbamate 
DI: discrimination index 
DMAP: 4-(dimethylamino)pyridine 
DMSO: dimethyl sulfoxide  
DSS: sodium dextran sulfate 
EDTA: ethylenediaminetetraacetic acid 
ECL: enhanced chemiluminescence 
EGCG: epigallocatechin gallate 
EPAC: exchange protein activated by cAMP  
ER-β: estrogen receptor beta 
EtOAc: ethyl acetate 
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EtOH: ethanol 
GCL: glutamate-cysteine ligase 
GSTP1: glutathione sulfotransferase-π  1 
GSTs: glutathione S transferases  
H30-FRET: epac-H30  Fluorescence Resonance Energy Transfer 
HAT: acetyltransferase 
HBSS: Hank’s balanced salt solution 
HIP: hippocampus 
HLP: hypotonic lysis buffer 
HMOX1: heme oxygenase 1 
HP-β-CD: 2-hydroxypropyl-β-cyclodextrin 
HPLC-ESI/MS: high performance liquid chromatography-electrospray ionization/mass 
spectrometry 
HPLC-UV: high performance liquid chromatography-UV 
HRP: horseradish peroxidase 
IBMX: 3-isobutyl-1-methylxanthine 
IkB: inhibitor of kappa B 
IKK: IκB kinase 
LAT: L-type aminoacids transporter 
LOD: limit of detection 
LOQ: limit of quantification 
MAPK: mitogen-activated protein kinases 
MTA1: metastasis associated protein 1 
mTORC1: mammalian target of rapamycin complex 1 
NADP: nicotinamide adenine dinucleotide phosphate 
NF-kB: nuclear factor kappaB 
NLB: nuclear lysis buffer 
NMR: nuclear magnetic resonance 
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NQO2: dihydronicotinamide riboside quinone reductase 2 
Nrf2/Keap1: nuclear factor erythroid 2 [NF-E2]-related factor 2/Kelch-like erythroid cell-derived 
protein with CNC homology [ECH]-associated protein 1 
NuRD: nucleosome remodeling deacetylase complex 
OCT: object in context test 
OEG: oligo ethyleneglycol 
ORT: object recognition test 
Pd/C: palladium/carbon 
PDE: phosphodiesterase  
PFc: prefrontal cortex 
PLCγ: phospholipase C γ 
PI3K: phosphatidylinositol 3-kinase 
PKA: protein kinase A 
PKC: protein kinase C 
PRNLc: perirhinal cortex 
PSD95: postsynaptic density protein 95 (the corresponding gene is named dlg4) 
PPAR: peroxisome proliferator-activated receptor 
Pt: pterostilbene 
Pt-S: pterostilbene 4’-Sulfate 
RIPA: radio immune assay (buffer) 
RbAp48: retinoblastoma associated protein 48 (also called RBBP4, retinoblastoma binding protein 
4, the corresponding gene is named rbbp4) 
REST: RE1-silencing transcription factor (also called neuron-restrictive silencer factor, NRSF) 
ROS: reactive oxygen species 
RT-qPCR: quantitative reverse transcription PCR 
Rv: resveratrol 
Rv-3-sulfate: resveratrol-3-Sulfate 
Rv-3,4’-disulfate: resveratrol-3,4’-diSulfate 
SIRT: sirtuin 
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SOD: superoxide dismutase 
TBS: tris-buffered saline 
TEA: triethylamine 
TFA: trifluoroacetic acid 
TFEB: transcription factor EB 
Tmax: time to maximal concentration 
TrkB: tropomyosin-related kinase receptor B  
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